UMAP 1,UMAP 2,index,Metadata_SMILES,Metadata_BROAD_ID,Scaffold,Var1,Metadata_moa.x
7.2176247,7.749367,0,CC1CS(=O)(=O)CCN1N=Cc1ccc(o1)[N+]([O-])=O,BRD-A00100033,O=S1(=O)CCN(N=Cc2ccco2)CC1,BRD-A00100033,dna inhibitor
12.182125,5.3409286,1,CCCCC#Cc1nc(NC)c2ncn(C3OC(CO)C(O)C3O)c2n1,BRD-A00267231,c1ncc2ncn(C3CCCO3)c2n1,BRD-A00267231,adenosine receptor agonist
9.270291,7.5126376,2,CCN(CC)CC1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12,BRD-A00520476,O=C1Nc2cccnc2N(C(=O)CN2CCCCC2)c2ccccc21,BRD-A00520476,acetylcholine receptor antagonist
4.2006516,6.901685,3,CC(C)NCC(O)COc1ccccc1CC=C,BRD-A00993607,c1ccccc1,BRD-A00993607,adrenergic receptor antagonist
6.6645417,9.388973,4,CCC(C(CC)c1ccc(O)cc1)c1ccc(O)cc1,BRD-A01078468,c1ccc(CCc2ccccc2)cc1,BRD-A01078468,synthetic estrogen
6.091402,7.8279166,5,CCCN(C\C=C\I)C1CCc2ccc(O)cc2C1,BRD-A01295252,c1ccc2c(c1)CCCC2,BRD-A01295252,dopamine receptor ligand
7.6249313,11.087699,6,OCc1cc(ccc1O)C(O)CNCCCCCCOCCCCc1ccccc1,BRD-A01320529,c1ccc(CCCCOCCCCCCNCCc2ccccc2)cc1,BRD-A01320529,adrenergic receptor agonist
3.6577356,9.41015,7,CC(=O)O[C@@]1(CCC2C3C=C(Cl)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O,BRD-A01593789,O=C1C=C2C=CC3C4CCCC4CCC3C2CC1,BRD-A01593789,5 alpha reductase inhibitor
8.763025,10.450693,8,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,BRD-A01636364,O=C(Nc1ccccc1)C1CCCCN1,BRD-A01636364,sodium channel blocker
4.2470655,6.8775578,9,COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1,BRD-A01787639,c1ccc(N2CCN(CCCOc3cccc4ccccc34)CC2)cc1,BRD-A01787639,adrenergic receptor antagonist
8.600857,11.102815,10,CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC,BRD-A02006392,C1=CC(c2ccccc2)C=CN1,BRD-A02006392,calcium channel blocker
6.736985,8.1154375,11,CC(=C)C1Cc2c(O1)ccc(C(O)=O)c2O,BRD-A02176148,c1ccc2c(c1)CCO2,BRD-A02176148,mitochondrial complex i inhibitor
6.6446176,9.210669,12,CCC1(CCCCN(C)C1)c1cccc(O)c1,BRD-A02710418,c1ccc(C2CCCCNC2)cc1,BRD-A02710418,opioid receptor agonist
5.1542797,8.823332,13,CC(=O)O[C@@H]1CC2[C@](C)(CCC(=O)C2(C)C)C2CC[C@@]3(C)[C@@H](OC(=O)C=C3[C@]12C)c1ccoc1,BRD-A02713983,O=C1CCC2C(CCC3C4=CC(=O)OC(c5ccoc5)C4CCC32)C1,BRD-A02713983,growth factor receptor activator
4.3302035,7.093298,14,CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1,BRD-A02759312,c1ccc(CCOCC2CC2)cc1,BRD-A02759312,adrenergic receptor antagonist
8.762731,10.449943,15,CN1CCCCC1C(=O)Nc1c(C)cccc1C,BRD-A03216249,O=C(Nc1ccccc1)C1CCCCN1,BRD-A03216249,potassium channel blocker
4.4077926,6.936663,16,OC(CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N,BRD-A03359064,O=C(NCCNCCCOc1ccccc1)Nc1ccccc1,BRD-A03359064,adrenergic receptor antagonist
4.3278623,7.1166453,17,COCCc1ccc(OCC(O)CNC(C)C)cc1,BRD-A03623303,c1ccccc1,BRD-A03623303,adrenergic receptor antagonist
6.5964284,8.467009,18,CCCCCCC(C)(C)c1ccc(C2CC(O)CCC2CCCO)c(O)c1,BRD-A03816571,c1ccc(C2CCCCC2)cc1,BRD-A03816571,cannabinoid receptor agonist|cc chemokine receptor antagonist
7.52168,11.0981,19,CC(C)NCC(O)c1ccc(O)c(O)c1,BRD-A04322457,c1ccccc1,BRD-A04322457,adrenergic receptor agonist
10.24483,6.9121704,20,Oc1cc2C(CN(CC=C)CCc2c(Cl)c1O)c1ccccc1,BRD-A04438777,c1ccc(C2CNCCc3ccccc32)cc1,BRD-A04438777,dopamine receptor agonist
9.698052,9.6158,21,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,BRD-A04553218,c1ccc(Cc2ccccn2)cc1,BRD-A04553218,histamine receptor antagonist
9.215022,8.702653,22,CCOC(OCC)P(O)(=O)CCCNCc1ccc(Cl)c(Cl)c1,BRD-A04668240,c1ccccc1,BRD-A04668240,gaba receptor antagonist
11.894398,5.6628966,23,CCCC(=O)Nc1ncnc2n(cnc12)C1OC2COP(O)(=O)OC2C1OC(=O)CCC,BRD-A04706586,O=[PH]1OCC2OC(n3cnc4cncnc43)CC2O1,BRD-A04706586,adenosine receptor agonist
7.7087994,10.203265,24,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,BRD-A05186015,c1ccccc1,BRD-A05186015,dopamine uptake inhibitor
9.915101,8.778669,25,CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1,BRD-A06352418,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1,BRD-A06352418,histamine receptor antagonist
8.836666,7.0862784,26,O=C1NC(=O)c2c1c1c3ccccc3n3C4CCC(O4)n4c5ccccc5c2c4c13,BRD-A06352508,O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1,BRD-A06352508,chk inhibitor
7.488815,6.130959,27,CC[C@H]1CN2CCC1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,BRD-A06390036,c1ccc2c(CC3CC4CCN3CC4)ccnc2c1,BRD-A06390036,antiarrhythmic
11.847582,5.7147884,28,CCCC(=O)Nc1nc2n(cnc2c(=O)[nH]1)C1O[C@H]2COP(O)(=O)O[C@@H]2[C@@H]1OC(=O)CCC,BRD-A06726973,O=c1[nH]cnc2c1ncn2C1CC2O[PH](=O)OCC2O1,BRD-A06726973,cgmp analog
5.331983,9.163023,29,C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)C2[C@H](O)C[C@@H]2[C@]1(C)C[C@H](OC(C)=O)\C2=C(/CCC=C(C)C)C(O)=O,BRD-A06935312,C=C1CCC2C1CCC1C3CCCCC3CCC21,BRD-A06935312,bacterial 30s ribosomal subunit inhibitor
6.0413084,7.1288986,30,CCCCOc1cc(CC2CNC(=O)N2)ccc1OC,BRD-A07207424,O=C1NCC(Cc2ccccc2)N1,BRD-A07207424,phosphodiesterase inhibitor
7.590144,11.107486,31,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(c1)C(N)=O,BRD-A07440155,c1ccc(CCCNCCc2ccccc2)cc1,BRD-A07440155,adrenergic receptor antagonist
7.505916,11.052278,32,CC(C)NCC(O)c1cc(O)cc(O)c1,BRD-A07780951,c1ccccc1,BRD-A07780951,adrenergic receptor agonist
7.14752,6.659638,33,O=C1CC(Oc2ccccc12)c1ccccc1,BRD-A07824748,O=C1CC(c2ccccc2)Oc2ccccc21,BRD-A07824748,11-beta hydroxysteroid dehydrogenase inhibitor
8.594255,11.106235,34,COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCC=Cc1ccccc1,BRD-A07875874,O=C(OCC=Cc1ccccc1)C1=CNC=CC1c1ccccc1,BRD-A07875874,calcium channel blocker
10.022682,7.5957913,35,CSc1ccc2Sc3ccccc3CC(N3CCN(C)CC3)c2c1,BRD-A07932845,c1ccc2c(c1)CC(N1CCNCC1)c1ccccc1S2,BRD-A07932845,anti-hcve2
8.138181,10.2547,36,CCC(C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS,BRD-A07952294,c1ccccc1,BRD-A07952294,farnesyltransferase inhibitor
8.474087,9.752201,37,CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1,BRD-A08187463,O=C(CCc1ccccc1)NCC(=O)OCc1ccccc1,BRD-A08187463,enkephalinase inhibitor
5.827826,8.699022,38,CO[C@H](C)C(O)(C(C)C)C(=O)OCC1=CCN2CC[C@H](O)[C@@H]12,BRD-A08709697,C1=CC2CCCN2C1,BRD-A08709697,pyrrolizidine alkaloid
5.7331986,7.2078233,39,COC1=CC23CCCN2CCc2cc4OCOc4cc2C3C1O,BRD-A08877921,C1=CC23CCCN2CCc2cc4c(cc2C3C1)OCO4,BRD-A08877921,protein synthesis inhibitor
6.1142745,7.33117,40,COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C1CCCO1,BRD-A09056319,O=C(NCCCNc1ncc2ccccc2n1)C1CCCO1,BRD-A09056319,adrenergic receptor antagonist
8.367152,9.5124035,41,CCC(C)(CN(C)C)OC(=O)c1ccccc1,BRD-A09062839,c1ccccc1,BRD-A09062839,local anesthetic
8.725221,8.025387,42,O=C1CC2OCC=C3CN4CC[C@@]56C4C[C@@H]3[C@@H]2C5N1c1ccccc61,BRD-A09094913,O=C1CC2OCC=C3CN4CCC56c7ccccc7N1C5C2C3CC46,BRD-A09094913,acetylcholine receptor antagonist
5.2496033,8.831361,43,CC(=O)O[C@@H]1CC(=O)OC(C)(C)C2CC(=O)[C@]3(C)C(CC[C@@]4(C)[C@@H](OC(=O)[C@H]5O[C@@]345)c3ccoc3)[C@@]12C,BRD-A09161221,O=C1CCC2C(CO1)CC(=O)C1C2CCC2C(c3ccoc3)OC(=O)C3OC321,BRD-A09161221,hsp inhibitor
3.6819842,9.365203,44,CC(=O)O[C@]1(CCC2C3CCC4=CC(=O)CC[C@@H]4C3CC[C@]12C)C#C,BRD-A09349126,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-A09349126,progesterone receptor agonist
9.917164,10.348374,45,CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1,BRD-A09467419,O=C(OCCCCNCCc1ccccc1)c1ccccc1,BRD-A09467419,acetylcholine receptor antagonist
8.907877,9.778102,46,FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1,BRD-A09472452,O=C(NCC1CCCCN1)c1ccccc1,BRD-A09472452,sodium channel blocker
6.022345,7.313786,47,COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC,BRD-A09533288,c1ccc(CCCCNCCc2ccccc2)cc1,BRD-A09533288,calcium channel blocker
4.726922,11.301643,48,CN1C2CC[C@H]1C[C@H](C2)OC(=O)C(O)c1ccccc1,BRD-A09539288,O=C(Cc1ccccc1)OC1CC2CCC(C1)N2,BRD-A09539288,acetylcholine receptor antagonist
10.205595,6.8715806,49,Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1,BRD-A09828896,c1ccc(C2CNCCc3ccccc32)cc1,BRD-A09828896,dopamine receptor agonist
7.5597973,11.041709,50,CCNCC(O)c1cccc(O)c1,BRD-A09925278,c1ccccc1,BRD-A09925278,adrenergic receptor agonist
4.1729617,6.899234,51,CC(C)NCC(O)COc1cccc2ccccc12,BRD-A10070317,c1ccc2ccccc2c1,BRD-A10070317,adrenergic receptor antagonist
8.300003,7.6851764,52,NC1(CCCCC1=O)c1ccccc1Cl,BRD-A10355991,O=C1CCCCC1c1ccccc1,BRD-A10355991,glutamate receptor antagonist
10.327354,10.986634,53,CCN1CCC(CNC(=O)c2cc(ccc2OC)S(N)(=O)=O)C1,BRD-A10715913,O=C(NCC1CCNC1)c1ccccc1,BRD-A10715913,dopamine receptor antagonist
8.326011,6.7531776,54,CCC1(Cc2ccccc2O1)C1=NCCN1,BRD-A10739734,c1ccc2c(c1)CC(C1=NCCN1)O2,BRD-A10739734,adrenergic receptor antagonist
8.528157,7.0671587,55,CCn1ccnc1CC1COc2ccccc2O1,BRD-A10903566,c1ccc2c(c1)OCC(Cc1ncc[nH]1)O2,BRD-A10903566,adrenergic receptor antagonist
5.7447996,7.2212605,56,CO[C@@H]1CC2N3CC(O)C2(C=C1)c1cc2OCOc2c(OC)c1C3,BRD-A10969569,C1=CC23CCN(Cc4cc5c(cc42)OCO5)C3CC1,BRD-A10969569,plant alkaloid
4.237754,6.849778,57,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,BRD-A10977446,c1ccc(OCCNCCCOc2cccc3[nH]c4ccccc4c23)cc1,BRD-A10977446,adrenergic receptor antagonist
6.228828,6.727061,58,COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CCC(NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC,BRD-A11605036,O=c1cccc2c(c1)CCCc1cc(OC3CCCCO3)ccc1-2,BRD-A11605036,gaba receptor antagonist
9.406005,7.57098,59,CN1CCC2(Cc3nc4ccccc4cc3CC2C1)c1cccc(O)c1,BRD-A11609859,c1ccc(C23CCNCC2Cc2cc4ccccc4nc2C3)cc1,BRD-A11609859,opioid receptor agonist
5.19886,8.764785,60,COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O,BRD-A11678676,O=C1OCC2C3=C(C(=O)c4occ1c42)C1CCC(=O)C1CC3,BRD-A11678676,pi3k inhibitor
4.7930894,7.212544,61,CN(CCc1ccc(Cl)c(Cl)c1)CC(O)COc1ccc(NS(C)(=O)=O)cc1,BRD-A11813248,c1ccc(CCNCCCOc2ccccc2)cc1,BRD-A11813248,potassium channel blocker
4.7599936,11.240196,62,CN1C2CCC1CC(C2)NC(=O)c1nn(C)c2ccccc12,BRD-A12016240,O=C(NC1CC2CCC(C1)N2)c1n[nH]c2ccccc12,BRD-A12016240,serotonin receptor antagonist
6.691632,7.196506,63,COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2ccccc2O1,BRD-A13188892,O=C(C1COc2ccccc2O1)N1CCN(c2ncc3ccccc3n2)CC1,BRD-A13188892,adrenergic receptor antagonist
12.158072,8.749434,64,Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)C(N2C1=O)C(O)=O)-c1c(F)cccc1Cl,BRD-A13650332,O=C(NC1C(=O)N2CCSC12)c1conc1-c1ccccc1,BRD-A13650332,bacterial cell wall synthesis inhibitor
7.8152246,8.512436,65,CC1=C(CC(O)=O)c2cc(F)ccc2C\1=C/c1ccc(cc1)S(C)=O,BRD-A13946108,C1=Cc2ccccc2C1=Cc1ccccc1,BRD-A13946108,cyclooxygenase inhibitor
10.957035,7.6882076,66,CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O,BRD-A14395271,c1ccc2c(c1)Sc1ccccc1N2CCC1CCCCN1,BRD-A14395271,dopamine receptor antagonist
4.646738,11.373337,67,CN1C2CC(CC1C1OC21)OC(=O)C(CO)c1ccccc1,BRD-A14566392,O=C(Cc1ccccc1)OC1CC2NC(C1)C1OC21,BRD-A14566392,acetylcholine receptor antagonist
8.945318,7.839814,68,Clc1ccc(cn1)C1=CCCC2CCC1N2,BRD-A14574269,C1=C(c2cccnc2)C2CCC(CC1)N2,BRD-A14574269,acetylcholine receptor agonist
7.1719265,6.9973373,69,COc1c(O)cc2C(=O)OC3C(O)C(O)C(CO)OC3c2c1O,BRD-A15034104,O=C1OC2CCCOC2c2ccccc21,BRD-A15034104,interleukin inhibitor
11.940147,5.6129727,70,CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2OP(O)(=O)OC[C@H]2[C@H]1OC(=O)CCC,BRD-A15070535,O=[PH]1OCC2CC(n3cnc4cncnc43)OC2O1,BRD-A15070535,adenosine receptor agonist|camp stimulant
9.684008,10.00652,71,CN(CCOc1ccc(CC(Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1,BRD-A15415227,O=C(c1ccccc1)c1ccccc1NCCc1ccc(OCCNc2ccccn2)cc1,BRD-A15415227,ppar receptor agonist
10.510305,9.128757,72,OC(CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1,BRD-A15435692,c1ccc(CCCCN2CCN(c3ncccn3)CC2)cc1,BRD-A15435692,sigma receptor antagonist|glutamate receptor antagonist|serotonin receptor agonist
4.031926,6.7731752,73,CC(C)OC(=O)c1cc2c(OCC(O)CNC(C)(C)C)cccc2[nH]1,BRD-A15530910,c1ccc2[nH]ccc2c1,BRD-A15530910,adrenergic receptor antagonist|serotonin receptor antagonist
6.024902,11.127138,74,CCCCCC(O)\C=C\C=O,BRD-A15914070,,BRD-A15914070,cytotoxic lipid peroxidation product
8.594872,9.399077,75,NC(=O)CS(=O)C(c1ccccc1)c1ccccc1,BRD-A16332958,c1ccc(Cc2ccccc2)cc1,BRD-A16332958,adrenergic receptor agonist
8.950685,8.635432,76,Clc1ccc(CCC(Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1,BRD-A16665823,c1ccc(CCC(Cn2ccnc2)Sc2ccccc2)cc1,BRD-A16665823,bacterial cell wall synthesis inhibitor
6.7983346,8.34307,77,CC(C)(c1ccc(OCC2CO2)cc1)c1ccc(OCC2CO2)cc1,BRD-A16694057,c1cc(OCC2CO2)ccc1Cc1ccc(OCC2CO2)cc1,BRD-A16694057,ppar receptor antagonist
5.607091,8.655485,78,CC1CCCC=CC2CC(O)CC2C(O)C=CC(=O)O1,BRD-A17065207,O=C1C=CCC2CCCC2C=CCCCCO1,BRD-A17065207,protein synthesis inhibitor
8.615614,6.1829057,79,CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12,BRD-A17428743,c1csc(COc2ccc3[nH]ccc3c2)c1,BRD-A17428743,serotonin receptor agonist
9.602908,7.820074,80,O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COc2ccccc2O1,BRD-A17453586,O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COc2ccccc2O1,BRD-A17453586,serotonin receptor agonist
8.95677,7.6867743,81,CN1C[C@@]2(C=C)C3CC4OC[C@@H]3[C@@H]1[C@H]2[C@@]41C(=O)Nc2ccccc12,BRD-A17535965,O=C1Nc2ccccc2C12C1CC3C(CO1)C1NCC3C12,BRD-A17535965,acetylcholine receptor antagonist
7.6169233,10.275747,82,CC(C)Cc1ccc(cc1)C(C)C(O)=O,BRD-A17655518,c1ccccc1,BRD-A17655518,cyclooxygenase inhibitor
8.90067,7.5853405,83,CN1C(=O)CC(C1=O)c1ccccc1,BRD-A18043272,O=C1CC(c2ccccc2)C(=O)N1,BRD-A18043272,succinimide antiepileptic
8.4191,7.717362,84,CCOC(=O)C12CC1C(=NO)c1ccccc1O2,BRD-A18202423,N=C1c2ccccc2OC2CC12,BRD-A18202423,glutamate receptor antagonist
12.163567,5.351656,85,Nc1ncnc2n(cc(I)c12)C1OC(CO)C(O)C1O,BRD-A18497530,c1ncc2ccn(C3CCCO3)c2n1,BRD-A18497530,adenosine kinase inhibitor|nucleoside transporter inhibitor
6.7055993,8.05967,86,CN(C)CC(O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12,BRD-A18579359,c1ccc2c(c1)[nH]c1ccccc12,BRD-A18579359,neural wiskott-aldrich syndrome protein inhibitor
8.340673,6.730117,87,C1CN=C(N1)C1COc2ccccc2O1,BRD-A18696154,c1ccc2c(c1)OCC(C1=NCCN1)O2,BRD-A18696154,adrenergic receptor antagonist
6.647003,8.047283,88,OC(CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12,BRD-A18763547,c1ccc2c(c1)c1ccccc1n2CCCN1CCNCC1,BRD-A18763547,cytochrome c release inhibitor
5.6834197,8.537775,89,CN1C2CCCC1CC(=O)C2,BRD-A19053259,O=C1CC2CCCC(C1)N2,BRD-A19053259,anthelmintic
10.831307,7.770007,90,CC(CN(C)C)CN1c2ccccc2CCc2ccccc12,BRD-A19195498,c1ccc2c(c1)CCc1ccccc1N2,BRD-A19195498,norepinephrine reuptake inhibitor
8.8683605,7.324461,91,Cc1nccn1CC1CCc2c(C1=O)c1ccccc1n2C,BRD-A19736161,O=C1c2c([nH]c3ccccc23)CCC1Cn1ccnc1,BRD-A19736161,serotonin receptor antagonist
4.3271914,7.08758,92,CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,BRD-A20239487,c1ccccc1,BRD-A20239487,adrenergic receptor antagonist
8.816075,7.800987,93,CN1C(c2ccc(Cl)cc2)S(=O)(=O)CCC1=O,BRD-A20348246,O=C1CCS(=O)(=O)C(c2ccccc2)N1,BRD-A20348246,gaba receptor modulator
7.4235244,9.872095,94,NC(CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O,BRD-A20968261,c1ccc(Oc2ccccc2)cc1,BRD-A20968261,glutamate transporter inhibitor
9.492771,5.8413415,95,Oc1ccc2CC3N(CC4CC4)CCC45C(Oc1c24)c1oc2ccccc2c1CC35O,BRD-A21723284,c1cc2c3c(c1)OC1c4oc5ccccc5c4CC4C(C2)N(CC2CC2)CCC314,BRD-A21723284,opioid receptor antagonist
8.406186,7.6083293,96,O=C(C1CCCCC1)N1CC2N(CCc3ccccc23)C(=O)C1,BRD-A21858158,O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1,BRD-A21858158,anthelmintic
8.275048,9.288398,97,CC(Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1,BRD-A22305049,O=C(OCCNCCc1ccccc1)c1ccccc1,BRD-A22305049,gluconeogenesis inhibitor
7.348462,6.5750866,98,COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,BRD-A22380646,O=S(Cc1ccccn1)c1nc2ccccc2[nH]1,BRD-A22380646,atpase inhibitor
7.435173,10.850554,99,CCC(NC(C)C)C(O)c1ccc(O)c2[nH]c(=O)ccc12,BRD-A22684332,O=c1ccc2ccccc2[nH]1,BRD-A22684332,adrenergic receptor agonist
6.0626574,8.3036995,100,CC#CCOC(=O)c1c(C)nc2sc3CC(O)CCc3c2c1N,BRD-A22707317,c1cnc2sc3c(c2c1)CCCC3,BRD-A22707317,gaba receptor modulator
10.156566,8.153756,101,CN1CCCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1,BRD-A22769835,c1ccc(C(c2ccccc2)N2CCCNCC2)cc1,BRD-A22769835,antihistamine
9.1689205,6.456634,102,CCC1(O)CC2CN(C1)CCc1c([nH]c3ccccc13)C(C2)(C(=O)OC)c1cc2c(cc1OC)N(C)C1C22CCN3CC=CC(CC)(C23)C(C(=O)OC)C1(O)C(=O)OC,BRD-A22783572,C1=CC2CCC3Nc4ccc(C5CC6CCCN(CCc7c5[nH]c5ccccc75)C6)cc4C34CCN(C1)C24,BRD-A22783572,microtubule formation inhibitor|tubulin inhibitor|tubulin polymerization inhibitor
9.042621,9.084323,103,CN1C(C(=O)Nc2ccccn2)C(=O)c2sccc2S1(=O)=O,BRD-A22844106,O=C(Nc1ccccn1)C1NS(=O)(=O)c2ccsc2C1=O,BRD-A22844106,cyclooxygenase inhibitor
5.592476,8.574345,104,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)C1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O,BRD-A23034328,O=C(NCC1CCCCO1)C1CCCN1,BRD-A23034328,protein synthesis inhibitor
9.690282,9.612241,105,CN(C)CCC(c1ccccc1)c1ccccn1,BRD-A23072235,c1ccc(Cc2ccccn2)cc1,BRD-A23072235,histamine receptor antagonist
4.155949,8.867516,106,CC(=O)OC1CCC2C3CCc4cc(O)ccc4C3CCC12C,BRD-A23226398,c1ccc2c(c1)CCC1C2CCC2CCCC21,BRD-A23226398,estrogen receptor agonist
9.040629,8.827426,107,C(Oc1cccc2C=C(CN3CCOCC3)COc12)C1CNCCO1,BRD-A23683907,C1=C(CN2CCOCC2)COc2c1cccc2OCC1CNCCO1,BRD-A23683907,serotonin receptor antagonist
8.242507,10.472084,108,CC(=O)OC1C2=C(C)C(CC(O)(C(OC(=O)c3ccccc3)C3C4(COC4CC(O)C3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)C(O)C(NC(=O)c1ccccc1)c1ccccc1,BRD-A23723433,O=C(CC(NC(=O)c1ccccc1)c1ccccc1)OC1C=C2CC(=O)C3CCC4OCC4C3C(OC(=O)c3ccccc3)C(C2)C1,BRD-A23723433,tubulin inhibitor|microtubule stabilizing|microtubule stimulant|p glycoprotein inhibitor|taxane
7.391266,9.865571,109,NCC(CS(O)(=O)=O)c1ccc(Cl)cc1,BRD-A24122750,c1ccccc1,BRD-A24122750,gaba receptor antagonist
9.168024,9.853736,110,CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1,BRD-A24191444,c1ccc(CCN2CCC(Cc3ccccc3)CC2)cc1,BRD-A24191444,adrenergic receptor antagonist
4.7591186,8.165965,111,CC1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O,BRD-A24228527,O=c1ccn2c3c(c(N4CCNCC4)ccc13)OCC2,BRD-A24228527,bacterial dna gyrase inhibitor
7.783955,8.539584,112,CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,BRD-A24514565,O=c1oc2ccccc2cc1Cc1ccccc1,BRD-A24514565,vitamin k antagonist
7.485006,10.9306755,113,CCC(NC(C)C)C(O)c1ccc(O)c(O)c1,BRD-A24587114,c1ccccc1,BRD-A24587114,adrenergic receptor agonist
5.679506,6.9170218,114,COc1ccc(CC2N(C)CCc3cc(OC)c(OC)cc23)cc1OC,BRD-A24817035,c1ccc(CC2NCCc3ccccc32)cc1,BRD-A24817035,central nervous system
6.1298738,8.699094,115,CCC1(CCC(=O)NC1=O)c1ccc(N)cc1,BRD-A25234499,O=C1CCC(c2ccccc2)C(=O)N1,BRD-A25234499,glucocorticoid receptor antagonist
5.7845488,8.33655,116,O=C1OC23C[C@@H](C=CC2=C1)N1CCCC[C@H]31,BRD-A25775766,O=C1C=C2C=CC3CC2(O1)C1CCCCN31,BRD-A25775766,gaba receptor antagonist|tp53 activator
10.892772,9.245322,117,CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12,BRD-A26032986,O=c1[nH]c2ccccc2n1C1CCN(CC2OCc3ccccc3-n3cccc32)CC1,BRD-A26032986,calmodulin antagonist
12.121274,5.404188,118,COc1ccc(CC(N)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,BRD-A26222320,O=C(CCc1ccccc1)NC1COC(n2cnc3cncnc32)C1,BRD-A26222320,protein synthesis inhibitor
4.4801807,6.9515114,119,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1,BRD-A26334849,O=C(CCc1ccccc1)c1ccccc1,BRD-A26334849,antiarrhythmic
7.7419677,7.7630467,120,NS(=O)(=O)c1cc(ccc1Cl)C1(O)NC(=O)c2ccccc12,BRD-A26384407,O=C1NC(c2ccccc2)c2ccccc21,BRD-A26384407,carbonic anhydrase inhibitor
8.592694,11.102229,121,COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1,BRD-A26711594,O=C(OCCNCc1ccccc1)C1=CNC=CC1c1ccccc1,BRD-A26711594,calcium channel blocker
4.1462297,6.8537316,122,CC(C)NCC(O)COc1ccccc1-n1cccc1,BRD-A26845397,c1ccc(-n2cccc2)cc1,BRD-A26845397,adrenergic receptor antagonist
6.737074,9.540527,123,Oc1ccc(CC(C#N)c2ccc(O)cc2)cc1,BRD-A27143604,c1ccc(CCc2ccccc2)cc1,BRD-A27143604,estrogen receptor agonist
6.217123,8.130214,124,CC1CCN=C(N)S1,BRD-A28318179,C1=NCCCS1,BRD-A28318179,nitric oxide synthase inhibitor
8.384606,6.8134475,125,C1CN=C(N1)C1CCCc2ccccc12,BRD-A28856712,c1ccc2c(c1)CCCC2C1=NCCN1,BRD-A28856712,adrenergic receptor agonist
4.262926,6.961985,126,CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O,BRD-A29260609,c1ccccc1,BRD-A29260609,adrenergic receptor antagonist
8.6126,11.051061,127,COC(=O)C1=C(C)NC(C)=C(C1C)C(=O)OCCSc1ccccc1,BRD-A29289453,O=C(OCCSc1ccccc1)C1=CNC=CC1,BRD-A29289453,platelet activating factor receptor antagonist
3.5039117,9.49272,128,C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]2(O)CCC(O)=O,BRD-A29322418,O=C1C=C2C=CC3C4CCCC4CCC3C2CC1,BRD-A29322418,mineralocorticoid receptor antagonist
9.722761,9.6518135,129,CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1,BRD-A29426959,c1ccc(Cc2ccccn2)cc1,BRD-A29426959,histamine receptor antagonist
12.204405,5.317757,130,Nc1nc2n(C3OC(CO)C(O)C3O)c(=O)n(CC=C)c2c(=O)[nH]1,BRD-A29437505,O=c1[nH]cnc2c1[nH]c(=O)n2C1CCCO1,BRD-A29437505,tlr agonist
9.540463,7.4329667,131,CN1CC(c2ccccc2)c2cccc(N)c2C1,BRD-A29644307,c1ccc(C2CNCc3ccccc32)cc1,BRD-A29644307,dopamine uptake inhibitor
9.361811,9.551445,132,CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C,BRD-A29734509,c1ccc(Cc2ccccn2)cc1,BRD-A29734509,sodium channel blocker
9.765299,8.823795,133,O=C(NCCCN1CCCCCC1)C(C1CCCCC1)c1ccccc1,BRD-A30590053,O=C(NCCCN1CCCCCC1)C(c1ccccc1)C1CCCCC1,BRD-A30590053,acetylcholine release enhancer
7.0325727,9.406769,134,CC(=O)C(C#N)C(=O)Nc1cc(Br)ccc1Br,BRD-A30655177,c1ccccc1,BRD-A30655177,btk inhibitor
2.499509,9.715767,135,CC(=O)OCC(=O)[C@@]1(O)[C@@H](CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)OC(C)=O,BRD-A30717181,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-A30717181,glucocorticoid receptor agonist
8.590635,11.055019,136,CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(Cl)c1Cl)C(=O)OC,BRD-A30815329,C1=CC(c2ccccc2)C=CN1,BRD-A30815329,calcium channel blocker
12.129407,5.417946,137,COC1C(O)C(CO)OC1n1cnc2c(NC3CCCCC3)ncnc12,BRD-A31007383,c1nc(NC2CCCCC2)c2ncn(C3CCCO3)c2n1,BRD-A31007383,adenosine receptor agonist
9.061953,9.231171,138,CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1,BRD-A31159102,c1ccc(COc2ccccc2)cc1,BRD-A31159102,selective serotonin reuptake inhibitor (ssri)
6.0961056,7.4316416,139,COc1cc(Br)c(OC)c2CC(CN)c12,BRD-A31195449,c1ccc2c(c1)CC2,BRD-A31195449,serotonin receptor agonist
4.4973216,6.9553123,140,COc1ccccc1OCC(O)COC(N)=O,BRD-A31521121,c1ccccc1,BRD-A31521121,muscle relaxant
4.4173107,7.228086,141,Cn1cc(nc1-c1ccc(OCC(O)CNCCOc2ccc(O)c(c2)C(N)=O)cc1)C(F)(F)F,BRD-A31575449,c1ccc(OCCNCCCOc2ccc(-c3ncc[nH]3)cc2)cc1,BRD-A31575449,adrenergic receptor antagonist
9.825299,8.652296,142,OC(CCN1CCCC1)(C1CCCCC1)c1ccccc1,BRD-A31800922,c1ccc(C(CCN2CCCC2)C2CCCCC2)cc1,BRD-A31800922,acetylcholine receptor antagonist
5.493816,8.497477,143,CCN1CC2(COC(=O)c3ccccc3N3C(=O)CC(C)C3=O)CCC(OC)C34C5CC6C(OC)C5C(O)(CC6OC)C(O)(C(OC)C23)C14,BRD-A32164164,O=C(OCC12CCCC34C5CC6CCC(C5C6)C(CC13)C4NC2)c1ccccc1N1C(=O)CCC1=O,BRD-A32164164,acetylcholine receptor antagonist
5.867459,9.527428,144,CCOC(=O)[C@H](CCc1ccccc1)N[C@H](C)C(=O)N1C2CCCCC2C[C@H]1C(O)=O,BRD-A32505112,O=C(CNCCCc1ccccc1)N1CCC2CCCCC21,BRD-A32505112,angiotensin converting enzyme inhibitor
5.4137597,8.672767,145,CC(=O)OC1CN2CCC1CC2,BRD-A32673558,C1CN2CCC1CC2,BRD-A32673558,acetylcholine receptor agonist
8.645637,10.88433,146,COC(=O)C1=C(C)N(CC#C)C(C)=C(C1c1cccc(c1)-n1oo1)C(=O)CCO,BRD-A32949107,C1=CC(c2cccc(-n3oo3)c2)C=CN1,BRD-A32949107,calcium channel blocker
7.5793104,11.040309,147,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1,BRD-A33168282,c1ccccc1,BRD-A33168282,adrenergic receptor antagonist
8.095879,5.183614,148,COC(=O)Nc1nc2ccc(cc2[nH]1)S(=O)c1ccccc1,BRD-A33447119,O=S(c1ccccc1)c1ccc2nc[nH]c2c1,BRD-A33447119,anthelmintic
10.033713,7.607721,149,CN1CCCC(CC2c3ccccc3Sc3ccccc23)C1,BRD-A33711280,c1ccc2c(c1)Sc1ccccc1C2CC1CCCNC1,BRD-A33711280,acetylcholine receptor antagonist
6.0013514,7.3725715,150,COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1,BRD-A34255068,O=C1CC(c2cccc(OC3CCCC3)c2)CN1,BRD-A34255068,phosphodiesterase inhibitor
9.809346,7.755178,151,CN1CCN(CC1)C(=O)OC1N(C(=O)c2nccnc12)c1ccc(Cl)cn1,BRD-A34309505,O=C(OC1c2nccnc2C(=O)N1c1ccccn1)N1CCNCC1,BRD-A34309505,benzodiazepine receptor agonist
3.9772048,6.799001,152,CC(C)(C)NCC(O)COc1cccc2[nH]c(=O)[nH]c12,BRD-A34706053,O=c1[nH]c2ccccc2[nH]1,BRD-A34706053,adrenergic receptor agonist
7.498736,7.2213125,153,CC1CC(CC(C)(C)C1)OC(=O)c1ccccc1O,BRD-A34751532,O=C(OC1CCCCC1)c1ccccc1,BRD-A34751532,hsp inducer
6.9009957,8.06448,154,CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O,BRD-A34788695,O=C1CC(=O)C2C(=O)C3C(=O)c4ccccc4CC3CC2C1,BRD-A34788695,bacterial 30s ribosomal subunit inhibitor
4.216305,9.511943,155,C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c2ccc(=O)oc2)[C@H](O)[C@H](O)[C@H]1O,BRD-A34806832,O=c1ccc(C2CCC3C2CCC2C4CCC(OC5CCCCO5)C=C4CCC23)co1,BRD-A34806832,atpase inhibitor
6.869686,6.3876076,156,Oc1cc(O)c2C(=O)CC(Oc2c1)c1ccc(O)c(O)c1,BRD-A35033682,O=C1CC(c2ccccc2)Oc2ccccc21,BRD-A35033682,cytochrome p450 inhibitor
12.028501,5.478687,157,CCNC(=O)C1OC(C(O)C1O)n1cnc2c(N)ncnc12,BRD-A35338386,c1ncc2ncn(C3CCCO3)c2n1,BRD-A35338386,adenosine receptor agonist
8.401151,9.858505,158,COC(=O)C(CCCNC(N)=N)NC(=O)CCCc1c([nH]c2c(F)cc(F)cc12)-c1ccccc1,BRD-A35511923,c1ccc(-c2cc3ccccc3[nH]2)cc1,BRD-A35511923,somatostatin receptor agonist
8.228408,7.6781015,159,Clc1ccc2NC(=O)CSC(c3ccccc3Cl)c2c1,BRD-A35623999,O=C1CSC(c2ccccc2)c2ccccc2N1,BRD-A35623999,mitochondrial na+/ca2+ exchanger antagonist|sodium/calcium exchange inhibitor
5.227867,6.4937997,160,CN1CCc2cccc-3c2C1Cc1ccc(O)c(O)c-31,BRD-A35931254,c1ccc2c(c1)CC1NCCc3cccc-2c31,BRD-A35931254,dopamine receptor agonist
4.1320715,8.882841,161,CC12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C1CCC2O,BRD-A36066264,O=C(Oc1ccc2c(c1)CCC1C2CCC2CCCC21)c1ccccc1,BRD-A36066264,estrogen receptor agonist
8.80274,9.434905,162,CC(Cc1ccccc1)(NC(=O)CN)c1ccccc1,BRD-A36074203,c1ccc(CCc2ccccc2)cc1,BRD-A36074203,glutamate receptor antagonist
8.849945,8.008158,163,O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1,BRD-A36217750,O=C1C(CCS(=O)c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,BRD-A36217750,uricosuric blocker
7.9015317,10.836995,164,CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1,BRD-A36267905,c1ccc(CCCNCCc2ccccc2)cc1,BRD-A36267905,adrenergic receptor agonist
8.875676,6.8410687,165,CN1C(=S)NC(Cc2c[nH]c3ccccc23)C1=O,BRD-A36318220,O=C1NC(=S)NC1Cc1c[nH]c2ccccc12,BRD-A36318220,ripk inhibitor
9.820055,8.618997,166,OC(CCN1CCCCC1)(C1C[C@H]2C[C@@H]1C=C2)c1ccccc1,BRD-A36471396,C1=CC2CC1CC2C(CCN1CCCCC1)c1ccccc1,BRD-A36471396,acetylcholine receptor antagonist
9.338621,8.664927,167,Clc1ccc(CC(=O)N2CCCCC2CN2CCCC2)cc1Cl,BRD-A37347161,O=C(Cc1ccccc1)N1CCCCC1CN1CCCC1,BRD-A37347161,opioid receptor agonist
4.6571155,11.356783,168,CC(C)[N+]1(C)[C@@H]2CC[C@@H]1C[C@H](C2)OC(=O)C(CO)c1ccccc1,BRD-A37432947,O=C(Cc1ccccc1)OC1CC2CCC(C1)[NH2+]2,BRD-A37432947,acetylcholine receptor antagonist
7.7652574,10.889436,169,CC(C)(C)NCC(O)c1ccccc1Cl,BRD-A37441042,c1ccccc1,BRD-A37441042,adrenergic receptor agonist
7.2988777,10.224165,170,CC(CN(C(C)=O)c1c(I)cc(I)c(N)c1I)C(O)=O,BRD-A37492983,c1ccccc1,BRD-A37492983,radiopaque medium
7.0263643,7.765544,171,CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1,BRD-A37704979,c1ccc(-c2nc(-c3ccccc3)c(-c3ccncc3)[nH]2)cc1,BRD-A37704979,p38 mapk inhibitor
9.519064,8.770119,172,CN(C(CN1CCCC1)c1cccc(OCC(O)=O)c1)C(=O)Cc1ccc(Cl)c(Cl)c1,BRD-A37776212,O=C(Cc1ccccc1)NC(CN1CCCC1)c1ccccc1,BRD-A37776212,opioid receptor agonist
8.310945,6.9427743,173,CCC1(Cc2ccccc2O1)c1ncc[nH]1,BRD-A38747044,c1ccc2c(c1)CC(c1ncc[nH]1)O2,BRD-A38747044,imidazoline receptor ligand
5.9074206,8.30648,174,CC(C)C1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O,BRD-A38898897,O=C1CC2C(CCN2C(=O)C=CCN2CCCCC2)N1,BRD-A38898897,leukocyte elastase inhibitor
7.2949576,8.767474,175,CC(C)C(N1C(=S)S\C(=C/c2ccc(Br)cc2)C1=O)C(O)=O,BRD-A38913120,O=C1NC(=S)SC1=Cc1ccccc1,BRD-A38913120,bcl inhibitor
4.659126,7.1388206,176,NC(=O)OCC(O)COc1ccc(Cl)cc1,BRD-A39230911,c1ccccc1,BRD-A39230911,muscle relaxant
6.220345,11.06117,177,CCCCC1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1,BRD-A39255369,O=C1c2ccccc2CC1C1CCCC1,BRD-A39255369,chloride channel blocker
8.960674,7.8408947,178,Clc1ccc(cn1)C1CC2CCC1N2,BRD-A39268308,c1cncc(C2CC3CCC2N3)c1,BRD-A39268308,acetylcholine receptor agonist
6.050046,11.292637,179,CCCCCCCCC=CCCCCCCCC(=O)NC(CO)Cc1ccc(O)cc1,BRD-A39522003,c1ccccc1,BRD-A39522003,faah inhibitor|faah reuptake inhibitor
4.138249,8.903142,180,CCCCC(=O)O[C@H]1CCC2C3CCc4cc(O)ccc4C3CC[C@]12C,BRD-A39747742,c1ccc2c(c1)CCC1C2CCC2CCCC21,BRD-A39747742,estrogen receptor agonist
3.5052087,9.4365015,181,COC(=O)C1CC2=CC(=O)CCC2(C)C23OC2CC2(C)C(CCC22CCC(=O)O2)C13,BRD-A39969961,O=C1C=C2CCC3C4CCC5(CCC(=O)O5)C4CC4OC43C2CC1,BRD-A39969961,cytochrome p450 inhibitor
4.288991,9.609546,182,CC(=O)OC1CC2(O)C3CCC4CC(CC[C@]4(C)C3CC[C@]2(C)C1C1=CC(=O)OC1)OC(C)=O,BRD-A40022950,O=C1C=C(C2CCC3C2CCC2C4CCCCC4CCC23)CO1,BRD-A40022950,atpase inhibitor
8.509149,9.0969305,183,OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1,BRD-A40639672,O=C(c1ccccc1)c1ccc2n1CCC2,BRD-A40639672,cyclooxygenase inhibitor
5.1727386,8.9654045,184,CC(=O)O[C@@H]1CC[C@@]2(C)C(CC[C@]3(C)C2CC=C2C4CC(C)(C)CC[C@@]4(CC[C@@]32C)C(O)=O)C1(C)C,BRD-A41112154,C1=C2C3CCCCC3CCC2C2CCC3CCCCC3C2C1,BRD-A41112154,g protein-coupled receptor agonist
6.362184,11.143568,185,COC(C)(C)CCCC(C)C\C=C\C(C)=C\C(O)=O,BRD-A41145729,,BRD-A41145729,retinoid receptor agonist
7.4003553,7.8097625,186,NS(=O)(=O)c1cc2c(NC(CC3CCCC3)NS2(=O)=O)cc1Cl,BRD-A41250306,O=S1(=O)NC(CC2CCCC2)Nc2ccccc21,BRD-A41250306,thiazide diuretic
6.3087444,11.174608,187,COC(C\C=C\C=C\CC\C=C/CC(C)\C=C/C(CC(O)=O)=C\C(O)=O)C(\C)=C/C=C(\C)C(O)=O,BRD-A41301928,,BRD-A41301928,"mitochondrial adp, atp translocase inhibitor"
4.3982124,7.1687646,188,CC(C)NCC(O)COc1ccc(NC(C)=O)cc1,BRD-A41304429,c1ccccc1,BRD-A41304429,adrenergic receptor antagonist
8.076887,7.8650756,189,CCC(C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl,BRD-A41451487,c1ccc(-c2nccc3ccccc23)cc1,BRD-A41451487,benzodiazepine receptor antagonist
6.7666044,9.334988,190,OC(CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1,BRD-A41519720,O=C1C(CCCc2ccccc2)C(c2ccccc2)N1c1ccccc1,BRD-A41519720,niemann-pick c1-like 1 protein antagonist
7.053473,7.4344764,191,COc1cc(ccc1-c1nc2ccncc2[nH]1)S(C)=O,BRD-A41722204,c1ccc(-c2nc3ccncc3[nH]2)cc1,BRD-A41722204,adenosine receptor antagonist
9.532993,5.8175135,192,Oc1ccc2CC3N(CC=C)CCC45C(Oc1c24)C(CCC35O)=NNC(=O)c1ccccc1,BRD-A41833852,O=C(NN=C1CCC2C3Cc4cccc5c4C2(CCN3)C1O5)c1ccccc1,BRD-A41833852,opioid receptor antagonist
6.4144363,6.1295543,193,OC[C@H]1OC([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccc(O)cc1,BRD-A41941932,O=c1cc(-c2ccccc2)oc2c(C3CCCCO3)cccc12,BRD-A41941932,antioxidant
3.976923,6.8048596,194,CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12,BRD-A42167015,O=C1CCc2ccccc2N1,BRD-A42167015,adrenergic receptor antagonist
6.28233,10.863815,195,CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC,BRD-A42335949,,BRD-A42335949,phosphatidylglycerophosphatase inhibitor
7.4108586,11.058548,196,CNCC(O)c1ccc(O)c(OC)c1,BRD-A42346008,c1ccccc1,BRD-A42346008,epinephrine metabolite
8.13085,7.655308,197,CC1(C)CC(=O)C(C2c3ccccc3OC3=C2C(=O)CC(C)(C)C3)C(=O)C1,BRD-A42553870,O=C1CCCC2=C1C(C1C(=O)CCCC1=O)c1ccccc1O2,BRD-A42553870,neuropeptide receptor antagonist
10.300626,8.415973,198,OC(=O)COCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1,BRD-A42571354,c1ccc(C(c2ccccc2)N2CCNCC2)cc1,BRD-A42571354,histamine receptor antagonist
7.4199142,10.185783,199,CCC(Cc1c(I)cc(I)c(N)c1I)C(O)=O,BRD-A42628519,c1ccccc1,BRD-A42628519,radiopaque medium
6.524639,8.240773,200,Cc1ncc(n1CC(O)CCl)[N+]([O-])=O,BRD-A42759514,c1c[nH]cn1,BRD-A42759514,antiprotozoal
6.748894,10.119744,201,CCCCCc1cc(O)c2C3C=C(CC[C@H]3C(C)(C)Oc2c1)C(O)=O,BRD-A42831637,C1=CC2c3ccccc3OCC2CC1,BRD-A42831637,anti-inflammatory|cannabinoid metabolite
5.4716654,8.839449,202,CC12C3CCC(O3)C1(C)C(=O)OC2=O,BRD-A43076080,O=C1OC(=O)C2C3CCC(O3)C12,BRD-A43076080,protein phosphatase inhibitor
5.895953,8.760749,203,COC1=CC(=O)OC1(O)C(C)=C,BRD-A43150328,O=C1C=CCO1,BRD-A43150328,antibiotic
4.1648555,6.8757033,204,CC(C)NCC(O)COc1ccccc1OCC=C,BRD-A43671941,c1ccccc1,BRD-A43671941,adrenergic receptor antagonist
5.592296,8.479591,205,CCN1C[C@]2(C)CC[C@H](O)[C@@]34[C@@H]5C[C@H]6C(O)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@H](C[C@H]23)C14,BRD-A43849199,C1CC2CNC3C4CC2C3(C1)C1CC2CCC4C1C2,BRD-A43849199,phytotoxin
8.579423,9.260183,206,Cc1ccccc1N1CCN(CC1)S(=O)(=O)CC12CCC(C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C,BRD-A43930669,O=S(=O)(CC12CCC(CC1)C2)N1CCN(c2ccccc2)CC1,BRD-A43930669,oxytocin receptor antagonist
5.4972253,6.7314243,207,COc1cc2CCN3Cc4c(CC3c2cc1OC)ccc(OC)c4OC,BRD-A43940795,c1ccc2c(c1)CC1c3ccccc3CCN1C2,BRD-A43940795,serotonin release inhibitor
9.120635,9.065321,208,CCOc1ccccc1OC(C1CNCCO1)c1ccccc1,BRD-A43974499,c1ccc(OC(c2ccccc2)C2CNCCO2)cc1,BRD-A43974499,adrenergic receptor antagonist
9.704159,9.639623,209,CN(C)CCOC(C)(c1ccccc1)c1ccccn1,BRD-A44008656,c1ccc(Cc2ccccn2)cc1,BRD-A44008656,histamine receptor antagonist
7.6235557,10.18246,210,CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O,BRD-A44090213,O=C1c2ccccc2CN1c1ccccc1,BRD-A44090213,cyclooxygenase inhibitor
9.717199,10.861245,211,CN1C(=O)COc2c1cc(Cl)cc2C(=O)NC1CN2CCC1CC2,BRD-A44133049,O=C1COc2c(cccc2C(=O)NC2CN3CCC2CC3)N1,BRD-A44133049,serotonin receptor antagonist
6.0310946,8.854872,212,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,BRD-A44448661,O=C1CC(=O)NC(=O)N1,BRD-A44448661,barbiturate antiepileptic
7.098065,9.202765,213,CC(=O)C(C#N)C(=O)Nc1ccc(OC(F)(F)F)cc1,BRD-A44551378,c1ccccc1,BRD-A44551378,egfr inhibitor
8.0840025,9.743116,214,CCCN(CCC)C(=O)C(CCC(O)=O)NC(=O)c1ccccc1,BRD-A44863528,c1ccccc1,BRD-A44863528,cck receptor antagonist
5.2667646,6.554328,215,COc1cc-2c(CC3N(C)CCc4cc(O)c(OC)c-2c34)cc1O,BRD-A44966919,c1ccc2c(c1)CC1NCCc3cccc-2c31,BRD-A44966919,acetylcholine receptor antagonist
6.8792763,8.202735,216,CN(C)[C@H]1[C@@H]2[C@@H](O)C3C(C(=O)c4c(O)ccc(Cl)c4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O,BRD-A45140972,C=C1c2ccccc2C(=O)C2C(=O)C3C(=O)CC(=O)CC3CC12,BRD-A45140972,bacterial 50s ribosomal subunit inhibitor
8.364706,9.177116,217,NC(Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O,BRD-A45499626,O=c1cc[nH]c(=O)n1Cc1ccccc1,BRD-A45499626,glutamate receptor antagonist
7.055611,9.931145,218,CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I,BRD-A45543382,O=C(NC1CCCOC1)c1ccccc1,BRD-A45543382,radiopaque medium
9.1144905,8.551577,219,C[N+]12CCC(CC1)C(C2)OC(=O)C(O)(c1ccccc1)c1ccccc1,BRD-A46066006,O=C(OC1C[NH+]2CCC1CC2)C(c1ccccc1)c1ccccc1,BRD-A46066006,muscarinic antagonist
5.322744,8.762959,220,C[C@]12CCC(=O)C(C)(C)C1C[C@@H](O)[C@]1(C)C2CC[C@@]2(C)[C@@H](OC(=O)C=C12)c1ccoc1,BRD-A47144777,O=C1CCC2C(CCC3C4=CC(=O)OC(c5ccoc5)C4CCC32)C1,BRD-A47144777,hsp90 inhibitor
7.459831,11.0845785,221,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1,BRD-A47494775,c1ccccc1,BRD-A47494775,adrenergic receptor agonist
6.9051332,8.73822,222,COC[C@H]([C@@H](O)[C@@H](O)C(=O)NCC[C@@H](C)c1nc(\C=C\C[C@H]2OC3(C[C@H](O)[C@H]2C)OC([C@@H](C[C@@H](O)[C@@H](C)[C@@H](O)[C@@H](C)\C=C(C)\C(C)=C\C=C\C(C)=C/C#N)OC)[C@@H](OP(O)(O)=O)C3(C)C)co1)N(C)C,BRD-A47513740,C(=Cc1cocn1)CC1CCCC2(CCCO2)O1,BRD-A47513740,protein phosphatase inhibitor
10.881573,7.788219,223,CN(C)CCCC1(OCc2cc(ccc12)C#N)c1ccc(F)cc1,BRD-A47598013,c1ccc(C2OCc3ccccc32)cc1,BRD-A47598013,selective serotonin reuptake inhibitor (ssri)
8.053499,10.283338,224,CC(C)CC(NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O,BRD-A47633927,c1ccc2c(c1)Cc1ccccc1-2,BRD-A47633927,icam1 antagonist
8.416207,7.8862987,225,ON=C1C2CC2(Oc2ccccc12)C(=O)Nc1ccccc1,BRD-A48257147,N=C1c2ccccc2OC2(C(=O)Nc3ccccc3)CC12,BRD-A48257147,glutamate receptor agonist
8.537857,8.362781,226,CC[C@H]1C2CC3[C@@H]4N(C)c5ccccc5[C@]44C[C@@H](C2C4O)N3[C@@H]1O,BRD-A48300215,c1ccc2c(c1)NC1C3CC4CCN3C3CC21CC43,BRD-A48300215,sodium channel blocker
12.059278,5.4679585,227,CNC(=O)[C@H]1O[C@H](C(O)[C@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12,BRD-A48809242,c1ccc(CNc2ncnc3c2ncn3C2CCCO2)cc1,BRD-A48809242,adenosine receptor agonist
8.993982,8.752657,228,OC(=O)C1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1,BRD-A49046702,C(CCN1CCCCC1)=C(c1ccccc1)c1ccccc1,BRD-A49046702,gaba uptake inhibitor
7.93026,7.1654463,229,Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,BRD-A49172652,O=S(Cc1ccccn1)c1nc2ccccc2[nH]1,BRD-A49172652,atpase inhibitor
10.926394,7.7146087,230,CC(CN(C)C)CN1c2ccccc2Sc2ccccc12,BRD-A49225603,c1ccc2c(c1)Nc1ccccc1S2,BRD-A49225603,histamine receptor agonist
7.166601,9.66352,231,CC(C)(Oc1ccc(cc1)C1CC1(Cl)Cl)C(O)=O,BRD-A49358627,c1ccc(C2CC2)cc1,BRD-A49358627,ppar receptor agonist
8.276138,8.611914,232,CC(N)Cn1ccc2cc(F)c(Cl)cc12,BRD-A49370193,c1ccc2[nH]ccc2c1,BRD-A49370193,serotonin receptor agonist
6.4598656,8.48988,233,CC(C)(O)\C=C\C(=O)[C@](C)(O)C1[C@H](O)C[C@@]2(C)[C@@H]3CC=C4C(CC(=O)C(=O)C4(C)C)[C@]3(C)C(=O)C[C@@]12C,BRD-A49680073,O=C1CC2=CCC3C4CCCC4CC(=O)C3C2CC1=O,BRD-A49680073,jak inhibitor|lipocortin synthesis stimulant|stat inhibitor
4.4966626,6.87724,234,COc1cc(=O)n(C)c2c(OCC(O)C(C)(C)O)cccc12,BRD-A49734948,O=c1ccc2ccccc2[nH]1,BRD-A49734948,plant alkaloid
4.6398897,11.382853,235,C[N+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1,BRD-A49906757,O=C(Cc1ccccc1)OC1CC2[NH2+]C(C1)C1OC21,BRD-A49906757,acetylcholine receptor antagonist
7.4362054,11.093852,236,CC(C)(C)NCC(O)c1cc(O)cc(O)c1,BRD-A50157456,c1ccccc1,BRD-A50157456,adrenergic receptor agonist
10.193093,8.259717,237,Cc1cccc(CN2CCN(CC2)C(c2ccccc2)c2ccc(Cl)cc2)c1,BRD-A50311610,c1ccc(CN2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1,BRD-A50311610,car agonist
7.595708,8.140274,238,Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)S(=O)C(F)(F)F,BRD-A50675702,c1ccc(-n2cccn2)cc1,BRD-A50675702,chloride channel blocker|gaba gated chloride channel blocker
10.273725,6.8595076,239,Oc1ccc(cc1)C1CNCCc2c(Cl)c(O)c(O)cc12,BRD-A50684349,c1ccc(C2CNCCc3ccccc32)cc1,BRD-A50684349,dopamine receptor agonist
7.7225413,9.573567,240,[O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F,BRD-A50737080,O=C(NCNC(=S)Nc1ccccc1)C(c1ccccc1)c1ccccc1,BRD-A50737080,atr kinase inhibitor
9.61263,7.769054,241,O=C1CC2(CCCC2)CC(=O)N1CCNCC1COc2ccccc2O1,BRD-A50764878,O=C1CC2(CCCC2)CC(=O)N1CCNCC1COc2ccccc2O1,BRD-A50764878,serotonin receptor antagonist
8.925561,5.900038,242,COC(=O)C1C(O)CCC2CN3CCc4c([nH]c5ccccc45)C3CC12,BRD-A51410489,c1ccc2c3c([nH]c2c1)C1CC2CCCCC2CN1CC3,BRD-A51410489,adrenergic receptor antagonist
7.306473,6.1842422,243,COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1,BRD-A51714012,c1ccc(CC2CCCCC2)cc1,BRD-A51714012,adrenergic inhibitor
8.9942045,8.54257,244,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,BRD-A51820102,c1ccc(COC(Cn2ccnc2)c2ccccc2)cc1,BRD-A51820102,bacterial cell wall synthesis inhibitor
9.95561,8.33423,245,OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1,BRD-A51829654,c1ccc(C(CCN2CCN(c3ccccc3)CC2)c2ccccc2)cc1,BRD-A51829654,serotonin receptor antagonist
10.096699,7.0640173,246,CN1CCc2cc(Br)c(O)cc2C(C1)c1ccccc1,BRD-A52588987,c1ccc(C2CNCCc3ccccc32)cc1,BRD-A52588987,dopamine receptor antagonist
8.504573,7.5075245,247,C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1,BRD-A52660433,c1cc2c(cc1C1CCCCC1)c1c3n2CCNC3CCC1,BRD-A52660433,monoamine oxidase inhibitor
6.0734434,7.267233,248,COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC,BRD-A52922642,c1ccc(CCCCNCCc2ccccc2)cc1,BRD-A52922642,l-type calcium channel blocker
6.7692604,10.87482,249,CN1c2ccccc2C(NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O,BRD-A53077924,O=S1(=O)Nc2ccccc2Cc2ccccc21,BRD-A53077924,selective serotonin reuptake enhancer (ssre)
5.9453197,11.202873,250,CCCCCCCCCCCCCC=CC(O)C(CO)NC(C)=O,BRD-A53416814,,BRD-A53416814,nitric oxide production inhibitor|phosphoenolpyruvate carboxylase activator|serine/threonine protein phosphatase activator
9.678067,9.622268,251,CN(C)CCOC(c1ccccc1)c1ccccc1C,BRD-A53576514,c1ccc(Cc2ccccc2)cc1,BRD-A53576514,acetylcholine receptor antagonist
8.629956,10.39815,252,CCCNC(C)C(=O)Nc1ccccc1C,BRD-A53952395,c1ccccc1,BRD-A53952395,local anesthetic
8.947999,6.6629305,253,CN(C(Cc1ccc(cc1)-c1ccccc1)C(=O)NC(Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1,BRD-A54029483,O=C(NC(Cc1ccc(-c2ccccc2)cc1)C(=O)NCCc1c[nH]c2ccccc12)c1ccccc1,BRD-A54029483,endothelin receptor antagonist
8.1117325,10.545768,254,CNC(C)C(O)c1ccccc1,BRD-A54236247,c1ccccc1,BRD-A54236247,adrenergic receptor agonist
8.301157,7.4329395,255,Cc1ccc2n3CCNC4CCCc(c34)c2c1,BRD-A54490543,c1ccc2c(c1)c1c3n2CCNC3CCC1,BRD-A54490543,monoamine oxidase inhibitor
9.841065,12.424101,256,CN1CC(CC2C1Cc1c[nH]c3cccc2c13)C(=O)NC1(C)OC2(O)C3CCCN3C(=O)C(Cc3ccccc3)N2C1=O,BRD-A54845972,O=C(NC1OC2C3CCCN3C(=O)C(Cc3ccccc3)N2C1=O)C1CNC2Cc3c[nH]c4cccc(c34)C2C1,BRD-A54845972,serotonin receptor agonist|adrenergic receptor partial agonist|dopamine receptor agonist
7.0229945,6.352931,257,COc1ccc(C2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1,BRD-A54927599,O=c1occcc1C1=NCCSC(c2ccccc2)C1,BRD-A54927599,p-selectin inhibitor
10.354649,11.012005,258,CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O,BRD-A55272860,O=C(NCC1CCCN1)c1ccccc1,BRD-A55272860,dopamine receptor antagonist
7.804125,10.986077,259,CC(NCC(O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1,BRD-A55369275,O=[PH](CCCNCc1ccccc1)CC1CCCCC1,BRD-A55369275,gaba receptor antagonist
3.5945928,9.389707,260,C[C@]12CCC3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@@H]2O,BRD-A55393291,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-A55393291,androgen receptor agonist
7.93209,9.646053,261,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O,BRD-A55424491,c1ccc(NCc2cnc3ncncc3n2)cc1,BRD-A55424491,dihydrofolate reductase inhibitor
9.767517,6.5816913,262,CC1CNCCN1S(=O)(=O)c1cccc2cnccc12,BRD-A55756846,O=S(=O)(c1cccc2cnccc12)N1CCNCC1,BRD-A55756846,pka inhibitor
7.4799623,6.4522376,263,COc1cc(NC(C)CCCN)c2ncccc2c1,BRD-A55913614,c1ccc2ncccc2c1,BRD-A55913614,antimalarial|dna inhibitor
5.591869,9.05709,264,CCCNC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](C(C)CC)C(=O)N1CCC[C@H]1C(=O)OC,BRD-A56020723,O=C(NCC(=O)N1CCCC1)C1CO1,BRD-A56020723,cathepsin inhibitor|antiamyloidogenic
7.394178,7.834746,265,NS(=O)(=O)c1cc2c(NC(CSCC=C)NS2(=O)=O)cc1Cl,BRD-A56675431,O=S1(=O)NCNc2ccccc21,BRD-A56675431,thiazide diuretic
11.879205,5.5685472,266,Nc1ncnc2n(cnc12)C1CCCO1,BRD-A56987319,c1ncc2ncn(C3CCCO3)c2n1,BRD-A56987319,adenylyl cyclase inhibitor
10.05946,8.1546755,267,CN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1,BRD-A57133233,c1ccc(C(c2ccccc2)N2CCNCC2)cc1,BRD-A57133233,histamine receptor antagonist
9.212834,9.056574,268,CN1C(C(=O)Nc2ccccn2)C(=O)c2ccccc2S1(=O)=O,BRD-A57382968,O=C(Nc1ccccn1)C1NS(=O)(=O)c2ccccc2C1=O,BRD-A57382968,cyclooxygenase inhibitor
8.598743,11.103618,269,COCCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C,BRD-A58048407,C1=CC(c2ccccc2)C=CN1,BRD-A58048407,calcium channel blocker
9.851389,9.004644,270,CN1C(CC(O)c2ccccc2)CCCC1CC(O)c1ccccc1,BRD-A59215453,c1ccc(CCC2CCCC(CCc3ccccc3)N2)cc1,BRD-A59215453,acetylcholine receptor antagonist
7.4249244,7.800779,271,CCC1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O,BRD-A59303141,O=C1NCNc2ccccc21,BRD-A59303141,thiazide diuretic
10.3568,10.996464,272,CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC,BRD-A60197193,O=C(NCC1CCCN1)c1ccccc1,BRD-A60197193,dopamine receptor antagonist
7.036614,9.363325,273,Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1,BRD-A61154809,O=C(NN1CC2CCCC2C1)NS(=O)(=O)c1ccccc1,BRD-A61154809,atp channel blocker|insulin secretagogue
9.351937,9.673075,274,OC(CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1,BRD-A61392169,c1ccc(CCN2CCC(Cc3ccccc3)CC2)cc1,BRD-A61392169,glutamate receptor antagonist
7.0360208,10.421321,275,CSCCC(NC=O)C(=O)NC(C)C(O)=O,BRD-A61470182,,BRD-A61470182,macrophage activator
7.726266,7.8286324,276,CC1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O,BRD-A61793559,O=C1c2ccccc2NCN1c1ccccc1,BRD-A61793559,carbonic anhydrase inhibitor
8.169924,9.018655,277,OC[C@H]1O[C@@H](Oc2ccccc2COC(=O)C2(O)C=CCCC2=O)[C@H](OC(=O)c2ccccc2)[C@@H](O)[C@@H]1O,BRD-A61856038,O=C(OC1CCCOC1Oc1ccccc1COC(=O)C1C=CCCC1=O)c1ccccc1,BRD-A61856038,lipoxygenase inhibitor
6.9134936,8.171708,278,Clc1cc2NC(=O)C3CNCCN3c2cc1Cl,BRD-A62021152,O=C1Nc2ccccc2N2CCNCC12,BRD-A62021152,serotonin receptor agonist
10.0095825,8.924581,279,OC(C1CCN(CCc2ccccc2)CC1)c1ccccc1,BRD-A62057054,c1ccc(CCN2CCC(Cc3ccccc3)CC2)cc1,BRD-A62057054,serotonin receptor antagonist
10.316413,8.359659,280,OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1,BRD-A62428732,c1ccc(C(c2ccccc2)N2CCNCC2)cc1,BRD-A62428732,antihistamine
6.2736936,8.48252,281,CCc1cn(C2OCC(O)C2CO)c(=O)nc1O,BRD-A62505706,O=c1ncccn1C1CCCO1,BRD-A62505706,dna polymerase inhibitor
3.004418,9.566651,282,C[C@]12CC(=O)C3C(CCC4=CC(=O)C=C[C@]34C)C1CC[C@]2(O)C(=O)CO,BRD-A62525898,O=C1C=CC2C(=C1)CCC1C3CCCC3CC(=O)C21,BRD-A62525898,glucocorticoid receptor agonist
9.511147,8.154165,283,CC1CN(CCCn2c3ccccc3c3ccccc23)CC(C)N1,BRD-A63346720,c1ccc2c(c1)c1ccccc1n2CCCN1CCNCC1,BRD-A63346720,sigma receptor antagonist|dopamine reuptake inhibitor
5.4822984,6.739241,284,COc1cc2CCN(C)C(CCc3ccc(Cl)cc3)c2cc1O,BRD-A63546914,c1ccc(CCC2NCCc3ccccc32)cc1,BRD-A63546914,glutamate receptor antagonist
9.815049,12.40613,285,CCC(CO)NC(=O)C1CN(C)C2Cc3c[nH]c4cccc(C2=C1)c34,BRD-A63667919,C1=C2c3cccc4[nH]cc(c34)CC2NCC1,BRD-A63667919,dopamine receptor antagonist|partial serotonin receptor agonist
8.128718,8.885323,286,CN(C)c1ccc(Cn2cnc3CN(C(Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C,BRD-A63836183,O=C(C(c1ccccc1)c1ccccc1)N1CCc2c(ncn2Cc2ccccc2)C1,BRD-A63836183,angiotensin receptor antagonist
2.484858,9.724797,287,CCC(=O)OC1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl,BRD-A63894585,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-A63894585,glucocorticoid receptor agonist
8.096346,8.637614,288,CC(N)COc1c(C)cccc1C,BRD-A64092382,c1ccccc1,BRD-A64092382,sodium channel blocker
5.239628,9.210271,289,C[C@H](CCC(O)=O)[C@H]1CCC2C3C(CC(=O)[C@]12C)[C@@]1(C)CCC(=O)CC1CC3=O,BRD-A64125466,O=C1CCC2C(C1)CC(=O)C1C3CCCC3C(=O)CC21,BRD-A64125466,choleretic
10.25609,6.9215646,290,Oc1cc2CCN(CC=C)CC(c3ccccc3)c2cc1O,BRD-A64227845,c1ccc(C2CNCCc3ccccc32)cc1,BRD-A64227845,dopamine receptor agonist
5.696606,8.705222,291,CC1C(=O)[C@H]2O[C@H]2C(=O)C1=O,BRD-A64228451,O=C1CC(=O)C2OC2C1=O,BRD-A64228451,btk inhibitor
5.508602,8.429773,292,OC[C@H]1OC(C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F,BRD-A64485570,O=c1ccn(C2CCCO2)c(=O)[nH]1,BRD-A64485570,dna polymerase inhibitor|thymidylate synthase inhibitor
12.151091,5.370882,293,Nc1nc(Nc2ccccc2)nc2n(cnc12)C1OC(CO)C(O)C1O,BRD-A64933752,c1ccc(Nc2ncc3ncn(C4CCCO4)c3n2)cc1,BRD-A64933752,adenosine receptor agonist
9.698581,7.77788,294,CN1CCN2C(C1)c1ccccc1Cc1cccnc21,BRD-A64977602,c1ccc2c(c1)Cc1cccnc1N1CCNCC21,BRD-A64977602,adrenergic receptor antagonist
9.631641,9.277858,295,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c1ccccc1,BRD-A65013509,c1ccc(CC2CCCCC2)cc1,BRD-A65013509,acetylcholine receptor antagonist
7.840659,8.724707,296,CC(=O)CC(c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O,BRD-A65051990,O=c1oc2ccccc2cc1Cc1ccccc1,BRD-A65051990,vitamin k antagonist
9.818647,12.402541,297,CC(C)[C@@]1(NC(=O)[C@@H]2CC3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,BRD-A65076780,O=C(NC1OC2C3CCCN3C(=O)C(Cc3ccccc3)N2C1=O)C1CNC2Cc3c[nH]c4cccc(c34)C2C1,BRD-A65076780,adrenergic receptor antagonist|prolactin inhibitor
7.4277887,10.084547,298,CC(C)(C)c1onc(O)c1CC(N)C(O)=O,BRD-A65145453,c1cnoc1,BRD-A65145453,glutamate receptor agonist
5.7122607,8.768927,299,CCc1c(C)[nH]c2CCC(CN3CCOCC3)C(=O)c12,BRD-A65280694,O=C1c2cc[nH]c2CCC1CN1CCOCC1,BRD-A65280694,dopamine receptor antagonist
7.5235643,11.113227,300,CC(C)NCC(O)c1ccc(N)c(c1)C#N,BRD-A65440446,c1ccccc1,BRD-A65440446,adrenergic receptor agonist
8.296621,6.687976,301,COC1(COc2ccccc2O1)C1=NCCN1,BRD-A65597028,c1ccc2c(c1)OCC(C1=NCCN1)O2,BRD-A65597028,adrenergic receptor antagonist
9.96283,10.718947,302,COc1cc(N)c(Cl)cc1C(=O)NC1CN2CCC1CC2,BRD-A65615053,O=C(NC1CN2CCC1CC2)c1ccccc1,BRD-A65615053,serotonin receptor antagonist
8.45627,8.633662,303,CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,BRD-A65671304,O=C(OCOC(=O)c1cccc2ncn(Cc3ccc(-c4ccccc4-c4nnn[nH]4)cc3)c12)OC1CCCCC1,BRD-A65671304,angiotensin receptor antagonist
12.16241,8.748853,304,CC(Oc1ccccc1)C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O,BRD-A66025870,O=C(COc1ccccc1)NC1C(=O)N2CCSC12,BRD-A66025870,bacterial cell wall synthesis inhibitor
5.0717993,8.991764,305,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)C5CC[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]1O[C@H](COC2O[C@H](CO)[C@@H](OC3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,BRD-A66199457,O=C(OC1CCCC(COC2CCC(OC3CCCCO3)CO2)O1)C12CCCCC1C1=CCC3C4CCCCC4CCC3C1CC2,BRD-A66199457,antineoplastic
7.242198,9.3245735,306,CC(CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1c[nH]cn1,BRD-A66435872,O=C(CCCCCNCCc1c[nH]cn1)Nc1ccccc1,BRD-A66435872,histamine receptor agonist
7.8824806,8.801889,307,CC(c1cnc[nH]1)c1cccc(C)c1C,BRD-A66563878,c1ccc(Cc2cnc[nH]2)cc1,BRD-A66563878,adrenergic receptor agonist
9.9182,10.572412,308,CNc1cc(OC)c(cc1Cl)C(=O)NC1CCN(Cc2ccccc2)C1C,BRD-A66927094,O=C(NC1CCN(Cc2ccccc2)C1)c1ccccc1,BRD-A66927094,dopamine receptor antagonist
4.287722,9.560981,309,CC1OC(O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)C(O)C(O)C1O,BRD-A67552019,O=C1C=C(C2CCC3C2CCC2C4CCC(OC5CCCCO5)CC4CCC23)CO1,BRD-A67552019,atpase inhibitor
9.732336,10.132821,310,CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12,BRD-A67862938,c1ccc2c(CCCC3CCCO3)cccc2c1,BRD-A67862938,adrenergic receptor antagonist
7.0805306,6.3875437,311,COc1ccc(cc1)C1CC(=O)c2ccc(OC)cc2O1,BRD-A68039575,O=C1CC(c2ccccc2)Oc2ccccc21,BRD-A68039575,aromatase inhibitor
7.6942697,10.9135275,312,CCCCCC(O)c1cccc(OCc2ccc3ccccc3n2)c1,BRD-A68281735,c1ccc(OCc2ccc3ccccc3n2)cc1,BRD-A68281735,leukotriene receptor antagonist
9.703932,9.647362,313,CN(C)CCC(c1ccc(Br)cc1)c1ccccn1,BRD-A68723818,c1ccc(Cc2ccccn2)cc1,BRD-A68723818,histamine receptor antagonist
10.061266,8.214433,314,CN1CCCC(CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O,BRD-A68888262,O=c1c2ccccc2c(Cc2ccccc2)nn1C1CCCNCC1,BRD-A68888262,histamine receptor antagonist
8.385654,9.888178,315,CC(NC(=O)Cc1cc(F)cc(F)c1)C(=O)NC(C(=O)OC(C)(C)C)c1ccccc1,BRD-A68929948,O=C(CNC(=O)Cc1ccccc1)NCc1ccccc1,BRD-A68929948,antiamyloidogenic|gamma secretase inhibitor
10.947914,7.706597,316,COc1ccc(cc1)C1Sc2ccccc2N(CCN(C)C)C(=O)C1OC(C)=O,BRD-A69636825,O=C1CC(c2ccccc2)Sc2ccccc2N1,BRD-A69636825,calcium channel blocker
4.799869,8.182678,317,CC1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O,BRD-A69777949,O=c1ccn2c3c(cccc13)CCC2,BRD-A69777949,topoisomerase inhibitor
4.873843,11.26937,318,CC1C(CCC(C)(C)N1C)OC(=O)C(O)c1ccccc1,BRD-A69786436,O=C(Cc1ccccc1)OC1CCCNC1,BRD-A69786436,acetylcholine receptor antagonist
6.52087,8.305598,319,CC(O)Cn1c(C)ncc1[N+]([O-])=O,BRD-A70083328,c1c[nH]cn1,BRD-A70083328,acetylcholinesterase inhibitor
4.7406864,11.241055,320,CC(C(=O)OC1CC2CCC(C1)N2C)c1ccc(Br)cc1,BRD-A70268693,O=C(Cc1ccccc1)OC1CC2CCC(C1)N2,BRD-A70268693,acetylcholine receptor agonist
5.6363955,9.149061,321,CCCCn1c(=O)n(CCCO)c2nc([nH]c2c1=O)C12CC3CC1CC(C2)C3,BRD-A70407468,O=c1[nH]c(=O)c2[nH]c(C34CC5CC(CC3C5)C4)nc2[nH]1,BRD-A70407468,adenosine receptor antagonist
8.68275,10.473274,322,CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,BRD-A70514680,c1ccsc1,BRD-A70514680,local anesthetic
8.946063,8.55589,323,Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,BRD-A70649075,c1ccc(CSC(Cn2ccnc2)c2ccccc2)cc1,BRD-A70649075,sterol demethylase inhibitor
6.2854204,8.096354,324,C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSCC1CCCO1,BRD-A71157293,C(=CSSCC1CCCO1)NCc1cncnc1,BRD-A71157293,vitamin b
5.317103,6.5756845,325,COc1cc2CCN3Cc4c(CC3c2cc1O)ccc(O)c4OC,BRD-A71203467,c1ccc2c(c1)CC1c3ccccc3CCN1C2,BRD-A71203467,dopamine receptor antagonist
7.946546,8.931364,326,FC(C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl,BRD-A71774530,O=C(NC(=O)c1ccccc1)Nc1ccccc1,BRD-A71774530,chitin inhibitor
5.669563,9.980269,327,CCC(C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)C12,BRD-A71816415,C1=CC2=CCCCC2CC1,BRD-A71816415,hmgcr inhibitor
7.2968836,9.8306465,328,COP(=O)(OC)OC(c1ccc(Cl)cc1)P(=O)(OC)OC,BRD-A72066420,c1ccccc1,BRD-A72066420,ppar receptor antagonist
10.741512,9.025417,329,O=C1NCN(c2ccccc2)C11CCN(CC2COc3ccccc3O2)CC1,BRD-A72483914,O=C1NCN(c2ccccc2)C12CCN(CC1COc3ccccc3O1)CC2,BRD-A72483914,serotonin receptor antagonist
7.721873,9.426241,330,CCOC(=O)NCC(Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)NC(C)=CC(=O)c1ccc(cc1)C(F)(F)F,BRD-A72596465,O=C(C=CNCCc1ccc(OCCc2coc(-c3ccccc3)n2)cc1)c1ccccc1,BRD-A72596465,ppar receptor antagonist
9.120737,8.601941,331,COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1,BRD-A72703248,c1ccc(CCCOC(Cn2ccnc2)c2ccccc2)cc1,BRD-A72703248,calcium channel blocker|cytochrome p450 inhibitor
6.975197,9.90415,332,CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O,BRD-A72711497,O=C(CCCCCc1ccccc1)CC1CCC(C2CCCCO2)O1,BRD-A72711497,bacterial permeability inducer
7.76312,10.087908,333,CC(C(O)=O)c1ccc(s1)C(=O)c1ccccc1,BRD-A72988804,O=C(c1ccccc1)c1cccs1,BRD-A72988804,cyclooxygenase inhibitor
9.911812,8.793198,334,CC(C)(C(O)=O)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1,BRD-A73368467,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1,BRD-A73368467,histamine receptor antagonist
4.946627,9.522685,335,CC(CCC(=O)NCC(O)=O)C1CCC2C3CCC4CC(O)CCC4(C)C3CC(O)C12C,BRD-A73859745,C1CCC2C(C1)CCC1C3CCCC3CCC21,BRD-A73859745,apoptosis stimulant
8.445342,9.699873,336,CCc1cccc2c3CCOC(CC)(CC(O)=O)c3[nH]c12,BRD-A74667430,c1ccc2c3c([nH]c2c1)COCC3,BRD-A74667430,cyclooxygenase inhibitor
12.140696,5.3804817,337,OC[C@H]1O[C@H](C(O)[C@H]1O)n1cnc2cc(Cl)c(Cl)cc12,BRD-A74904029,c1ccc2c(c1)ncn2C1CCCO1,BRD-A74904029,casein kinase inhibitor
4.7916374,8.186133,338,COc1c(N2CCNC(C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1,BRD-A74980173,O=c1ccn(C2CC2)c2cc(N3CCNCC3)ccc12,BRD-A74980173,bacterial dna gyrase inhibitor
8.27822,7.665579,339,COC1=CC(=O)OC(C1)\C=C\c1ccccc1,BRD-A75455249,O=C1C=CCC(C=Cc2ccccc2)O1,BRD-A75455249,calcium channel modulator|mtor inhibitor|sodium channel blocker
7.4037795,8.804601,340,CC(C)C(NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O,BRD-A75478957,c1ccc(-c2ccccc2)cc1,BRD-A75478957,collagenase inhibitor|metalloproteinase inhibitor|stromelysin inhibitor
9.162118,9.117123,341,CN1C(C(=O)Nc2cc(C)on2)C(=O)c2ccccc2S1(=O)=O,BRD-A75552914,O=C(Nc1ccon1)C1NS(=O)(=O)c2ccccc2C1=O,BRD-A75552914,cyclooxygenase inhibitor
9.4830065,5.883575,342,CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(CC1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O,BRD-A75769826,c1cc2c3c(c1)OC1c4[nH]c5ccccc5c4CC4C(C2)NCCC314,BRD-A75769826,opioid receptor antagonist
8.762603,7.9890127,343,Cc1ccc2N=C3N(CCC3(O)C(=O)c2c1)c1ccccc1,BRD-A75817871,O=C1c2ccccc2N=C2C1CCN2c1ccccc1,BRD-A75817871,atpase inhibitor
4.7914934,8.175647,344,CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12,BRD-A75850590,O=c1cc[nH]c2cc(N3CCNCC3)ccc12,BRD-A75850590,bacterial dna gyrase inhibitor
4.9222927,5.3638277,345,CC1(C)Oc2ccc(cc2C(C1O)N1CCCC1=O)C#N,BRD-A76093993,O=C1CCCN1C1CCOc2ccccc21,BRD-A76093993,potassium channel activator
9.617709,9.936315,346,CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1,BRD-A77291778,c1ccc(CC2CCCC2)cc1,BRD-A77291778,acetylcholine receptor antagonist
8.227698,8.705538,347,ClC(Cl)(Cl)C(NC(=O)C=Cc1ccccc1)NC(=S)Nc1cccc2cccnc12,BRD-A77299732,O=C(C=Cc1ccccc1)NCNC(=S)Nc1cccc2cccnc12,BRD-A77299732,eukaryotic translation initiation factor inhibitor
6.0171375,10.928623,348,CCCCCCCCCCCCCCCC(=O)C1C(=O)OC(CO)C1=O,BRD-A77349281,O=C1COC(=O)C1,BRD-A77349281,heparanase inhibitor|tyrosine phosphatase inhibitor
7.5624876,6.065458,349,CC[C@H]1CN2CCC1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12,BRD-A78295502,c1ccc2c(CC3CC4CCN3CC4)ccnc2c1,BRD-A78295502,anti-arrhythmia
8.538689,11.048254,350,CCOC(=O)C1=C(C)NC(=S)NC1c1cccc(O)c1,BRD-A78377521,S=C1NC=CC(c2ccccc2)N1,BRD-A78377521,kinesin-like spindle protein inhibitor
9.669414,7.7603188,351,CN1CCOC(c2ccccc2)c2ccccc2C1,BRD-A78877355,c1ccc(C2OCCNCc3ccccc32)cc1,BRD-A78877355,cyclooxygenase inhibitor
4.154927,6.8041573,352,CC(C)NC(C)C(O)COc1ccc(C)c2CCCc12,BRD-A78942461,c1ccc2c(c1)CCC2,BRD-A78942461,adrenergic receptor antagonist
4.7187605,11.248433,353,CN1[C@H]2CC[C@@H]1CC(C2)OC(=O)C1C=Nc2ccccc12,BRD-A79226577,O=C(OC1CC2CCC(C1)N2)C1C=Nc2ccccc21,BRD-A79226577,serotonin receptor antagonist|polarization inhibitor|sodium channel blocker
8.80345,9.760971,354,CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1,BRD-A79672927,O=C(Cc1ccccc1)NCc1ccncc1,BRD-A79672927,acetylcholine receptor antagonist
7.3012867,6.1210637,355,COc1ccc(OC)c(c1)C(O)CNC(=O)CN,BRD-A79981887,c1ccccc1,BRD-A79981887,adrenergic receptor agonist
7.37342,7.89895,356,NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F,BRD-A80017228,O=S1(=O)NC(Cc2ccccc2)Nc2ccccc21,BRD-A80017228,sodium/potassium/chloride transporter inhibitor
9.153575,9.867053,357,CCN(CC)CCCC(C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1,BRD-A80213327,c1cnc2ccc(Nc3ccncn3)cc2c1,BRD-A80213327,ras gtpase inhibitor
2.4816985,9.726795,358,CCCCC(=O)O[C@@]1([C@@H](C)CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(O)C[C@]12C)C(=O)CO,BRD-A80594172,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-A80594172,glucocorticoid receptor agonist
8.07837,10.23534,359,CC(C)CC(NC(=O)N1CCCCCC1)C(=O)NC(Cc1cn(C)c2ccccc12)C(=O)NC(Cc1ccccn1)C(O)=O,BRD-A80641450,O=C(CNC(=O)N1CCCCCC1)NC(Cc1c[nH]c2ccccc12)C(=O)NCCc1ccccn1,BRD-A80641450,endothelin receptor antagonist
9.830422,6.510941,360,CN(C(Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12,BRD-A81177136,O=C(C(Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)NS(=O)(=O)c1cccc2cnccc12)N1CCN(c2ccccc2)CC1,BRD-A81177136,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist
7.6550007,10.044523,361,NC(Cc1ccc(Cl)cc1)C(O)=O,BRD-A81615860,c1ccccc1,BRD-A81615860,tryptophan hydroxylase inhibitor
4.0692844,9.224978,362,CCN(CC)CCOC1CCC2(C)C3CCC4(C)C(CCC4=O)C3CC=C2C1,BRD-A81795050,O=C1CCC2C1CCC1C3CCCCC3=CCC21,BRD-A81795050,oxidosqualene cyclase inhibitor
11.993095,5.529603,363,CCNC(=O)C1OC(C(O)C1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12,BRD-A81866333,c1ccc(CCNc2ncc3ncn(C4CCCO4)c3n2)cc1,BRD-A81866333,adenosine receptor agonist
2.9344444,9.589045,364,CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(O1)C(=O)CO,BRD-A82238138,O=C1C=CC2C(=C1)CCC1C2CCC2C1CC1OCOC12,BRD-A82238138,glucocorticoid receptor agonist
12.129296,5.3803153,365,Nc1nc(Cl)nc2n(cnc12)C1OC(CO)C(O)C1F,BRD-A82371568,c1ncc2ncn(C3CCCO3)c2n1,BRD-A82371568,ribonucleotide reductase inhibitor|dna polymerase inhibitor|dna repair enzyme inhibitor|dna synthesis inhibitor|ribonucleotide reductase inhibitor
8.662438,9.28367,366,CN(Cc1ccccc1)C(=O)C(Cc1ccc2ccccc2c1)NC(=O)C1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O,BRD-A82590476,O=C(NCc1ccccc1)C(Cc1ccc2ccccc2c1)NC(=O)C1CCCN1C(=O)Nc1ccccc1,BRD-A82590476,tachykinin antagonist
9.496932,5.85258,367,Oc1ccc2CC3N(CC4CC4)CCC45C(Oc1c24)c1[nH]c2ccccc2c1CC35O,BRD-A82656074,c1cc2c3c(c1)OC1c4[nH]c5ccccc5c4CC4C(C2)N(CC2CC2)CCC314,BRD-A82656074,opioid receptor antagonist
6.4149413,6.9374638,368,Oc1ccc2C3c4cc(O)c(O)cc4CC3(O)COc2c1,BRD-A83326220,c1ccc2c(c1)CC1COc3ccccc3C21,BRD-A83326220,nitric oxide production inhibitor
8.646339,9.524697,369,CC(C)=CC1C(C(=O)OCc2coc(Cc3ccccc3)c2)C1(C)C,BRD-A83431637,O=C(OCc1coc(Cc2ccccc2)c1)C1CC1,BRD-A83431637,cytochrome p450 inhibitor
4.9319596,5.380679,370,CCS(=O)(=O)N(C)C1C(O)C(C)(C)Oc2ccc(cc12)C#N,BRD-A83695761,c1ccc2c(c1)CCCO2,BRD-A83695761,potassium channel blocker
9.495764,5.815633,371,Oc1ccc2CC3N(CC4CC4)CCC45C(Oc1c24)C(=O)CCC35O,BRD-A83855350,O=C1CCC2C3Cc4cccc5c4C2(CCN3CC2CC2)C1O5,BRD-A83855350,opioid receptor antagonist
8.795628,7.728298,372,CCC1(NC(=O)N(C)C1=O)c1ccccc1,BRD-A83937277,O=C1NC(=O)C(c2ccccc2)N1,BRD-A83937277,hydantoin antiepileptic
9.152699,9.048288,373,CN1C(C(=O)Nc2ncc(C)s2)C(=O)c2ccccc2S1(=O)=O,BRD-A84174393,O=C(Nc1nccs1)C1NS(=O)(=O)c2ccccc2C1=O,BRD-A84174393,cyclooxygenase inhibitor
7.4896293,9.928928,374,NCC(CC(O)=O)c1ccc(Cl)cc1,BRD-A84174873,c1ccccc1,BRD-A84174873,benzodiazepine receptor agonist
7.3151073,6.3622527,375,CCOC(=O)c1ncn-2c1C1CCCN1C(=O)c1cc(OC)ccc-21,BRD-A84389091,O=C1c2ccccc2-n2cncc2C2CCCN12,BRD-A84389091,gaba receptor inverse agonist
4.7169757,11.179931,376,CN1C2CCC1CC(C2)OC(=O)c1cc(C)cc(C)c1,BRD-A84389633,O=C(OC1CC2CCC(C1)N2)c1ccccc1,BRD-A84389633,serotonin receptor antagonist
6.737247,9.087489,377,C\C=C/C1=C(N2C(SC1)C(NC(=O)C(N)c1ccc(O)cc1)C2=O)C(O)=O,BRD-A85137183,O=C(Cc1ccccc1)NC1C(=O)N2C=CCSC12,BRD-A85137183,bacterial cell wall synthesis inhibitor
12.175498,5.344587,378,OCC1OC(C(O)C1O)n1cnc2c(NC3CCCC3)ncnc12,BRD-A85234536,c1nc(NC2CCCC2)c2ncn(C3CCCO3)c2n1,BRD-A85234536,adenosine receptor agonist
5.636735,8.227239,379,CCCN1CCCC2Cc3n[nH]cc3CC12,BRD-A85280935,c1[nH]nc2c1CC1NCCCC1C2,BRD-A85280935,dopamine receptor agonist
7.307306,9.479214,380,CS(=O)(=O)c1ccc(Cn2c3C(CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1,BRD-A85472596,c1ccc(Cn2c3c(c4ccccc42)CCCC3)cc1,BRD-A85472596,prostanoid receptor antagonist
4.7262774,11.163826,381,CN1C2CCC1CC(C2)OC(=O)c1cc(Cl)cc(Cl)c1,BRD-A85587465,O=C(OC1CC2CCC(C1)N2)c1ccccc1,BRD-A85587465,serotonin receptor antagonist
7.6831155,9.999404,382,CC(C(O)=O)c1ccc(c(F)c1)-c1ccccc1,BRD-A86044036,c1ccc(-c2ccccc2)cc1,BRD-A86044036,cyclooxygenase inhibitor
8.148203,8.014772,383,NC(=O)N1C(=O)C(C(=O)c2cccs2)c2cc(Cl)ccc12,BRD-A87479750,O=C1Nc2ccccc2C1C(=O)c1cccs1,BRD-A87479750,cyclooxygenase inhibitor
7.4249597,6.215098,384,COc1ccc2cc(ccc2c1)C(C)C(O)=O,BRD-A87719232,c1ccc2ccccc2c1,BRD-A87719232,cyclooxygenase inhibitor
7.5241976,11.108043,385,CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,BRD-A88254928,c1ccccc1,BRD-A88254928,adrenergic receptor agonist
5.467085,8.528272,386,CCN1C[C@]2(COC)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@@]5(C[C@@H]6OC)OCO[C@]5([C@@H](O)[C@H]23)C14,BRD-A88282067,C1CC2CNC3C4(C1)C2CC31OCOC12CCC1CC4C2C1,BRD-A88282067,antiarrhythmic
10.200094,6.9207973,387,Oc1cc2CCNCC(c3ccccc3)c2cc1O,BRD-A88548664,c1ccc(C2CNCCc3ccccc32)cc1,BRD-A88548664,dopamine receptor agonist
4.339902,9.631384,388,CC12C[C@@H](O)C3C(CCC4CC(O)CCC34C)C1(O)CCC2C1=CC(=O)OC1,BRD-A89434049,O=C1C=C(C2CCC3C2CCC2C4CCCCC4CCC23)CO1,BRD-A89434049,atpase inhibitor
8.695639,7.916625,389,OC(C1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F,BRD-A89585551,c1ccc2c(CC3CCCCN3)ccnc2c1,BRD-A89585551,adenosine receptor antagonist|hemoglobin antagonist
7.894596,10.868907,390,C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1,BRD-A89672324,O=[PH](CCCNCc1ccccc1)Cc1ccccc1,BRD-A89672324,gaba receptor antagonist
11.996209,5.4828978,391,Nc1nc(Cl)nc2n(cnc12)C1C[C@@H](O)C(CO)O1,BRD-A89947015,c1ncc2ncn(C3CCCO3)c2n1,BRD-A89947015,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor
6.1591215,11.104209,392,CC1(C)CC1C(=O)NC(=CCCCCSCC(N)C(O)=O)C(O)=O,BRD-A90311807,C1CC1,BRD-A90311807,dehydropeptidase inhibitor
12.094752,5.4287863,393,OC[C@H]1OC2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O,BRD-A90462498,N=c1ccn2c(n1)OC1CCOC12,BRD-A90462498,antineoplastic
4.1697583,8.87142,394,CC12CCC3C(C1CCC2O)C(CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31,BRD-A90490067,c1ccc2c(c1)CCC1C2CCC2CCCC21,BRD-A90490067,estrogen receptor antagonist|dna polymerase inhibitor|soluble epoxide hydrolase inhibitor
4.4984264,6.8764644,395,COc1ccccc1OCC(O)CO,BRD-A90515964,c1ccccc1,BRD-A90515964,expectorant
8.612687,11.034458,396,COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C,BRD-A90799790,C1=CC(c2cccc3nonc23)C=CN1,BRD-A90799790,calcium channel blocker
9.044332,8.875588,397,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,BRD-A91008255,c1ccc(CN(CCN2CCCC2)c2ccccc2)cc1,BRD-A91008255,calcium channel blocker
9.289983,9.822151,398,CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,BRD-A91699651,c1ccc2ncccc2c1,BRD-A91699651,antimalarial
6.214971,11.308435,399,OC(=O)CCC\C=C/CC1C2CCC(O2)C1CNNC(=O)Nc1ccccc1,BRD-A91866971,O=C(NNCC1CC2CCC1O2)Nc1ccccc1,BRD-A91866971,thromboxane receptor antagonist
5.535889,8.539491,400,CN1[C@H]2CC3CC1C(O)C2O3,BRD-A92161634,C1C2CC3OC1CC3N2,BRD-A92161634,acetylcholine receptor antagonist
3.4819074,9.505507,401,CCCC1CC2=CC(=O)CCC2(C)C2CCC3(C)C(CCC3(O)CCC(O)=O)C12,BRD-A92585442,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-A92585442,cytochrome p450 inhibitor
8.600299,10.443121,402,CC(N)C(=O)Nc1c(C)cccc1C,BRD-A92670106,c1ccccc1,BRD-A92670106,sodium channel blocker
5.732645,8.226621,403,O=C1CCCC2C3CC(CN12)[C@@H]1CCCCN1C3,BRD-A92826379,O=C1CCCC2C3CC(CN12)C1CCCCN1C3,BRD-A92826379,sodium channel blocker
6.0178857,9.089445,404,CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1,BRD-A93000692,O=C1NC(=O)C(Cc2ccc(OCC3CCCCC3)cc2)S1,BRD-A93000692,ppar receptor agonist
4.4450397,7.209212,405,CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNCC(O)COc2ccc(O)cc2)cc1,BRD-A93206962,O=S(=O)(Nc1ccc(CCNCCCOc2ccccc2)cc1)c1ccccc1,BRD-A93206962,adrenergic receptor agonist|adrenergic receptor partial agonist
8.229081,7.6323385,406,O=C1N(C2CCC(=O)NC2=O)C(=O)c2ccccc12,BRD-A93255169,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,BRD-A93255169,tnf production inhibitor
8.120116,8.642261,407,OC(Cc1ccncc1)C(Cl)(Cl)Cl,BRD-A93477898,c1ccncc1,BRD-A93477898,caspase activator
9.425659,8.780899,408,COC(=O)N1CCN(C(CN2CCCC2)C1)C(=O)Cc1ccc(Cl)c(Cl)c1,BRD-A93659613,O=C(Cc1ccccc1)N1CCNCC1CN1CCCC1,BRD-A93659613,opioid receptor agonist
4.6887264,11.313952,409,CN1C2CCC1CC(C2)OC(=O)C(CO)c1ccccc1,BRD-A93739713,O=C(Cc1ccccc1)OC1CC2CCC(C1)N2,BRD-A93739713,muscarinic antagonist
8.729659,8.372936,410,[O-][N+](=O)c1ccccc1S(=O)(=O)NCC1CCC(CNCC2CCc3ccccc3C2)CC1,BRD-A94413429,O=S(=O)(NCC1CCC(CNCC2CCc3ccccc3C2)CC1)c1ccccc1,BRD-A94413429,neuropeptide receptor antagonist
8.924293,8.571881,411,c1cn(cn1)C(c1ccccc1)c1ccc(cc1)-c1ccccc1,BRD-A94543220,c1ccc(-c2ccc(C(c3ccccc3)n3ccnc3)cc2)cc1,BRD-A94543220,sterol demethylase inhibitor
11.921247,5.6340294,412,CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC,BRD-A94624445,O=[PH]1OCC2OC(n3cnc4cncnc43)CC2O1,BRD-A94624445,adenosine receptor agonist|camp stimulant
6.9234385,6.3764944,413,Oc1ccc(cc1)C1CC(=O)c2c(O)cc(O)cc2O1,BRD-A94669766,O=C1CC(c2ccccc2)Oc2ccccc21,BRD-A94669766,aromatase inhibitor
6.524588,8.396044,414,Cc1cc(C)cc(OCC2CNC(=O)O2)c1,BRD-A94709349,O=C1NCC(COc2ccccc2)O1,BRD-A94709349,muscle relaxant
9.944478,8.250702,415,Fc1ccc(cc1)N1CCN(CCC2OCCc3ccccc23)CC1,BRD-A95096829,c1ccc(N2CCN(CCC3OCCc4ccccc43)CC2)cc1,BRD-A95096829,dopamine receptor antagonist
3.7698605,9.372536,416,CC(=O)O[C@@]1(CCC2C3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)C3CC[C@]12C)C(C)=O,BRD-A95207036,O=C1C=C2C=CC3C4CCCC4CCC3C2C2CC12,BRD-A95207036,androgen receptor antagonist
6.2977667,7.002571,417,Oc1ccc2C3Oc4cc5OCOc5cc4C3COc2c1,BRD-A95445494,c1ccc2c(c1)OCC1c3cc4c(cc3OC21)OCO4,BRD-A95445494,interleukin synthesis inhibitor|sodium/glucose cotransporter inhibitor
3.533835,9.348971,418,C[C@]12CCC3C(CCC4=CC(=O)C=C[C@]34C)C1CCC2=O,BRD-A95513702,O=C1C=CC2C(=C1)CCC1C2CCC2C(=O)CCC21,BRD-A95513702,aromatase inhibitor
9.154924,9.198627,419,CNCCC(Oc1ccccc1OC)c1ccccc1,BRD-A95696066,c1ccc(COc2ccccc2)cc1,BRD-A95696066,norepinephrine reuptake inhibitor
7.6239986,8.057331,420,CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,BRD-A95869247,O=C(NN1CCc2ccccc21)c1ccccc1,BRD-A95869247,thiazide diuretic
8.874894,8.562574,421,Clc1ccc(C(Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1,BRD-A95939040,c1ccc(C(Cn2ccnc2)OCc2csc3ccccc23)cc1,BRD-A95939040,sterol demethylase inhibitor
4.804737,7.306064,422,CCCc1c(OCC(O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O,BRD-A96456596,O=c1ccoc2cc(OCCCOc3ccccc3)ccc12,BRD-A96456596,leukotriene receptor antagonist
8.399851,9.407541,423,CCOC(=O)C1CN(Cc2ccccc2)C(=O)C1=O,BRD-A96485169,O=C1CCN(Cc2ccccc2)C1=O,BRD-A96485169,aldose reductase inhibitor
8.900989,6.5418024,424,CC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F,BRD-A96882008,O=C(CCc1c[nH]c2ccccc12)OCc1ccccc1,BRD-A96882008,tachykinin antagonist
3.682862,9.305474,425,CC12CC=C3C(CCC4=CC(=O)C=CC34C)C1CC[C@@H]2C(=O)CN1CCN(CC1)c1cc(nc(n1)N1CCCC1)N1CCCC1,BRD-A96897502,O=C1C=CC2C(=C1)CCC1C2=CCC2C(C(=O)CN3CCN(c4cc(N5CCCC5)nc(N5CCCC5)n4)CC3)CCC12,BRD-A96897502,lipid peroxidase inhibitor
7.581199,10.976529,426,CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1,BRD-A97104540,c1ccc(CCNCCc2ccccc2)cc1,BRD-A97104540,adrenergic receptor agonist
4.763825,11.349524,427,CCN1CCCC(C1)OC(=O)C(c1ccccc1)c1ccccc1,BRD-A97479839,O=C(OC1CCCNC1)C(c1ccccc1)c1ccccc1,BRD-A97479839,acetylcholine receptor antagonist
4.109718,6.90415,428,CC(C)NCC(O)COc1cccc2[nH]ccc12,BRD-A97701745,c1ccc2[nH]ccc2c1,BRD-A97701745,adrenergic receptor antagonist|serotonin receptor antagonist
8.314408,9.5169735,429,CC(CNC1CCCCC1)OC(=O)c1ccccc1,BRD-A97730597,O=C(OCCNC1CCCCC1)c1ccccc1,BRD-A97730597,sodium channel blocker
7.734421,9.97703,430,CC(C(O)=O)c1cccc(c1)C(=O)c1ccccc1,BRD-A97739905,O=C(c1ccccc1)c1ccccc1,BRD-A97739905,cyclooxygenase inhibitor
8.688949,8.26178,431,Nc1c2C(O)CCCc2nc2ccccc12,BRD-A98299281,c1ccc2nc3c(cc2c1)CCCC3,BRD-A98299281,calcium channel activator
8.272912,8.8377,432,FC(F)(F)c1cccc(Nc2ncccc2C(=O)OC2OC(=O)c3ccccc23)c1,BRD-A98378129,O=C1OC(OC(=O)c2cccnc2Nc2ccccc2)c2ccccc21,BRD-A98378129,cyclooxygenase inhibitor|calcium channel blocker|calcium-activated chloride channel blocker|mucin production inhibitor
6.1836133,10.699611,433,CC1(C)[C@H](CC[C@@]2(C)C1CC[C@]1(C)C2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O,BRD-A98702003,O=C1C=C2C3CCCCC3CCC2C2CCC3CCCCC3C12,BRD-A98702003,11-beta-hsd1 inhibitor
9.772619,12.356573,434,CCC(CO)NC(=O)C1CN(C)C2Cc3cn(C)c4cccc(C2=C1)c34,BRD-A98725278,C1=C2c3cccc4[nH]cc(c34)CC2NCC1,BRD-A98725278,serotonin receptor antagonist
5.5550094,8.616188,435,CCN1C[C@]2(C)CC[C@H](OC)[C@]34[C@@H]2[C@H](OC(C)=O)[C@@]2(OCO[C@@]22C[C@H](OC)[C@H]5C[C@]3(O)[C@@H]2[C@H]5OC)C14,BRD-A99177642,C1CC2CNC3C4(C1)C2CC31OCOC12CCC1CC4C2C1,BRD-A99177642,acetylcholine receptor antagonist
12.10699,8.728303,436,CCOc1ccc2ccccc2c1NC(=O)[C@H]1[C@H]2SC(C)(C)C(N2C1=O)C(O)=O,BRD-A99402294,O=C(Nc1cccc2ccccc12)C1C(=O)N2CCSC12,BRD-A99402294,bacterial cell wall synthesis inhibitor
6.53197,6.271739,437,OC[C@H]1OC(Oc2cc3ccc(=O)oc3cc2O)[C@H](O)[C@@H](O)[C@@H]1O,BRD-A99411506,O=c1ccc2cc(OC3CCCCO3)ccc2o1,BRD-A99411506,antioxidant
5.9630604,10.7300205,438,CCCCCCCCN1C(=O)C(C(C)=O)=C(C)C1(C)O,BRD-A99449986,O=C1C=CCN1,BRD-A99449986,adenine nucleotide translocase inhibitor|caspase activator|neurotrophic
8.17488,7.8953347,439,COc1c2CC(Oc2nc2ccccc12)C(C)(O)CO,BRD-A99571536,c1ccc2nc3c(cc2c1)CCO3,BRD-A99571536,anti-epileptic
7.754475,7.8055716,440,Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)C,BRD-K00141480,O=C1C(=O)c2c(ccc3c2CCCC3)-c2occc21,BRD-K00141480,anti-inflammatory|interleukin inhibitor
8.91037,6.8611693,441,O=Cc1c2[nH]c3ccccc3c2cc2[nH]c3ccccc3c12,BRD-K00184207,c1ccc2c(c1)[nH]c1cc3c(cc12)[nH]c1ccccc13,BRD-K00184207,aryl hydrocarbon receptor ligand
7.828453,9.3372755,442,CCC(C)(C)N=C(NC#N)Nc1cccnc1,BRD-K00206590,c1ccncc1,BRD-K00206590,atp channel activator
6.1776066,6.7464347,443,COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC,BRD-K00259736,O=c1cccc2c(c1)CCCc1ccccc1-2,BRD-K00259736,microtubule inhibitor
6.6033,9.242027,444,CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1,BRD-K00312224,c1ccc(-c2cc(-c3ccccc3)n(-c3ccccc3)n2)cc1,BRD-K00312224,estrogen receptor agonist
9.315727,8.237377,445,Clc1ccccc1CN1CCc2sccc2C1,BRD-K00603606,c1ccc(CN2CCc3sccc3C2)cc1,BRD-K00603606,purinergic receptor antagonist|platelet aggregation inhibitor
10.669224,9.511265,446,Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1,BRD-K00610438,O=C(c1ccccc1)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1,BRD-K00610438,serotonin receptor antagonist|collagen stimulant
8.886086,8.288013,447,Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F,BRD-K00662280,c1ccc(-c2ccc3nncn3n2)cc1,BRD-K00662280,gaba receptor agonist
7.003634,8.355695,448,NC(N)=Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1,BRD-K00673382,c1cscn1,BRD-K00673382,histamine receptor antagonist
9.49194,8.7989855,449,O=C(NCCCCN1CCOCC1)c1cc2ccccc2o1,BRD-K00675675,O=C(NCCCCN1CCOCC1)c1cc2ccccc2o1,BRD-K00675675,metalloproteinase inhibitor
2.8675466,9.603399,450,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,BRD-K00824317,O=C1C=C2CCC3C(CCC4C3CC3OCOC34)C2CC1,BRD-K00824317,glucocorticoid receptor agonist
3.6872067,9.459025,451,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,BRD-K01095011,O=C1C=CC2C(CCC3C4CCCC4CCC23)N1,BRD-K01095011,5 alpha reductase inhibitor
12.16577,8.749831,452,Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl,BRD-K01244426,O=C(NC1C(=O)N2CCSC12)c1conc1-c1ccccc1,BRD-K01244426,bacterial cell wall synthesis inhibitor
10.790182,9.298626,453,Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1,BRD-K01292756,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccccc2)c2ccccc2)CC1,BRD-K01292756,dopamine receptor antagonist
8.261609,9.20174,454,O=C(CC(=O)c1ccccc1)c1ccccc1,BRD-K01555864,O=C(CC(=O)c1ccccc1)c1ccccc1,BRD-K01555864,antineoplastic
8.373845,7.6700544,455,O=C1c2ccccc2-c2n[nH]c3cccc1c23,BRD-K01567962,O=C1c2ccccc2-c2n[nH]c3cccc1c23,BRD-K01567962,jnk inhibitor
6.2047815,11.280349,456,CC\C=C/C\C=C/C\C=C/CCCCCCCCCCCC(O)=O,BRD-K01624546,,BRD-K01624546,ltb4 inhibitor
9.190055,6.873684,457,CN1CCc2c(Cc3ccccc3CC1)[nH]c1ccccc21,BRD-K01648091,c1ccc2c(c1)CCNCCc1c([nH]c3ccccc13)C2,BRD-K01648091,dopamine receptor antagonist
9.883973,8.672095,458,OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1,BRD-K01663662,c1ccc(C(CCCN2CCCCC2)c2ccccc2)cc1,BRD-K01663662,muscarinic antagonist
9.000903,6.6093574,459,OCc1c[nH]c2ccccc12,BRD-K01815685,c1ccc2[nH]ccc2c1,BRD-K01815685,aryl hydrocarbon receptor agonist
10.235345,10.418345,460,COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1,BRD-K01868942,O=C(OCCCN1CCCCC1)c1ccccc1,BRD-K01868942,serotonin receptor antagonist
8.669929,10.32089,461,Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C,BRD-K01902415,c1ccc(Nc2ccncn2)cc1,BRD-K01902415,ppar receptor agonist
9.661526,7.568702,462,Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1,BRD-K02265150,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1O2,BRD-K02265150,norepinephrine reuptake inhibitor
6.6491632,9.021341,463,CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O,BRD-K02275692,O=C(Cc1cscn1)NC1C(=O)N2C=C(CSc3nnn[nH]3)CSC12,BRD-K02275692,bacterial cell wall synthesis inhibitor
8.069055,9.968409,464,O[C@H]1C[C@H](OCc2ccc(cc2)-c2ccccc2)[C@H](CC\C=C/CCC(O)=O)[C@H]1N1CCCCC1,BRD-K02283807,c1ccc(-c2ccc(COC3CCC(N4CCCCC4)C3)cc2)cc1,BRD-K02283807,thromboxane receptor antagonist
5.9704833,9.076186,465,Cn1cnc2n(C)c(=O)n(C)c(=O)c12,BRD-K02404261,O=c1[nH]c(=O)c2[nH]cnc2[nH]1,BRD-K02404261,adenosine receptor antagonist
8.063946,5.142726,466,CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1,BRD-K02407574,c1ccc2[nH]cnc2c1,BRD-K02407574,tubulin polymerization inhibitor
8.06616,9.011882,467,CC(C)(c1ccc(NS(=O)(=O)C(F)(F)F)cc1)c1ccc(cc1)C(C)(C)c1cccc(NS(=O)(=O)C(F)(F)F)c1,BRD-K02581333,c1ccc(Cc2ccc(Cc3ccccc3)cc2)cc1,BRD-K02581333,tyrosine phosphatase inhibitor
6.5051594,8.860706,468,CC1=CC[C@@H]2[C@@H](C1)c1c(O)cc(CC#CCCCNS(C)(=O)=O)cc1OC2(C)C,BRD-K02590140,C1=CCC2c3ccccc3OCC2C1,BRD-K02590140,cannabinoid receptor antagonist
5.2674513,6.552975,469,COc1cc2CCN(C)[C@H]3Cc4cccc(Oc5c(O)c(OC)cc6CC[N+](C)(C)[C@H](Cc7ccc(O)c(Oc1cc23)c7)c56)c4,BRD-K02607075,c1cc2cc(c1)Oc1ccc3c(c1)C(Cc1cccc(c1)Oc1cccc4c1C(C2)[NH2+]CC4)NCC3,BRD-K02607075,acetylcholine receptor antagonist
7.3150845,7.7283115,470,Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F,BRD-K02637541,c1ccc(-c2ccnn2-c2ccccc2)cc1,BRD-K02637541,cyclooxygenase inhibitor
8.056318,5.1307077,471,COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1,BRD-K02764365,c1ccc2[nH]cnc2c1,BRD-K02764365,anthelmintic
9.186706,8.3350115,472,Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1,BRD-K02867583,c1ccc(-c2ccc(NCCN3CCOCC3)nn2)cc1,BRD-K02867583,serotonin reuptake inhibitor
6.908492,8.599047,473,CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1,BRD-K02900412,c1ccc(Cc2ccccc2)cc1,BRD-K02900412,protein synthesis inhibitor
6.825991,6.1823983,474,C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O,BRD-K02953697,O=C1CC(c2ccccc2)Oc2cc(OC3OCCCC3OC3CCCCO3)ccc21,BRD-K02953697,cytochrome p450 inhibitor
5.7804813,8.699297,475,CN1CCN(CCCC(=O)O[C@H]2[C@@H](O)[C@H]3C(C)(C)CC[C@H](O)[C@]3(C)[C@@]3(O)C(=O)C[C@@](C)(O[C@]23C)C=C)CC1,BRD-K03015355,O=C(CCCN1CCNCC1)OC1CC2CCCCC2C2C(=O)CCOC12,BRD-K03015355,adenylyl cyclase activator|adenylate cyclase stimulant|growth hormone receptor agonist|phosphokinase stimulant
5.5292406,6.7178597,476,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12,BRD-K03067624,c1ccc2c(c1)CCNC2CC1CCN2CCc3ccccc3C2C1,BRD-K03067624,protein synthesis inhibitor
8.869925,8.304839,477,ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O,BRD-K03109492,O=C1C=C(NCCN2CCOCC2)C(=O)c2ncccc21,BRD-K03109492,cdc inhibitor
8.087863,8.447681,478,CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1,BRD-K03384561,O=C(Nc1ccccc1)c1cc2ccccc2[nH]c1=O,BRD-K03384561,angiogenesis inhibitor
5.2766595,6.5281425,479,COc1cc-2c(C[C@@H]3N(C)CCc4cc(O)c(OC)c-2c34)cc1O,BRD-K03440695,c1ccc2c(c1)CC1NCCc3cccc-2c31,BRD-K03440695,acetylcholine receptor antagonist
7.2725115,6.719056,480,O=C(O[C@H]1Cc2c(OC(=O)c3ccccc3)cc(OC(=O)c3ccccc3)cc2O[C@@H]1c1ccc(OC(=O)c2ccccc2)c(OC(=O)c2ccccc2)c1)c1ccccc1,BRD-K03600606,O=C(Oc1cc(OC(=O)c2ccccc2)c2c(c1)OC(c1ccc(OC(=O)c3ccccc3)c(OC(=O)c3ccccc3)c1)C(OC(=O)c1ccccc1)C2)c1ccccc1,BRD-K03600606,beta secretase inhibitor
8.185071,9.629343,481,CC(C)n1c(\C=C\[C@H](O)C[C@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12,BRD-K03602135,c1ccc(-c2c[nH]c3ccccc23)cc1,BRD-K03602135,hmgcr inhibitor
8.943489,8.518759,482,Clc1ccccc1CNCC1CCC(CNCc2ccccc2Cl)CC1,BRD-K03642198,c1ccc(CNCC2CCC(CNCc3ccccc3)CC2)cc1,BRD-K03642198,hedgehog pathway inhibitor
6.565027,5.012894,483,Oc1cc(C=C(C#N)C#N)cc(O)c1O,BRD-K03670461,c1ccccc1,BRD-K03670461,egfr inhibitor
5.5355816,8.669654,484,CC(=C)[C@H]1O[C@H]2CC[C@]3(C)[C@]4(C)[C@@H](CC[C@@]3(O)[C@]22O[C@@H]2[C@H]1O)[C@@H]1OC(C)(C)[C@H]2C[C@@H]3C(=C)Cc5c(Cl)cc6[nH]c4c1c6c5[C@]23O,BRD-K03842655,C=C1Cc2ccc3[nH]c4c5c3c2C2C(COC5C3CCC5C(CCC6OCCC7OC675)C43)CC12,BRD-K03842655,potassium channel blocker
3.6116974,9.366198,485,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C,BRD-K03981224,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-K03981224,progestogen hormone
6.018304,11.386802,486,CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1CCCCCCC(O)=O,BRD-K04010869,O=C1C=CCC1,BRD-K04010869,hsp inducer|nfkb pathway inhibitor
4.2283473,8.926524,487,C[C@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O,BRD-K04046242,O=C1CCC2C3=CCc4ccccc4C3CCC12,BRD-K04046242,estrogen receptor agonist
10.352421,11.005411,488,CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,BRD-K04111260,O=C(NCC1CCCN1)c1ccccc1,BRD-K04111260,dopamine receptor antagonist
6.9753895,7.3562236,489,COc1cc(C(O)=O)c2Oc3c(C=O)c(O)cc(C)c3C(=O)Oc2c1C,BRD-K04170657,O=C1Oc2ccccc2Oc2ccccc21,BRD-K04170657,ras gtpase inhibitor
9.892675,10.320714,490,CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC,BRD-K04185004,c1ccccc1,BRD-K04185004,local anesthetic
8.337485,8.911469,491,CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1,BRD-K04414442,O=C(NCc1ccccc1)c1cc(-c2ccccc2)nc2ccccc12,BRD-K04414442,tachykinin antagonist
7.132243,8.109829,492,[O-][N+](=O)c1cccc2cn[nH]c12,BRD-K04430056,c1ccc2[nH]ncc2c1,BRD-K04430056,nitric oxide synthase inhibitor
9.45411,8.59606,493,Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1,BRD-K04704168,c1ccc(Cn2c(CN3CCCC3)nc3ccccc32)cc1,BRD-K04704168,hcv inhibitor
6.3671904,6.2288117,494,Nc1ccc(cc1)-c1cc(=O)c2cc(O)ccc2o1,BRD-K04976539,O=c1cc(-c2ccccc2)oc2ccccc12,BRD-K04976539,pkc inhibitor|src inhibitor
6.633086,9.37146,495,CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1,BRD-K05151076,c1ccc(-c2cc3ccccc3[nH]2)cc1,BRD-K05151076,estrogen receptor antagonist
10.834572,8.692573,496,Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl,BRD-K05181084,O=C(NCCCCN1CCN(c2ccccc2)CC1)c1ccc2c(c1)Cc1ccccc1-2,BRD-K05181084,dopamine receptor antagonist
9.114942,6.7922316,497,OC1(CCN(Cc2c[nH]c3ccccc23)CC1)c1ccc(Cl)cc1,BRD-K05181463,c1ccc(C2CCN(Cc3c[nH]c4ccccc34)CC2)cc1,BRD-K05181463,dopamine receptor antagonist
9.874977,6.5548177,498,NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12,BRD-K05434375,c1ccc2cnccc2c1,BRD-K05434375,calcium channel blocker
9.110085,9.811391,499,COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1,BRD-K05464208,O=C(c1ccccc1)N1CCC(Cc2ccccc2)CC1,BRD-K05464208,p38 mapk inhibitor
8.110725,10.715555,500,CCCCCCCCCC(=O)N[C@H](CN1CCOCC1)[C@H](O)c1ccccc1,BRD-K05653692,c1ccc(CCCN2CCOCC2)cc1,BRD-K05653692,glucosyltransferase inhibitor
12.161622,8.750542,501,Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl,BRD-K05673000,O=C(NC1C(=O)N2CCSC12)c1conc1-c1ccccc1,BRD-K05673000,bacterial cell wall synthesis inhibitor
9.73034,12.283442,502,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(C)C1,BRD-K05901394,c1cc2c3c(c[nH]c3c1)CC1NCCCC21,BRD-K05901394,dopamine receptor agonist
5.316707,8.787168,503,CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1,BRD-K05906022,O=C1CC2OCC3CC(=O)C4C(CCC5C(c6ccoc6)OC(=O)C6OC654)C32CO1,BRD-K05906022,hiv protease inhibitor
7.5621986,8.560477,504,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,BRD-K05977355,c1ccc(C(Cn2cncn2)Cn2cncn2)cc1,BRD-K05977355,sterol demethylase inhibitor
8.277008,10.392363,505,CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12,BRD-K06014311,c1ccc(Cc2cc3ccccc3[nH]2)cc1,BRD-K06014311,melatonin receptor antagonist
6.0819063,11.23373,506,CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCCC(O)=O,BRD-K06024458,,BRD-K06024458,cannabinoid receptor agonist
9.328539,7.484578,507,CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1,BRD-K06147391,O=C1Nc2ccccc2N(C(=O)CN2CCNCC2)c2cscc21,BRD-K06147391,acetylcholine receptor antagonist
8.52532,9.303952,508,OC(=O)Cc1cc2ccccc2nc1C(O)=O,BRD-K06159959,c1ccc2ncccc2c1,BRD-K06159959,inhibitor of the binding of homoquinolinic acid to non-nmda sensitive sites
6.0578995,7.2808514,509,COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC,BRD-K06208435,c1ccc(CCNCCc2ccccc2)cc1,BRD-K06208435,calcium channel blocker
7.711577,8.068969,510,CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1,BRD-K06221026,c1ccc(-c2ccsc2-c2ccccc2)cc1,BRD-K06221026,cyclooxygenase inhibitor
8.443125,7.8384237,511,c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1,BRD-K06234293,c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1,BRD-K06234293,tgf beta receptor inhibitor|p38 mapk inhibitor
7.4421325,8.094285,512,Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O,BRD-K06426971,O=C1C(Nc2ccccc2)=CC(=O)c2scnc21,BRD-K06426971,histone lyinse methyltransferase inhibitor
8.944797,5.941232,513,COC(=O)[C@@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12,BRD-K06467078,c1ccc2c3c([nH]c2c1)C1CC2CCCCC2CN1CC3,BRD-K06467078,adrenergic receptor antagonist
8.8525305,6.9316354,514,Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12,BRD-K06543683,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12,BRD-K06543683,pkc inhibitor|glycogen synthase kinase inhibitor|leucine rich repeat kinase inhibitor|sirt inhibitor
7.654753,9.098496,515,CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C,BRD-K06593056,c1ccc(C2=Nc3cc4c(cc3Nc3ccccc32)CCCC4)cc1,BRD-K06593056,retinoid receptor agonist
6.4685235,6.6542864,516,COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,BRD-K06753942,O=c1cc(-c2ccccc2)oc2ccccc12,BRD-K06753942,mek inhibitor
7.4160523,9.219184,517,CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O,BRD-K06854232,O=C(Nc1ccccc1)c1ccc2c(c1)CCCC2,BRD-K06854232,retinoid receptor agonist
10.908815,7.713821,518,CN(C)CCCN1c2ccccc2Sc2ccccc12,BRD-K06980535,c1ccc2c(c1)Nc1ccccc1S2,BRD-K06980535,dopamine receptor antagonist
6.4502087,6.650528,519,CC(C)=CCOc1c2occc2cc2ccc(=O)oc12,BRD-K07117950,O=c1ccc2cc3ccoc3cc2o1,BRD-K07117950,cdk inhibitor
6.3960004,6.5591884,520,C\C=C(\C)C(=O)O[C@@H]1Cc2c(OC1(C)C)ccc1ccc(=O)oc21,BRD-K07212038,O=c1ccc2ccc3c(c2o1)CCCO3,BRD-K07212038,mast cell stabilizer
10.405638,8.382674,521,C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1,BRD-K07220430,C(=Cc1ccccc1)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,BRD-K07220430,calcium channel blocker
6.5792117,6.626712,522,Oc1cc(\C=C\c2ccc(O)c(O)c2)oc(=O)c1,BRD-K07325606,O=c1cccc(C=Cc2ccccc2)o1,BRD-K07325606,pkc inhibitor
7.666965,10.873026,523,C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1,BRD-K07507905,c1ccc(CCNCCc2ccccc2)cc1,BRD-K07507905,adrenergic receptor agonist
9.100849,10.127953,524,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,BRD-K07691486,c1ccc(CNc2ncnc3[nH]cnc23)cc1,BRD-K07691486,cdk inhibitor
9.101118,10.263504,525,CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1,BRD-K07762753,c1ccc(Nc2ncnc3[nH]cnc23)cc1,BRD-K07762753,cdk inhibitor|tyrosine kinase inhibitor
6.4937963,4.5935335,526,Oc1ccc(\C=C(/C#N)C(=O)c2ccc(O)c(O)c2)cc1O,BRD-K07888196,O=C(C=Cc1ccccc1)c1ccccc1,BRD-K07888196,igf-1 inhibitor
5.332974,6.625312,527,COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34,BRD-K08078237,c1cc2cc(c1)Oc1ccc(cc1)CC1NCCc3ccc(cc31)Oc1cccc3c1C(C2)NCC3,BRD-K08078237,calcium channel blocker
7.9142733,7.3197517,528,Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12,BRD-K08109516,O=c1[nH]c2ccccc2cc1-c1cccc(Oc2ccccc2)c1,BRD-K08109516,glutamate receptor antagonist
6.589012,5.0483255,529,Oc1cc(C=C(C#N)C#N)cc(c1O)[N+]([O-])=O,BRD-K08115555,c1ccccc1,BRD-K08115555,catechol o methyltransferase inhibitor|tumor necrosis factor inhibitor
6.4489136,4.709385,530,COc1cc(C=C(C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O,BRD-K08132273,c1ccc(CSc2nc3ccccc3s2)cc1,BRD-K08132273,egfr inhibitor
8.596016,6.2275677,531,CCCCCCCCCOc1ccc2[nH]cc(CCN)c2c1,BRD-K08219523,c1ccc2[nH]ccc2c1,BRD-K08219523,serotonin receptor agonist
8.650803,9.913585,532,OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,BRD-K08252256,c1ccc(Nc2ccccc2)cc1,BRD-K08252256,cyclooxygenase inhibitor
6.542695,9.573427,533,CCCCOC(=O)c1ccc(O)cc1,BRD-K08287586,c1ccccc1,BRD-K08287586,dna synthesis inhibitor
6.4974127,7.2001796,534,COc1cc2OC[C@H]3Oc4c5C[C@@H](Oc5ccc4C(=O)[C@H]3c2cc1OC)C(C)=C,BRD-K08316444,O=C1c2ccc3c(c2OC2COc4ccccc4C12)CCO3,BRD-K08316444,inhibitor of mitochondrial electron transport
8.934432,8.878747,535,Clc1ccc(CN(CCCNC(=S)NCCCc2c[nH]cn2)c2ccc(Br)cn2)cc1Cl,BRD-K08438429,S=C(NCCCc1c[nH]cn1)NCCCN(Cc1ccccc1)c1ccccn1,BRD-K08438429,glucosylceramidase inhibitor|somatostatin receptor agonist
7.509333,7.5171723,536,CCOc1ccc(cc1)-c1nc2cc(ccc2[nH]1)-c1nc2cc(ccc2[nH]1)N1CCN(C)CC1,BRD-K08554278,c1ccc(-c2nc3cc(-c4nc5cc(N6CCNCC6)ccc5[nH]4)ccc3[nH]2)cc1,BRD-K08554278,dna binding
11.000161,7.6741915,537,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1,BRD-K08619574,c1ccc2c(c1)Sc1ccccc1N2CCCN1CCNCC1,BRD-K08619574,dopamine receptor antagonist
5.9258666,8.253039,538,C(C#CCN1CCCC1)N1CCCC1,BRD-K08619838,C(#CCN1CCCC1)CN1CCCC1,BRD-K08619838,acetylcholine receptor agonist
10.764881,8.53657,539,Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O,BRD-K08640512,O=c1cc[nH]c(=O)n1CCCN1CCN(c2ccccc2)CC1,BRD-K08640512,adrenergic receptor antagonist
3.9287496,6.8117924,540,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,BRD-K08806317,c1nsnc1N1CCOCC1,BRD-K08806317,adrenergic receptor antagonist
7.61967,8.167678,541,NC(=O)NN=Cc1ccc(Oc2ccc(F)cc2)cc1,BRD-K08890269,c1ccc(Oc2ccccc2)cc1,BRD-K08890269,sodium channel blocker
6.064327,11.189804,542,CCCCC\C=C/C\C=C/CCCCCCCC(O)=O,BRD-K08973992,,BRD-K08973992,oxidative stress inducer
9.533455,8.674587,543,C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1,BRD-K08996725,c1cc(CN2CCCCC2)cc(OCCCNc2nc3ccccc3s2)c1,BRD-K08996725,histamine receptor antagonist
10.406025,8.754273,544,Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1,BRD-K08998509,O=S1(=O)c2cccc3cccc(c23)N1CCCN1CCN(c2ccccc2)CC1,BRD-K08998509,dopamine receptor antagonist|serotonin receptor antagonist
7.7220826,7.895266,545,NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCCOc2c1,BRD-K09132007,c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1,BRD-K09132007,casein kinase inhibitor|tgf beta receptor inhibitor
7.266533,8.466093,546,Oc1c(I)cc(Cl)c2cccnc12,BRD-K09255212,c1ccc2ncccc2c1,BRD-K09255212,chelating
9.177155,7.5470047,547,NC1CCN(CC1)c1cccc(Cl)n1,BRD-K09397065,c1ccc(N2CCCCC2)nc1,BRD-K09397065,serotonin receptor agonist
5.669821,9.98122,548,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12,BRD-K09416995,O=C1CCCC(CCC2CC=CC3=CCCCC32)O1,BRD-K09416995,hmgcr inhibitor
4.7580767,8.155545,549,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O,BRD-K09471561,O=c1ccn2c3c(c(N4CCNCC4)ccc13)OCC2,BRD-K09471561,bacterial dna gyrase inhibitor
8.312553,7.623709,550,COC1=CC(=O)O[C@H](C1)\C=C\c1ccccc1,BRD-K09497549,O=C1C=CCC(C=Cc2ccccc2)O1,BRD-K09497549,calcium channel modulator|mtor inhibitor|sodium channel blocker
8.39239,7.1756377,551,O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1,BRD-K09537769,O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12,BRD-K09537769,dna dependent protein kinase inhibitor|mtor inhibitor|pi3k inhibitor
8.247707,8.902674,552,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,BRD-K09549677,c1ccc2c(c1)CCC(CCNCCCc1nc3ccccc3[nH]1)C2,BRD-K09549677,t-type calcium channel blocker|angiogenesis inhibitor|calcium channel blocker|calcium channel inhibitor|l-type calcium channel blocker|sodium channel blocker
9.144402,6.465355,553,CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC,BRD-K09598619,C1=CC2CCC3Nc4ccc(C5CC6CCCN(CCc7c5[nH]c5ccccc75)C6)cc4C34CCN(C1)C24,BRD-K09598619,tubulin polymerization inhibitor
5.789737,8.32285,554,S=P(N1CC1)(N1CC1)N1CC1,BRD-K09631521,S=P(N1CC1)(N1CC1)N1CC1,BRD-K09631521,cytochrome p450 inhibitor
8.103177,10.693949,555,CCCCCCCCCCCCCC(=O)N[C@@H](C)[C@H](O)c1ccccc1,BRD-K09635134,c1ccccc1,BRD-K09635134,negative control for d-erythro-mapp
8.154788,8.994458,556,Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F,BRD-K09635314,O=S(=O)(Nc1ccccc1)c1ccccc1,BRD-K09635314,phospholipase activator
8.166814,7.7135577,557,c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34,BRD-K09668667,c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34,BRD-K09668667,carcinogen
6.0432124,11.249023,558,CCCCCCCC\C=C/C\C=C/C\C=C/CCCC(=O)NCCO,BRD-K09764130,,BRD-K09764130,cannabinoid receptor agonist
6.9882436,10.353514,559,CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1,BRD-K09778810,c1ccc(-c2cc3ccccc3[nH]2)cc1,BRD-K09778810,inositol monophosphatase inhibitor
8.28975,9.992435,560,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,BRD-K09963420,O=C(CNC(=O)c1ccc2ccccc2n1)NC(CCN1CCC2CCCCC2C1)Cc1ccccc1,BRD-K09963420,hiv protease inhibitor
8.5578,8.755951,561,Ic1cccc(CSc2nnc(o2)-c2ccncc2)c1,BRD-K09991945,c1ccc(CSc2nnc(-c3ccncc3)o2)cc1,BRD-K09991945,glycogen synthase kinase inhibitor|pkc inhibitor|superoxide dismutase expression inhibitor
9.650305,7.59231,562,Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1,BRD-K10042277,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1N2,BRD-K10042277,cetylcholine receptor agonist|dopamine receptor agonist|dopamine receptor antagonist|dopamine receptor partial agonist|serotonin receptor antagonist|serotonin receptor inverse agonist
7.5211,7.5548096,563,Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12,BRD-K10065684,O=C1c2ccccc2C(=O)c2ccccc21,BRD-K10065684,laxative
7.9174747,7.2718062,564,Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12,BRD-K10176267,O=C(c1cc2ccccc2[nH]c1=O)C1CC1,BRD-K10176267,glutamate receptor antagonist
8.766124,7.735236,565,CC[C@@H]1CN2C(=N1)c1[nH]c(nc1N(C)C2=O)-c1ccccc1,BRD-K10177585,O=C1Nc2nc(-c3ccccc3)[nH]c2C2=NCCN12,BRD-K10177585,adenosine receptor antagonist
7.0911107,9.854227,566,CC[C@H]([C@H]1O[C@@](CC)(C[C@@H]1C)[C@H]1CC[C@](O)(CC)[C@H](C)O1)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O,BRD-K10207760,O=C(CCCCCc1ccccc1)CC1CCC(C2CCCCO2)O1,BRD-K10207760,bacterial permeability inducer
9.573082,9.961902,567,CN(C)CCOC(=O)COc1ccc(Cl)cc1,BRD-K10314788,c1ccccc1,BRD-K10314788,nootropic
7.490937,8.378183,568,OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1,BRD-K10670311,O=S(=O)(Nc1ccccn1)c1ccc(N=Nc2ccccc2)cc1,BRD-K10670311,antirheumatic
7.2660656,6.1546464,569,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1,BRD-K10705233,O=C(c1ccccc1)n1cc(CCN2CCOCC2)c2ccccc21,BRD-K10705233,cannabinoid receptor agonist
8.978435,7.9971533,570,CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1,BRD-K10843433,O=C1CC(=O)N(c2ccccc2)N1c1ccccc1,BRD-K10843433,cyclooxygenase inhibitor
6.433625,4.517048,571,Oc1ccc(\C=C(\C#N)C(=O)OC\C=C\c2ccccc2)cc1O,BRD-K10870738,O=C(C=Cc1ccccc1)OCC=Cc1ccccc1,BRD-K10870738,lipoxygenase inhibitor
8.000647,8.656947,572,CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1,BRD-K10974103,O=C(Oc1ccccc1)c1ccco1,BRD-K10974103,protein synthesis inhibitor
10.952981,7.6964607,573,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1,BRD-K10995081,c1ccc2c(c1)Sc1ccccc1N2CCCN1CCNCC1,BRD-K10995081,dopamine receptor antagonist
6.757164,8.432006,574,CNC(NCCSCc1csc(N=C(N)N)n1)=NC#N,BRD-K11107424,c1cscn1,BRD-K11107424,histamine receptor antagonist
7.5556574,9.670802,575,Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1,BRD-K11129031,c1ccccc1,BRD-K11129031,lipoprotein lipase activator
6.401884,4.483986,576,C[C@@H](NC(=O)C(=C/c1ccc(O)c(O)c1)\C#N)c1ccccc1,BRD-K11158509,O=C(C=Cc1ccccc1)NCc1ccccc1,BRD-K11158509,egfr inhibitor
8.785551,7.108773,577,O=c1[nH]c2ccccc2c2ccccc12,BRD-K11163873,O=c1[nH]c2ccccc2c2ccccc12,BRD-K11163873,parp inhibitor
7.6091366,10.465503,578,CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl,BRD-K11298197,c1ccccc1,BRD-K11298197,protein synthesis inhibitor
8.315049,8.4047985,579,CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nnn[nH]3)C(=O)CCc2c(CC)n1,BRD-K11373525,O=C1CCc2cnccc2N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,BRD-K11373525,angiotensin receptor antagonist
8.44367,9.74309,580,NC(=N)NC(=N)NCCc1ccccc1,BRD-K11399644,c1ccccc1,BRD-K11399644,ampk activator
10.431337,8.580635,581,Fc1ccc(cc1)C(OCCN1CCN(CC=Cc2ccccc2)CC1)c1ccc(F)cc1,BRD-K11634954,C(=Cc1ccccc1)CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1,BRD-K11634954,dopamine uptake inhibitor
8.315014,6.719214,582,C1CN=C(N1)c1cnc2ccccc2n1,BRD-K11696279,c1ccc2nc(C3=NCCN3)cnc2c1,BRD-K11696279,imidazoline receptor agonist
7.7610254,8.813075,583,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,BRD-K11717138,O=C(c1ccccc1)c1coc2ccccc12,BRD-K11717138,chloride channel blocker
7.2221184,8.728976,584,Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1,BRD-K11742128,C(CN1CCCC1)=C(c1ccccc1)c1ccccn1,BRD-K11742128,histamine receptor antagonist
9.627561,9.230509,585,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1,BRD-K11911061,O=C(Nc1cccc(N2CCNCC2)c1)c1ccc(-c2ccc(-c3ncon3)cc2)cc1,BRD-K11911061,serotonin receptor antagonist
8.53198,8.064964,586,Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O,BRD-K11927976,O=c1c2ccccc2[nH]c2ccccc12,BRD-K11927976,mediator release inhibitor|syk inhibitor
8.40747,9.48417,587,O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1,BRD-K12102668,O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1,BRD-K12102668,monoamine oxidase inhibitor
8.323777,9.120416,588,NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1,BRD-K12120659,c1ccc(N2CCN(C3CCNCC3)CC2)cc1,BRD-K12120659,integrin antagonist
10.400048,8.414127,589,Fc1ccc(cc1)C(N1CCN(CC=Cc2ccccc2)CC1)c1ccc(F)cc1,BRD-K12184470,C(=Cc1ccccc1)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,BRD-K12184470,calcium channel blocker|t-type calcium channel blocker
7.0649304,9.582652,590,Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,BRD-K12219985,O=C(NC1CCCCC1)NS(=O)(=O)c1ccc(CCNC(=O)c2cnccn2)cc1,BRD-K12219985,sulfonylurea
8.234287,8.232635,591,N\C(Sc1ccc(N)cc1)=C(\C#N)c1ccccc1C(F)(F)F,BRD-K12244279,C(=Cc1ccccc1)Sc1ccccc1,BRD-K12244279,mek inhibitor
6.4151583,4.502416,592,Oc1ccc(C=C(C#N)C(=O)NCc2ccccc2)cc1O,BRD-K12357156,O=C(C=Cc1ccccc1)NCc1ccccc1,BRD-K12357156,egfr inhibitor|erbb2 inhibitor|jak2 inhibitor
8.197899,9.609006,593,OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1,BRD-K12513978,c1ccc(-c2ccccc2)cc1,BRD-K12513978,cyclooxygenase inhibitor
8.102741,5.184054,594,COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1,BRD-K12539581,O=C(c1ccc2[nH]cnc2c1)c1cccs1,BRD-K12539581,tubulin polymerization inhibitor
6.9592986,8.2394495,595,CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1,BRD-K12932420,O=c1nc(-c2ccccc2)c2cccnc2[nH]1,BRD-K12932420,phosphodiesterase inhibitor
7.876692,7.990274,596,Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1,BRD-K12994359,c1ccc(-c2conc2-c2ccccc2)cc1,BRD-K12994359,cyclooxygenase inhibitor
7.369537,8.368514,597,Oc1ccc([N+][O-])c2cccnc12,BRD-K13169950,c1ccc2ncccc2c1,BRD-K13169950,hdac inhibitor
9.962283,8.691746,598,Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1,BRD-K13211965,c1ccc(CCN2CCC(c3cc(-c4ccccc4)on3)CC2)cc1,BRD-K13211965,dopamine receptor antagonist
5.604645,8.2477455,599,CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12,BRD-K13261168,c1ncc2c(n1)CC1CCCNC1C2,BRD-K13261168,dopamine receptor agonist
7.110345,8.3831415,600,CC(=O)N=c1sc(nn1C)S(N)(=O)=O,BRD-K13356952,N=c1[nH]ncs1,BRD-K13356952,carbonic anhydrase inhibitor
5.7626324,8.933485,601,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,BRD-K13533483,O=C1CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CN1,BRD-K13533483,calcineurin inhibitor|cyclophilin inhibitor|immunosuppressant|insulin expression inhibitor|t cell inhibitor
5.2139053,6.4904265,602,CCCN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31,BRD-K13544237,c1ccc2c(c1)CC1NCCc3cccc-2c31,BRD-K13544237,dopamine receptor agonist|antiamyloidogenic
7.8404155,10.113443,603,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O,BRD-K13571841,,BRD-K13571841,aspartic protease inhibitor
6.4809437,6.1103334,604,OC[C@H]1O[C@@H](Oc2cc(O)c3c(c2)oc(cc3=O)-c2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,BRD-K13642330,O=c1cc(-c2ccccc2)oc2cc(OC3CCCCO3)ccc12,BRD-K13642330,cytochrome p450 inhibitor
8.950975,7.8232975,605,C1CN2Cc3ccccc3N=C2C1,BRD-K13819402,c1ccc2c(c1)CN1CCCC1=N2,BRD-K13819402,acetylcholinesterase inhibitor
4.1740537,6.866002,606,CC(C)NC[C@H](O)COc1cccc2ccccc12,BRD-K13994703,c1ccc2ccccc2c1,BRD-K13994703,adrenergic receptor antagonist
8.836458,5.807236,607,CCOC(=O)Oc1c(OC)cc(cc1OC)C(=O)O[C@@H]1C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]([C@H]1OC)C(=O)OC,BRD-K14200658,O=C(OC1CCC2CC3c4[nH]c5ccccc5c4CCN3CC2C1)c1ccccc1,BRD-K14200658,vesicular monoamine transporter inhibitor
8.08536,7.992639,608,Cc1cc(ccc1N=Nc1cc(c2ccccc2c1N)S(O)(=O)=O)-c1ccc(N=Nc2cc(c3ccccc3c2N)S(O)(=O)=O)c(C)c1,BRD-K14221570,c1ccc2cc(N=Nc3ccc(-c4ccc(N=Nc5ccc6ccccc6c5)cc4)cc3)ccc2c1,BRD-K14221570,hiv entry inhibitor
9.49644,8.229301,609,Nc1ccc(CCN2CCN(CC2)c2cccc(c2)C(F)(F)F)cc1,BRD-K14282469,c1ccc(CCN2CCN(c3ccccc3)CC2)cc1,BRD-K14282469,serotonin receptor antagonist
6.4157486,4.490491,610,Oc1ccc(C=C(C#N)C(=O)NCCCCc2ccccc2)cc1O,BRD-K14441456,O=C(C=Cc1ccccc1)NCCCCc1ccccc1,BRD-K14441456,egfr inhibitor
9.885327,12.487015,611,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C,BRD-K14496212,O=C(NC1OC2C3CCCN3C(=O)CN2C1=O)C1C=C2c3cccc4[nH]cc(c34)CC2NC1,BRD-K14496212,dopamine receptor agonist
6.6006837,6.270891,612,COc1ccc(\C=C\c2cc(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1,BRD-K14536225,C(=Cc1cccc(OC2CCCCO2)c1)c1ccccc1,BRD-K14536225,glucosidase inhibitor
8.292742,8.412101,613,O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1,BRD-K14618467,O=C(c1ccc(Nc2nccc(-c3cc4ccccc4s3)n2)cc1)N1CCC(N2CCCC2)CC1,BRD-K14618467,ikk inhibitor
8.926811,8.002052,614,O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1,BRD-K14765469,c1ccc(C2CCN(C3CCCCC3)CC2)cc1,BRD-K14765469,acetylcholinesterase inhibitor
7.338757,7.3371882,615,COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F,BRD-K14767410,c1ccc(-c2ccnn2-c2ccccc2)cc1,BRD-K14767410,cyclooxygenase inhibitor
7.652755,9.282326,616,CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F,BRD-K14807180,O=C(Nc1cccnc1)N1CCc2ccccc21,BRD-K14807180,serotonin receptor antagonist
7.440422,8.72522,617,FC(F)(F)Oc1ccc(NN=C(C#N)C#N)cc1,BRD-K14821540,c1ccccc1,BRD-K14821540,mitochondrial oxidative phosphorylation uncoupler
5.9042425,8.186836,618,Nc1cc(nc(=N)n1O)N1CCCCC1,BRD-K14888893,N=c1nc(N2CCCCC2)cc[nH]1,BRD-K14888893,katp activator
7.633258,10.226473,619,CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O,BRD-K14965640,c1ccccc1,BRD-K14965640,cyclooxygenase inhibitor
5.8874464,8.817393,620,CCC1(C)CC(=O)NC(=O)C1,BRD-K14993104,O=C1CCCC(=O)N1,BRD-K14993104,chemoreceptor agonist
7.319733,8.346031,621,Cc1ccc(cc1)S(=O)(=O)\C=C\C#N,BRD-K15025317,c1ccccc1,BRD-K15025317,nfkb pathway inhibitor
7.7911315,7.2480903,622,CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1,BRD-K15086322,O=C(c1nc2ccccc2[nH]1)N1CCNCC1,BRD-K15086322,histamine receptor antagonist|histamine receptor silent antagonist
8.648624,8.306411,623,Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl,BRD-K15164005,O=C1C(=O)N(Cc2ccccc2)c2ccccc21,BRD-K15164005,carboxylesterase inhibitor
7.6997046,8.832903,624,CC(C)n1nnc2cc(ccc12)C(O)=O,BRD-K15196155,c1ccc2[nH]nnc2c1,BRD-K15196155,hydroxycarboxylic acid receptor agonist
8.135461,8.29319,625,C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1,BRD-K15519488,c1ccc2sc(C3(N4CCCCC4)CCCCC3)cc2c1,BRD-K15519488,dopamine receptor agonist
6.300665,7.1148205,626,COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,BRD-K15567136,c1ccc(Cc2nccc3ccccc23)cc1,BRD-K15567136,phosphodiesterase inhibitor
9.024988,8.926088,627,COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1,BRD-K15588452,c1ccc(CCc2ccccc2OCCC2CCCN2)cc1,BRD-K15588452,serotonin receptor antagonist
8.801376,8.521171,628,FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F,BRD-K15601958,c1ccc(-c2csc(-c3nc(-c4ccccc4)no3)c2)cc1,BRD-K15601958,lysophospholipid receptor agonist
7.592008,8.704648,629,Clc1cccc(NN=C(C#N)C#N)c1,BRD-K15616905,c1ccccc1,BRD-K15616905,mitochondrial oxidative phosphorylation uncoupler
9.863695,7.62757,630,CN1CCN(CC1)C1=Nc2cc(F)ccc2Cc2ccccc12,BRD-K15715913,c1ccc2c(c1)Cc1ccccc1C(N1CCNCC1)=N2,BRD-K15715913,dopamine receptor antagonist|serotonin receptor antagonist
6.670945,9.019057,631,Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O,BRD-K15766189,N=C(C(=O)NC1C(=O)N2C=CCSC12)c1cscn1,BRD-K15766189,bacterial cell wall synthesis inhibitor
9.059768,8.08119,632,FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F,BRD-K15791587,c1ccc(COC2CCCNC2c2ccccc2)cc1,BRD-K15791587,tachykinin antagonist
10.028901,10.476091,633,CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC,BRD-K15868788,c1ccccc1,BRD-K15868788,serotonin receptor antagonist
8.733503,8.481472,634,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,BRD-K15916496,c1ccc(C(c2ccccc2)(c2ccccc2)n2ccnc2)cc1,BRD-K15916496,cytochrome p450 inhibitor|imidazoline receptor ligand
6.3176622,7.5945644,635,CCCN(CCC)CCc1cccc2NC(=O)Cc12,BRD-K15933101,O=C1Cc2ccccc2N1,BRD-K15933101,dopamine receptor agonist|dopamine receptor modulator
8.18136,10.250284,636,CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)\C=C\S(C)(=O)=O,BRD-K15935639,c1ccccc1,BRD-K15935639,pgph inhibitor|proteasome inhibitor
7.981984,8.271216,637,O=C1c2ccccc2C(=O)c2ccccc12,BRD-K15957397,O=C1c2ccccc2C(=O)c2ccccc21,BRD-K15957397,cdc inhibitor
8.167833,6.7071505,638,Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C,BRD-K16195444,c1ccc(CC2=NCCN2)cc1,BRD-K16195444,adrenergic receptor agonist
7.8902507,8.553245,639,CC(C)C(=O)c1c(nn2ccccc12)C(C)C,BRD-K16444452,c1ccn2nccc2c1,BRD-K16444452,phosphodiesterase inhibitor|leukotriene receptor antagonist|toll-like receptor antagonist|macrophage migration inhibiting factor inhibitor|macrophage migration inhibiting factor modulator|mediator release inhibitor|nitric oxide synthase inhibitor
7.7614994,9.370073,640,Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1,BRD-K16485616,O=C(Nc1ccccc1)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1,BRD-K16485616,hdac inhibitor|cell cycle inhibitor
8.522357,7.9919176,641,CN1c2ccc(Cl)cc2C(=NCC1=O)c1ccccc1,BRD-K16508793,O=C1CN=C(c2ccccc2)c2ccccc2N1,BRD-K16508793,benzodiazepine receptor agonist
8.006308,8.060938,642,CCCOc1ccccc1-c1nc2[nH]nnc2c(=O)[nH]1,BRD-K16542329,O=c1[nH]c(-c2ccccc2)nc2[nH]nnc12,BRD-K16542329,phosphodiesterase inhibitor
9.0027685,7.195087,643,Cn1c2CCNCCc2c2ccccc12,BRD-K16551401,c1ccc2c3c([nH]c2c1)CCNCC3,BRD-K16551401,serotonin receptor agonist
5.211066,6.4750295,644,CCCN1CCc2cc(O)cc-3c2[C@H]1Cc1ccc(O)c(O)c-31,BRD-K16604360,c1ccc2c(c1)CC1NCCc3cccc-2c31,BRD-K16604360,antiamyloidogenic|dopamine receptor agonist
8.277336,8.047965,645,c1ccc(cc1)-c1n[nH]c2c1oc1ccccc21,BRD-K16664969,c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1,BRD-K16664969,flt3 inhibitor|tyrosine kinase inhibitor
8.716971,8.167081,646,Nc1ncnc2n(ncc12)-c1ccccc1,BRD-K16977723,c1ccc(-n2ncc3cncnc32)cc1,BRD-K16977723,egfr inhibitor
4.128642,8.9158325,647,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O,BRD-K17016787,c1ccc2c(c1)CCC1C2CCC2CCCC21,BRD-K17016787,estrogen receptor agonist
8.559952,8.787671,648,CC(C)c1ccc(Cn2ccc3c2ccc2nc(NC4CC4)nc(N)c32)cc1,BRD-K17140735,c1ccc(Cn2ccc3c4cnc(NC5CC5)nc4ccc32)cc1,BRD-K17140735,proteasome inhibitor
10.076594,10.578461,649,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,BRD-K17294426,O=C(NC1CCN(Cc2ccccc2)CC1)c1ccccc1,BRD-K17294426,dopamine receptor antagonist
3.522805,9.382076,650,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O,BRD-K17368287,O=C1C=C2CCC3C4CCC(=O)C4CC(=O)C3C2CC1,BRD-K17368287,11-beta hydroxysteroid dehydrogenase inhibitor
10.826839,8.687449,651,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1,BRD-K17378184,O=C(NCCCCN1CCN(c2ccccc2)CC1)c1ccc2ccccc2c1,BRD-K17378184,dopamine receptor agonist
6.437932,4.517147,652,C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1,BRD-K17415526,O=C(C=Cc1ccccc1)NCc1ccccc1,BRD-K17415526,protein tyrosine kinase inhibitor
6.8058076,6.810934,653,Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1,BRD-K17497770,O=C(C=Cc1ccccc1)c1ccccc1,BRD-K17497770,egfr inhibitor|src inhibitor
9.654007,8.578199,654,OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1,BRD-K17565903,c1ccc(C(CCN2CCCCC2)c2ccccc2)cc1,BRD-K17565903,muscle relaxant
2.432979,9.734153,655,C[C@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(C)=O)C(=O)COC(C)=O,BRD-K17674993,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K17674993,corticosteroid agonist
7.987049,9.309772,656,CC(=O)OCCNC(=O)c1cccnc1,BRD-K17693482,c1ccncc1,BRD-K17693482,potassium channel activator
8.273168,9.552611,657,CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1,BRD-K17705806,O=C(Nc1ccc2ncccc2c1)c1ccccc1COc1ccccc1,BRD-K17705806,opioid receptor antagonist
8.178123,8.939533,658,ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1,BRD-K17743125,O=S(=O)(Nc1ccccc1)c1ccccc1,BRD-K17743125,hdac inhibitor|cell cycle inhibitor
8.165875,9.083355,659,NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1,BRD-K17743697,c1ccc(COc2ccccc2)cc1,BRD-K17743697,sodium/calcium exchange inhibitor
8.252189,8.513879,660,CCCn1c(C)c(C(=O)c2cccc3ccccc23)c2ccccc12,BRD-K17796732,O=C(c1cccc2ccccc12)c1c[nH]c2ccccc12,BRD-K17796732,cannabinoid receptor agonist
8.53548,7.345561,661,O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O,BRD-K17894950,O=C1Nc2ccccc2C1=C1Nc2ccccc2C1=O,BRD-K17894950,cdk inhibitor|glycogen synthase kinase inhibitor
9.77553,8.96536,662,CCC(=O)N(C1CCN(CCc2ccc(cc2)N=C=S)CC1)c1ccccc1,BRD-K17896185,c1ccc(CCN2CCC(Nc3ccccc3)CC2)cc1,BRD-K17896185,opioid receptor agonist
6.1502047,11.131998,663,CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O,BRD-K18059238,,BRD-K18059238,cyclooxygenase inhibitor|prostanoid receptor stimulant|thromboxane synthase stimulant
8.7847595,9.340923,664,CNC(C)(C)Cc1ccccc1,BRD-K18194590,c1ccccc1,BRD-K18194590,adrenergic receptor agonist
9.870224,10.365649,665,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,BRD-K18250272,c1ccccc1,BRD-K18250272,local anesthetic
6.216398,7.6206913,666,COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C,BRD-K18316707,C1=CC(c2ccccc2)CCC1,BRD-K18316707,cannabinoid receptor antagonist
7.36538,7.076971,667,COc1c(O)cc2C(=O)O[C@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]3c2c1O,BRD-K18550767,O=C1OC2CCCOC2c2ccccc21,BRD-K18550767,interleukin inhibitor
12.173565,8.749549,668,CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O,BRD-K18574842,O=C(NC1C(=O)N2CCSC12)c1cccc2ccccc12,BRD-K18574842,bacterial cell wall synthesis inhibitor
4.308306,9.586654,669,C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1,BRD-K18619710,O=C1C=C(C2CCC3C2CCC2C4CCCCC4CCC23)CO1,BRD-K18619710,steroid
9.826504,6.5200467,670,CNCCNS(=O)(=O)c1cccc2cnccc12,BRD-K18742343,c1ccc2cnccc2c1,BRD-K18742343,pka inhibitor
6.015324,11.382655,671,CCCCC[C@H](O)\C=C\[C@H]1[C@H]2C[C@H](CO2)[C@@H]1C\C=C/CCCC(O)=O,BRD-K18757346,C1CC2CC1CO2,BRD-K18757346,thromboxane receptor agonist
8.970506,9.106812,672,CNCCCCOc1ccccc1Cc1ccccc1,BRD-K18779551,c1ccc(Cc2ccccc2)cc1,BRD-K18779551,acetylcholine release stimulant|adrenergic transmitter uptake inhibitor|reducing
8.251592,8.214824,673,N\C(Sc1ccccc1N)=C(C#N)/C(C#N)=C(\N)Sc1ccccc1N,BRD-K18787491,C(C=CSc1ccccc1)=CSc1ccccc1,BRD-K18787491,mek inhibitor
7.8634157,8.043037,674,FC(F)(F)CCCS(=O)(=O)Oc1cccc(Oc2cccc(c2C#N)C(F)(F)F)c1,BRD-K18799075,c1ccc(Oc2ccccc2)cc1,BRD-K18799075,cannabinoid receptor partial agonist
8.646031,6.2229576,675,CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1,BRD-K18816859,c1ccc(Cc2noc(-c3ccc4[nH]ccc4c3)n2)cc1,BRD-K18816859,serotonin receptor agonist
9.685321,7.819988,676,CN1CCN(CC1)c1nc2cc(ccc2n2cccc12)C(F)(F)F,BRD-K18909381,c1ccc2c(c1)nc(N1CCNCC1)c1cccn12,BRD-K18909381,serotonin receptor agonist
4.1085796,8.889794,677,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,BRD-K18910433,c1ccc2c(c1)CCC1C2CCC2CCCC21,BRD-K18910433,estrogen receptor agonist
7.4598565,9.734258,678,CC(C)(Oc1ccc(Cl)cc1)C(O)=O,BRD-K19111024,c1ccccc1,BRD-K19111024,ppar receptor agonist
6.7868633,7.6475487,679,CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,BRD-K19295594,c1ccc2cc(-c3ccc4ccccc4c3)ccc2c1,BRD-K19295594,bcl inhibitor|mcl1 inhibitor
9.166959,8.257058,680,C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1,BRD-K19309090,c1ccc2c(c1)CCCc1cc(NCCN3CCOCC3)nnc1-2,BRD-K19309090,acetylcholine receptor agonist
10.918375,7.7780232,681,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1,BRD-K19352500,c1ccc2c(c1)Sc1ccccc1N2CCCN1CCNCC1,BRD-K19352500,dopamine receptor antagonist
9.838766,12.433371,682,CC(C)[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C,BRD-K19360254,O=C(NC1OC2C3CCCN3C(=O)CN2C1=O)C1C=C2c3cccc4[nH]cc(c34)CC2NC1,BRD-K19360254,dopamine receptor agonist
10.402055,9.939927,683,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,BRD-K19462402,O=C(CCCN1CCCC1)c1ccccc1,BRD-K19462402,adrenergic receptor antagonist|calcium channel blocker
7.11233,7.127226,684,COc1ccc(C=CC(=O)Nc2ccccc2C(O)=O)cc1OC,BRD-K19533706,O=C(C=Cc1ccccc1)Nc1ccccc1,BRD-K19533706,angiogenesis inhibitor
9.287177,7.558599,685,Clc1cncc(n1)N1CCNCC1,BRD-K19554809,c1cnc(N2CCNCC2)cn1,BRD-K19554809,serotonin receptor agonist
8.944238,9.556604,686,Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1,BRD-K19605405,c1ccc(CCNc2ncn3nc(-c4ccco4)nc3n2)cc1,BRD-K19605405,adenosine receptor antagonist
9.153833,9.311043,687,CNCC[C@@H](Oc1ccccc1C)c1ccccc1,BRD-K20141153,c1ccc(COc2ccccc2)cc1,BRD-K20141153,norepinephrine transporter inhibitor|adrenergic transmitter uptake inhibitor
6.058748,11.239747,688,CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O,BRD-K20152659,,BRD-K20152659,cholesterol inhibitor
8.580967,7.3673863,689,CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34,BRD-K20620780,c1ccc2c(c1)CCc1cccc3c1C2CN1CCCCC31,BRD-K20620780,dopamine receptor antagonist
9.590769,10.352462,690,CCN(CC)CCNC(=O)COc1ccc(OC)cc1,BRD-K20655524,c1ccccc1,BRD-K20655524,psychoactive drug
9.764092,10.773878,691,Cn1cc(C(=O)C(=O)N[C@H]2CN3CCC2CC3)c2ccccc12,BRD-K20714604,O=C(NC1CN2CCC1CC2)C(=O)c1c[nH]c2ccccc12,BRD-K20714604,serotonin receptor partial agonist
10.219772,10.563648,692,COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1,BRD-K20742498,O=C(CCC1CCNCC1)c1ccccc1OCc1ccccc1,BRD-K20742498,serotonin receptor antagonist
6.8076773,9.123592,693,Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1,BRD-K20755323,c1ccc(Nc2nc(-c3ccccc3)cs2)cc1,BRD-K20755323,sphingosine kinase inhibitor
9.404623,8.617113,694,CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1,BRD-K20995441,O=C(NC1CCCCC1N1CCCC1)c1ccccc1,BRD-K20995441,opioid receptor agonist
7.383255,8.345666,695,Nc1nc2ccc(OC(F)(F)F)cc2s1,BRD-K21283037,c1ccc2scnc2c1,BRD-K21283037,glutamate inhibitor
8.308023,9.929014,696,Nc1nc(N)c(nc1Cl)C(=O)NC(=N)Nc1ccccc1,BRD-K21350491,N=C(NC(=O)c1cnccn1)Nc1ccccc1,BRD-K21350491,acid sensing ion channel blocker|sodium channel blocker|trpp3 channel inhibitor|trpv modulator
7.580756,7.9705467,697,NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O,BRD-K21450440,O=S1(=O)NC(CSCc2ccccc2)=Nc2ccccc21,BRD-K21450440,carbonic anhydrase inhibitor
7.2512116,8.575613,698,CC(=O)NS(=O)(=O)c1ccc(N)cc1,BRD-K21520694,c1ccccc1,BRD-K21520694,paba antagonist
10.870392,7.8255296,699,CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1,BRD-K21548250,O=C(CCN1CCOCC1)N1c2ccccc2Sc2ccccc21,BRD-K21548250,sodium channel blocker
8.64509,10.401825,700,Cc1cccc(C)c1NC1=NCCCS1,BRD-K21565985,c1ccc(NC2=NCCCS2)cc1,BRD-K21565985,adrenergic receptor agonist
6.0551605,11.30424,701,CCCCCC=CCC=CCC=CCC=CCCCC(=O)Nc1ccc(O)cc1,BRD-K21667562,c1ccccc1,BRD-K21667562,faah transport inhibitor|anandamide transport inhibitor|nucelar factor of activated t-cells inhibitor|trpv agonist
7.480788,7.554109,702,OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12,BRD-K21680192,O=C1c2ccccc2C(=O)c2ccccc21,BRD-K21680192,topoisomerase inhibitor
7.960641,8.009845,703,CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1,BRD-K21733600,O=C1OCC(c2ccccc2)=C1c1ccccc1,BRD-K21733600,cyclooxygenase inhibitor
6.6523795,5.1587276,704,Clc1cc(Cl)cc(c1)\C=C(/C#N)c1cccnc1,BRD-K21853356,C(=Cc1cccnc1)c1ccccc1,BRD-K21853356,egfr inhibitor
7.667764,8.870079,705,OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F,BRD-K22031190,c1ccc(-c2ccccc2)cc1,BRD-K22031190,prostanoid receptor antagonist
5.6897974,9.953282,706,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12,BRD-K22134346,O=C1CCCC(CCC2CC=CC3=CCCCC32)O1,BRD-K22134346,hmgcr inhibitor
7.3497477,6.4215164,707,COc1ccc(C(=O)c2ccccc2O)c(O)c1,BRD-K22193694,O=C(c1ccccc1)c1ccccc1,BRD-K22193694,topical sunscreen
8.475925,7.3045225,708,O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1,BRD-K22385716,O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12,BRD-K22385716,casein kinase inhibitor|mtor inhibitor|pi3k inhibitor
6.4059563,6.110981,709,Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1,BRD-K22861715,O=c1cc(-c2ccccc2)oc2ccccc12,BRD-K22861715,breast cancer resistance protein inhibitor
7.6569643,10.460772,710,OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O,BRD-K22969690,c1ccccc1,BRD-K22969690,bacterial 50s ribosomal subunit inhibitor
7.3727207,8.573255,711,Oc1c(Br)cc(Br)c2cccnc12,BRD-K23301018,c1ccc2ncccc2c1,BRD-K23301018,antiprotozoal
8.687903,8.947241,712,C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1,BRD-K23335153,c1ccc(C(NCCNC(c2ccccc2)c2ccccc2)c2ccccc2)cc1,BRD-K23335153,glutamate receptor positive allosteric modulator
8.491256,8.660432,713,OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F,BRD-K23383398,O=S(=O)(Nc1ccccc1)c1ccccc1,BRD-K23383398,lxr agonist|abc transporter expression enhancer|ror inverse agonist
4.3390403,9.5755415,714,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4C[C@@H](O)[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,BRD-K23478508,O=C1C=C(C2CCC3C2CCC2C4CCC(OC5CCC(OC6CCC(OC7CCCCO7)CO6)CO5)CC4CCC23)CO1,BRD-K23478508,atpase inhibitor
6.6056604,8.427011,715,CN(C)CCCSC(N)=N,BRD-K23541596,,BRD-K23541596,histamine receptor agonist
7.227333,8.454384,716,CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O,BRD-K23566484,O=C1CNC(=O)N1c1ccccc1,BRD-K23566484,androgen receptor antagonist
7.7505727,8.787458,717,OC(=O)c1cc(ccc1O)N(Cc1ccccc1O)Cc1cc(O)ccc1O,BRD-K23583188,c1ccc(CN(Cc2ccccc2)c2ccccc2)cc1,BRD-K23583188,egfr inhibitor|tyrosine kinase inhibitor
7.843185,8.238789,718,Fc1cccc(C=NN=Cc2cccc(F)c2)c1,BRD-K23623876,C(=NN=Cc1ccccc1)c1ccccc1,BRD-K23623876,ultrasound contrast
8.270355,7.4607797,719,Clc1oc(=O)c2ccccc2c1Cl,BRD-K23704908,O=c1occc2ccccc12,BRD-K23704908,serine protease inhibitor
7.85397,7.3115945,720,O=c1ccc2ccccc2o1,BRD-K23913458,O=c1ccc2ccccc2o1,BRD-K23913458,vitamin k antagonist
5.9977317,8.209294,721,CN1CCC=C(C1)C(=O)OCC#C,BRD-K23922020,C1=CCNCC1,BRD-K23922020,acetylcholine receptor agonist
6.1217966,9.104009,722,Cn1cnc2[nH]c(=O)n(C)c(=O)c12,BRD-K24084088,O=c1[nH]c(=O)c2[nH]cnc2[nH]1,BRD-K24084088,adenosine receptor antagonist
6.87241,7.0806937,723,COc1cc(cc(OC)c1OC)\C=C\C(=O)N1CCC=CC1=O,BRD-K24132293,O=C1C=CCCN1C(=O)C=Cc1ccccc1,BRD-K24132293,glutathione transferase inhibitor
10.097603,9.2859955,724,CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1,BRD-K24201553,O=S(=O)(c1ccccc1)N1CCCC1CCN1CCCCC1,BRD-K24201553,serotonin receptor antagonist
7.0269628,7.848509,725,CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1,BRD-K24240364,C1=NN=C(c2ccccc2)c2cc3c(cc2C1)OCO3,BRD-K24240364,glutamate receptor antagonist
6.658978,8.594146,726,NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)C12CC3CC(CC(C3)C1)C2,BRD-K24396733,c1ccc2c(c1)COC(C13CC4CC(CC(C4)C1)C3)C2,BRD-K24396733,dopamine receptor agonist
4.923395,5.35834,727,CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N,BRD-K24526313,O=C1CCCN1C1CCOc2ccccc21,BRD-K24526313,potassium channel activator
10.626326,9.510195,728,Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1,BRD-K25224017,O=C(c1ccccc1)C1CCN(CCc2cnc3ccccn3c2=O)CC1,BRD-K25224017,serotonin receptor antagonist
8.272338,9.115825,729,OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1,BRD-K25394294,c1ccc(-c2ncoc2-c2ccccc2)cc1,BRD-K25394294,cyclooxygenase inhibitor
9.409615,8.217478,730,CNCCCC12CCC(c3ccccc13)c1ccccc21,BRD-K25433859,c1ccc2c(c1)C1CCC2c2ccccc21,BRD-K25433859,norepinephrine reuptake inhibitor|tricyclic antidepressant
6.3829675,6.9099927,731,COc1ccc2c(OC)c3ccoc3nc2c1OC,BRD-K25741894,c1ccc2nc3occc3cc2c1,BRD-K25741894,acetylcholinesterase inhibitor
9.859504,6.4574018,732,Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1,BRD-K25875056,O=S(=O)(NCCCCCCc1ccccc1)c1cccc2ccccc12,BRD-K25875056,protein tyrosine kinase activator
8.956871,8.598688,733,C(C1CCNCC1)c1c[nH]cn1,BRD-K25906698,c1nc(CC2CCNCC2)c[nH]1,BRD-K25906698,histamine receptor agonist
8.358712,6.792525,734,Clc1cccc2CN(Cc12)C1=NCCN1,BRD-K26160755,c1ccc2c(c1)CN(C1=NCCN1)C2,BRD-K26160755,imidazoline receptor agonist
7.7317705,8.287007,735,NC(=O)c1sc(cc1N)-c1ccsc1,BRD-K26373640,c1csc(-c2ccsc2)c1,BRD-K26373640,ikk inhibitor
9.738722,8.715071,736,CC(C)=CCCN1CCC(CC1)NC(=O)[C@@](O)(C1CCCC1)c1ccccc1,BRD-K26429091,O=C(NC1CCNCC1)C(c1ccccc1)C1CCCC1,BRD-K26429091,acetylcholine receptor antagonist
5.955973,11.475711,737,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O,BRD-K26521938,O=C1CCCC1,BRD-K26521938,prostanoid receptor agonist
5.663001,8.185916,738,CCCN1CCC[C@@H]2Cc3n[nH]cc3C[C@@H]12,BRD-K26548821,c1[nH]nc2c1CC1NCCCC1C2,BRD-K26548821,dopamine receptor agonist
6.994775,8.561941,739,CN(C)c1ccc(cc1)\C=C1CCCN=C/1c1cccnc1,BRD-K26573499,C(=C1CCCN=C1c1cccnc1)c1ccccc1,BRD-K26573499,adrenergic receptor agonist
7.846939,9.239538,740,OC(=O)c1ccc(Cl)cc1NC(=O)Nc1cccc(c1)C(F)(F)F,BRD-K26979635,O=C(Nc1ccccc1)Nc1ccccc1,BRD-K26979635,glutamate receptor antagonist
7.5186763,6.265957,741,COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1,BRD-K26997899,O=C(c1ccccc1)c1cc2ccccc2[nH]1,BRD-K26997899,microtubule inhibitor|tubulin inhibitor
9.660824,8.313967,742,O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12,BRD-K27141178,O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12,BRD-K27141178,serotonin receptor antagonist
8.423808,7.271247,743,O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1,BRD-K27305650,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,BRD-K27305650,mtor inhibitor|pi3k inhibitor|dna dependent protein kinase inhibitor|phosphodiesterase inhibitor|plk inhibitor
5.8579493,8.342932,744,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,BRD-K27316855,C=C1CCCCC1=CC=C1CCCC2CCCC12,BRD-K27316855,vitamin d receptor agonist
3.7325878,9.401546,745,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O,BRD-K27351809,O=C1C=C2C=CC3C4CCCC4CCC3C2CC1,BRD-K27351809,progesterone receptor agonist
11.76505,5.5885577,746,CCCCCC[C@@H]([C@@H](C)O)n1cnc2c(N)ncnc12,BRD-K27450477,c1ncc2nc[nH]c2n1,BRD-K27450477,adenosine deaminase inhibitor
6.0052166,11.393181,747,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O,BRD-K27499107,C=C1CC2CCCC2C1,BRD-K27499107,ip receptor activator
8.113113,7.5102043,748,O=C1CCc2c(O1)ccc1ccccc21,BRD-K27710560,O=C1CCc2c(ccc3ccccc23)O1,BRD-K27710560,sirt inhibitor
9.835781,6.53182,749,Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1,BRD-K27737647,O=S(=O)(NCCNCC=Cc1ccccc1)c1cccc2cnccc12,BRD-K27737647,pka inhibitor
9.783179,12.36845,750,CN1C[C@H](CO)C=C2[C@H]1Cc1c[nH]c3cccc2c13,BRD-K27871032,C1=C2c3cccc4[nH]cc(c34)CC2NCC1,BRD-K27871032,ergoline alkaloid
8.552971,8.058295,751,Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl,BRD-K28115081,O=C(CCc1cc2c(s1)-n1cnnc1CN=C2c1ccccc1)N1CCOCC1,BRD-K28115081,platelet activating factor receptor antagonist
7.7046175,8.256541,752,ClC(=Cn1cncn1)c1ccc(Cl)cc1Cl,BRD-K28137194,C(=Cn1cncn1)c1ccccc1,BRD-K28137194,gaba receptor agonist
9.983746,7.5056486,753,CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12,BRD-K28143534,C1=Cc2ccccc2C(=C2CCNCC2)c2ccccc21,BRD-K28143534,histamine receptor antagonist
7.9919863,9.8389015,754,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1,BRD-K28183345,c1ccccc1,BRD-K28183345,dihydrofolate reductase inhibitor
7.2495832,9.027724,755,CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O,BRD-K28307902,c1ccccc1,BRD-K28307902,androgen receptor antagonist
9.787095,10.218629,756,CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O,BRD-K28453807,c1ccc(C2CCCC2)cc1,BRD-K28453807,cholinergic receptor antagonist
7.423746,6.341179,757,CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1,BRD-K28578425,O=C(CCCOc1ccc2[nH]c(=O)ccc2c1)NC1CCCCC1,BRD-K28578425,phosphodiesterase inhibitor
4.795604,11.07431,758,COc1cc(ccc1O)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C,BRD-K28667196,O=C(OC1CC2CCC(C1)N2)c1ccccc1,BRD-K28667196,increases arterial blood pressure
9.097847,6.5642056,759,COC(=O)c1cc2c(cn1)[nH]c1ccccc21,BRD-K28680267,c1ccc2c(c1)[nH]c1cnccc12,BRD-K28680267,cck receptor antagonist
10.664724,7.6159377,760,OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1,BRD-K28761384,C(CCN1CCNCC1)=C1c2ccccc2Sc2ccccc21,BRD-K28761384,dopamine receptor antagonist
6.7682986,9.616,761,CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12,BRD-K28761891,c1cc2c(c3c1CCC3)CCO2,BRD-K28761891,melatonin receptor agonist
8.945161,6.839102,762,Ic1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1,BRD-K28806945,c1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1,BRD-K28806945,dopamine receptor antagonist
9.689709,10.836385,763,Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2,BRD-K28863208,O=C(NC1CN2CCC1CC2)c1ccccc1,BRD-K28863208,cholinergic receptor agonist
7.529302,9.156076,764,OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2,BRD-K28907958,c1cc(-c2ccc3ccccc3c2)cc(C23CC4CC(CC(C4)C2)C3)c1,BRD-K28907958,retinoid receptor agonist
9.983861,7.5165315,765,CN1CCC(CC1)=C1c2ccsc2C(=O)Cc2ccccc12,BRD-K28936863,O=C1Cc2ccccc2C(=C2CCNCC2)c2ccsc21,BRD-K28936863,histamine receptor agonist|leukotriene receptor antagonist|phosphodiesterase inhibitor
7.553808,8.75662,766,CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1,BRD-K29113274,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1,BRD-K29113274,sterol demethylase inhibitor
6.692289,6.975676,767,COc1c2ccoc2nc2ccccc12,BRD-K29178788,c1ccc2nc3occc3cc2c1,BRD-K29178788,furoquinoline alkaloid
8.588388,7.9712305,768,O=c1n([se]c2ccccc12)-c1ccccc1,BRD-K29359156,O=c1c2ccccc2[se]n1-c1ccccc1,BRD-K29359156,h+/k+-atpase inhibitor
6.1102357,11.25943,769,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(N)=O,BRD-K29555132,,BRD-K29555132,cannabinoid receptor agonist
10.420258,8.41865,770,Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1,BRD-K29582677,C(=Cc1ccccc1)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,BRD-K29582677,calcium channel blocker
9.52386,8.46693,771,CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1,BRD-K29668683,c1ccc(CCN2CCNCC2)cc1,BRD-K29668683,sigma receptor antagonist
6.746217,7.705192,772,Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O,BRD-K29673530,O=c1c2cccc3c4cccc5c(=O)c6cccc7c8cccc1c8c(c23)c(c54)c67,BRD-K29673530,tyrosine kinase inhibitor
9.727539,10.061914,773,CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1,BRD-K29950728,C(=C(c1ccccc1)c1ccccc1)c1ccccc1,BRD-K29950728,estrogen receptor antagonist
8.542166,6.2461343,774,COc1ccc2[nH]cc(CCN)c2c1,BRD-K30197592,c1ccc2[nH]ccc2c1,BRD-K30197592,serotonin receptor agonist
9.799835,8.713304,775,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,BRD-K30240666,c1ccc(C(OCCC2CCCN2)c2ccccc2)cc1,BRD-K30240666,histamine receptor antagonist
3.9394963,6.814961,776,CC(C)(C)NC[C@@H](O)COc1nsnc1N1CCOCC1,BRD-K30421593,c1nsnc1N1CCOCC1,BRD-K30421593,adrenergic receptor antagonist
7.566585,9.202516,777,CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1,BRD-K30480208,c1ccc(Nc2ccncc2)cc1,BRD-K30480208,electrolyte reabsorption inhibitor
7.4663343,10.08693,778,N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O,BRD-K30685142,c1ccc(Oc2ccccc2)cc1,BRD-K30685142,thyroid hormone stimulant
9.55757,9.6528425,779,COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C,BRD-K30867024,O=C(Nc1ccccc1)c1ccc(-c2ccc(-c3ncon3)cc2)cc1,BRD-K30867024,serotonin receptor antagonist
7.2476263,6.503895,780,COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1,BRD-K30990140,O=C(c1nc(-c2ccccc2)c(-c2ccccc2)s1)N1CCNCC1,BRD-K30990140,cyclooxygenase inhibitor
10.742089,8.641041,781,COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1,BRD-K31054881,O=C1CC2(CCCC2)CC(=O)N1CCN1CCN(c2ccccc2)CC1,BRD-K31054881,adrenergic receptor antagonist
8.294126,7.9491987,782,CN1c2ccccc2C(=N[C@H](NC(=O)c2cc3ccccc3[nH]2)C1=O)c1ccccc1,BRD-K31238592,O=C(NC1N=C(c2ccccc2)c2ccccc2NC1=O)c1cc2ccccc2[nH]1,BRD-K31238592,cck receptor antagonist|gastrin inhibitor
8.884404,6.8921633,783,CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12,BRD-K31342827,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12,BRD-K31342827,pkc inhibitor
8.347591,9.840349,784,NC(=N)NC(=N)Nc1ccccc1,BRD-K31491153,c1ccccc1,BRD-K31491153,serotonin receptor agonist
8.064144,9.892532,785,COc1c(C)c2COC(=O)c2c(O)c1CC=C(C)CCC(O)=O,BRD-K31542390,O=C1OCc2ccccc21,BRD-K31542390,dehydrogenase inhibitor|inositol monophosphatase inhibitor
6.0311813,11.403171,786,O[C@@H](COc1cccc(c1)C(F)(F)F)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,BRD-K31611373,C(=CC1CCCC1)CCOc1ccccc1,BRD-K31611373,prostanoid receptor agonist
2.8532126,9.634975,787,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,BRD-K31627533,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K31627533,glucocorticoid receptor agonist
4.727439,11.255477,788,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O,BRD-K31633810,O=C1Nc2ccccc2CN1C(=O)OC1CC2CCC(C1)N2,BRD-K31633810,acetylcholine receptor antagonist
7.5963264,7.060411,789,COc1cccc(C=NC=Nc2cccc(OC)c2)c1,BRD-K31699485,C(=NC=Nc1ccccc1)c1ccccc1,BRD-K31699485,glutamate receptor modulator
6.8851624,8.493213,790,Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1,BRD-K31792052,c1ccc(-c2cn3c4c(sc3n2)CCCC4)cc1,BRD-K31792052,interleukin receptor antagonist
7.32657,9.158867,791,[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1,BRD-K31843556,O=C(Nc1ccncc1)c1ccccc1,BRD-K31843556,ppar receptor antagonist|ppar receptor antagonist
9.8198395,6.6320925,792,Nc1nc(NCC2CCC(CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12,BRD-K31912990,O=S(=O)(NCC1CCC(CNc2ncc3ccccc3n2)CC1)c1cccc2ccccc12,BRD-K31912990,neuropeptide receptor antagonist
5.9782653,11.19531,793,CCCCCCCCC=CCCCCCCCC(=O)NCCO,BRD-K31987754,,BRD-K31987754,cannabinoid receptor agonist
7.06041,9.3935995,794,Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1,BRD-K32164935,O=C(NN1CCCCCC1)NS(=O)(=O)c1ccccc1,BRD-K32164935,atp channel blocker
8.78242,7.643715,795,CCC1(C(=O)NCNC1=O)c1ccccc1,BRD-K32247306,O=C1NCNC(=O)C1c1ccccc1,BRD-K32247306,gaba receptor antagonist
7.9856906,7.793497,796,Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1,BRD-K32292990,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc21,BRD-K32292990,egfr inhibitor
5.303092,6.5937414,797,COc1ccc2C[C@H]3N(C)CCc4cc(O)cc(c34)-c2c1O,BRD-K32412559,c1ccc2c(c1)CC1NCCc3cccc-2c31,BRD-K32412559,adrenergic receptor antagonist
10.38085,8.753964,798,Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1,BRD-K32501161,c1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1,BRD-K32501161,dopamine uptake inhibitor
6.6620226,8.3940935,799,CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O,BRD-K32526544,O=c1[nH]c2ccccc2[nH]1,BRD-K32526544,potassium channel activator
7.9263043,8.774795,800,OC(=O)c1ccc2nc(-c3ccccc3)c(nc2c1)-c1ccccc1,BRD-K32584078,c1ccc(-c2nc3ccccc3nc2-c2ccccc2)cc1,BRD-K32584078,akt inhibitor|hcv ns5b rdrp inhibitor
8.539618,6.200812,801,CCCN(CCC)CCc1c[nH]c2ccc(cc12)C(N)=O,BRD-K32645441,c1ccc2[nH]ccc2c1,BRD-K32645441,serotonin receptor agonist
9.042831,7.000844,802,C1Cc2c(CN1)[nH]c1ccccc21,BRD-K32696739,c1ccc2c3c([nH]c2c1)CNCC3,BRD-K32696739,monoamine oxidase inhibitor
6.134489,8.543855,803,CCN(CC)C(=S)SSC(=S)N(CC)CC,BRD-K32744045,,BRD-K32744045,aldehyde dehydrogenase inhibitor|dna methyltransferase inhibitor|trpv agonist
8.879562,5.8098207,804,CO[C@H]1[C@H](O)C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(O)=O,BRD-K32755366,c1ccc2c3c([nH]c2c1)C1CC2CCCCC2CN1CC3,BRD-K32755366,norepinephrine transporter inhibitor
6.4241414,8.539117,805,Cn1cnc(c1Sc1[nH]cnc2ncnc12)[N+]([O-])=O,BRD-K32821942,c1nc2nc[nH]c(Sc3cnc[nH]3)c-2n1,BRD-K32821942,dehydrogenase inhibitor
5.659624,7.1242123,806,CN1Cc2c3OCOc3ccc2[C@H]2[C@@H](O)Cc3cc4OCOc4cc3[C@@H]12,BRD-K32828673,c1c2c(cc3c1OCO3)C1NCc3c(ccc4c3OCO4)C1CC2,BRD-K32828673,tubulin polymerization inhibitor
8.478741,9.856216,807,NC(=N)NC(=O)Cc1c(Cl)cccc1Cl,BRD-K32830106,c1ccccc1,BRD-K32830106,adrenergic receptor agonist
6.5410233,4.8976526,808,NC(=C(C#N)C#N)C(\C#N)=C\c1ccc2[nH]ccc2c1,BRD-K33204703,c1ccc2[nH]ccc2c1,BRD-K33204703,pdgfr receptor inhibitor
6.785981,6.4669385,809,COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1,BRD-K33211335,c1ccc2c(c1)CC1NCCC23CCCCC13,BRD-K33211335,glutamate receptor antagonist|sigma receptor agonist
8.373104,7.6036367,810,O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12,BRD-K33308633,O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc21,BRD-K33308633,calcineurin inhibitor
6.2411757,11.254457,811,CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O,BRD-K33396764,,BRD-K33396764,omega 3 fatty acid stimulant
8.441767,8.754744,812,C[C@@H]1CN(CC[C@]1(C(O)=O)c1ccccc1)[C@H]1CC[C@](CC1)(C#N)c1ccc(F)cc1,BRD-K33453211,c1ccc(C2CCC(N3CCC(c4ccccc4)CC3)CC2)cc1,BRD-K33453211,histamine receptor antagonist
8.485855,10.121126,813,Cc1ccccc1NC(=N)Nc1ccccc1C,BRD-K33459542,N=C(Nc1ccccc1)Nc1ccccc1,BRD-K33459542,sigma receptor agonist
6.853237,6.9156084,814,Oc1ccc(cc1)\C=C\C(=O)c1ccc(O)cc1O,BRD-K33583600,O=C(C=Cc1ccccc1)c1ccccc1,BRD-K33583600,guanylate cyclase activator
6.5453224,8.924241,815,CCc1cc(ccn1)C(N)=S,BRD-K33710385,c1ccncc1,BRD-K33710385,mycolic synthesis inhibitor
8.677902,9.817238,816,OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1,BRD-K33818169,c1ccc(CN(CCCOc2ccccc2)CC(c2ccccc2)c2ccccc2)cc1,BRD-K33818169,lxr agonist|abc transporter expression enhancer
8.76686,6.3599896,817,CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O,BRD-K33864865,O=c1c2ccccc2nc(CCc2c[nH]c3ccccc23)n1-c1ccccc1,BRD-K33864865,cck receptor antagonist
9.08003,6.6226044,818,CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC,BRD-K33882852,c1ccc(COc2ccc3[nH]c4cnccc4c3c2)cc1,BRD-K33882852,benzodiazepine receptor agonist
7.346886,6.2923856,819,COc1ccc2cc(ccc2c1)[C@H](C)CO,BRD-K34014345,c1ccc2ccccc2c1,BRD-K34014345,anti-inflammatory
10.441615,8.562099,820,C(CN1CCN(CC=Cc2ccccc2)CC1)OC(c1ccccc1)c1ccccc1,BRD-K34034388,C(=Cc1ccccc1)CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1,BRD-K34034388,dopamine uptake inhibitor
6.0998707,11.392561,821,CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCc1ccc(O)c(OC)c1,BRD-K34092021,c1ccccc1,BRD-K34092021,trpv agonist|cannabinoid receptor agonist
6.840668,10.005391,822,CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12,BRD-K34154330,c1cnc2[nH]ncc2c1,BRD-K34154330,gaba receptor modulator
6.9522347,6.9624386,823,COC(=O)C=Cc1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1,BRD-K34170797,O=C(C1CCCCC1)N(Cc1ccc(-c2ccccc2)cc1)c1ccccc1,BRD-K34170797,fxr agonist
9.647212,10.08171,824,COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1,BRD-K34415467,O=C(NCc1ccccc1)c1ccccc1,BRD-K34415467,histamine receptor antagonist
9.724756,10.230497,825,CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1,BRD-K34568562,O=C1c2ccccc2-c2ccccc21,BRD-K34568562,interferon inducer
7.185931,9.599428,826,Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1,BRD-K34608650,O=C(NC1CCCCC1)c1nn(-c2ccccc2)c2c1Cc1ccccc1-2,BRD-K34608650,cannabinoid receptor agonist
9.835276,12.428556,827,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34,BRD-K34685430,C1=C2c3cccc4[nH]cc(c34)CC2NCC1,BRD-K34685430,dopamine receptor antagonist|serotonin receptor antagonist
6.4449587,4.535526,828,CC(C)c1cc(cc(C(C)C)c1O)\C=C(/C#N)C(=O)NCCCc1ccccc1,BRD-K34995470,O=C(C=Cc1ccccc1)NCCCc1ccccc1,BRD-K34995470,receptor tyrosine protein kinase inhibitor|vascular endothelial growth factor receptor 2 (vegfr2) inhibitor|vegfr inhibitor
2.9085605,9.598472,829,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,BRD-K35240538,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K35240538,glucocorticoid receptor agonist
4.1949596,6.8560805,830,CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12,BRD-K35430135,c1ccc(OCCCNC2CCCc3ccccc32)cc1,BRD-K35430135,adrenergic receptor antagonist
8.729954,8.009658,831,CC1=NN(C(=O)C1)c1ccccc1,BRD-K35458079,O=C1CC=NN1c1ccccc1,BRD-K35458079,nootropic
8.477001,8.515933,832,OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23,BRD-K35498378,O=C1NC(=O)c2cccc3cccc1c23,BRD-K35498378,aldose reductase inhibitor
8.406697,8.764653,833,OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl,BRD-K35629949,O=C(Nc1nc(-c2ccccc2)cs1)c1cc2ccccc2[nH]1,BRD-K35629949,cck receptor antagonist
4.3038015,9.557096,834,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O,BRD-K35708212,O=C1C=C(C2CCC3C2CCC2C4CCC(OC5CCCCO5)CC4CCC23)CO1,BRD-K35708212,atpase inhibitor
9.787954,12.374057,835,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34,BRD-K35941380,C1=C2c3cccc4[nH]cc(c34)CC2NCC1,BRD-K35941380,serotonin receptor antagonist
7.3066435,9.214174,836,Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O,BRD-K35960502,O=C(Nc1ccccc1)c1ccccc1,BRD-K35960502,dna replication inhibitor|stat inhibitor
12.126117,5.398093,837,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1,BRD-K36007650,O=C(CCc1ccccc1)NC1COC(n2cnc3cncnc32)C1,BRD-K36007650,protein synthesis inhibitor
8.8657055,8.71913,838,COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3ccc4ccccc4c3)CC2)C1=O,BRD-K36009368,O=C1NCN(c2ccccc2)C12CCN(Cc1ccc3ccccc3c1)CC2,BRD-K36009368,opioid receptor agonist
8.440468,7.355796,839,Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1,BRD-K36021395,c1ccc(-c2cc(-c3ccc(N4CCOCC4)nc3)nc3ncncc23)cc1,BRD-K36021395,adenosine kinase inhibitor
5.847721,8.844266,840,C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1,BRD-K36055864,O=C1CC(CCC2CCCCC2=O)CC(=O)N1,BRD-K36055864,protein synthesis inhibitor
6.2389674,8.69421,841,CCC1(CC)C(=O)NC=CC1=O,BRD-K36116267,O=C1C=CNC(=O)C1,BRD-K36116267,psychoactive drug
8.843536,9.357206,842,Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO,BRD-K36198571,O=C(NCCOc1ccc(S(=O)(=O)N(Cc2ccccc2)c2ccccc2)cc1)c1cc2ccccc2o1,BRD-K36198571,metalloproteinase inhibitor
7.3590703,9.159597,843,[O-][N+](=O)c1cc(C(=O)NCC=C)c2nc(Nc3ccc(Cl)c(Cl)c3)[nH]c(=O)c2c1,BRD-K36258877,O=c1[nH]c(Nc2ccccc2)nc2ccccc12,BRD-K36258877,caspase inhibitor
6.5937047,6.4598694,844,CC(C)(O)[C@@H]1Cc2cc3ccc(=O)oc3cc2O1,BRD-K36377456,O=c1ccc2cc3c(cc2o1)OCC3,BRD-K36377456,angiogenesis inhibitor
7.677123,9.282478,845,Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1,BRD-K36395411,O=C(Nc1cccnc1)N1CCc2cc3[nH]ccc3cc21,BRD-K36395411,serotonin receptor antagonist|serotonin receptor partial agonist
8.803654,7.9436913,846,C1CC[C@@H](NC1)c1cccnc1,BRD-K36638830,c1cncc(C2CCCCN2)c1,BRD-K36638830,acetylcholine receptor agonist
6.3671474,7.5954213,847,CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC,BRD-K36756879,c1ccc(Cc2nccc3ccccc23)cc1,BRD-K36756879,calcium channel blocker
7.39715,7.8676615,848,NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F,BRD-K36862742,O=S1(=O)NCNc2ccccc21,BRD-K36862742,sodium/potassium/chloride transporter inhibitor
9.310974,8.709084,849,CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1,BRD-K36864847,c1ccccc1,BRD-K36864847,adrenergic receptor antagonist
7.020144,9.597348,850,COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,BRD-K36927236,O=C(NC1CCCCC1)NS(=O)(=O)c1ccc(CCNC(=O)c2ccccc2)cc1,BRD-K36927236,sulfonylurea
8.358098,9.80178,851,NC(=N)NC(=N)Nc1cccc(Cl)c1,BRD-K36965586,c1ccccc1,BRD-K36965586,serotonin receptor agonist
9.799947,8.714157,852,COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1,BRD-K37249724,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1,BRD-K37249724,histamine receptor antagonist
3.7590492,9.280125,853,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C,BRD-K37270826,O=C1C=C2CCC3C(=C2CC1)C(c1ccccc1)CC1CCCC13,BRD-K37270826,glucocorticoid receptor antagonist|progesterone receptor antagonist
9.82883,7.6926446,854,CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12,BRD-K37289225,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1N2,BRD-K37289225,dopamine receptor antagonist
8.613868,7.434166,855,Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1,BRD-K37312348,O=C1Cc2c([nH]c3ccccc23)-c2ccccc2N1,BRD-K37312348,cdk inhibitor|glycogen synthase kinase inhibitor
7.224821,8.284103,856,Cc1ccc(C=C2CNCC(=Cc3ccc(C)cc3)C2=O)cc1,BRD-K37392901,O=C1C(=Cc2ccccc2)CNCC1=Cc1ccccc1,BRD-K37392901,ubiquitin hydrolase inhibitor|ubiquitin isopeptidase inhibitor
5.723015,7.1807847,857,COc1c2OCOc2cc2CCN(C)Cc12,BRD-K37447567,c1c2c(cc3c1OCO3)CNCC2,BRD-K37447567,opioid receptor antagonist
7.0281014,6.9882784,858,COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1,BRD-K37561857,O=c1ccc(-c2ccccc2)n[nH]1,BRD-K37561857,phosphodiesterase inhibitor
8.819963,9.416094,859,Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1,BRD-K37618799,O=C(Cc1ccccc1)Nc1nc2ccccc2c2nc(-c3ccco3)nn12,BRD-K37618799,adenosine receptor antagonist
4.8591647,8.207657,860,CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1,BRD-K37682401,O=c1cc[nH]c2nc(N3CCCC3)ncc12,BRD-K37682401,bacterial dna gyrase inhibitor
10.047701,8.55857,861,Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1,BRD-K37688416,O=C(COc1ccccc1)N1CCN(Cc2ccc3c(c2)OCO3)CC1,BRD-K37688416,psychoactive drug
7.354381,8.559953,862,CC(C)c1cccc(=O)c(O)c1,BRD-K37691127,O=c1cccccc1,BRD-K37691127,tyrosinase inhibitor
5.793048,9.472912,863,CCCCn1c2ncn(CC(C)=O)c2c(=O)n(CCCC)c1=O,BRD-K37792168,O=c1[nH]c(=O)c2[nH]cnc2[nH]1,BRD-K37792168,phosphodiesterase inhibitor
6.262737,7.196965,864,COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,BRD-K37798499,O=C1OCC2C(OC3CCC4OCOCC4O3)c3cc4c(cc3C(c3ccccc3)C12)OCO4,BRD-K37798499,topoisomerase inhibitor
6.959427,9.099484,865,NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O,BRD-K37848908,O=C(Cc1ccccc1)NC1C(=O)N2C=C(CSc3nnn[nH]3)CSC12,BRD-K37848908,penicillin binding protein inhibitor
8.4001465,9.293214,866,CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1,BRD-K37865504,c1ccc(-c2ccc(Cc3nnn[nH]3)cc2)cc1,BRD-K37865504,faah inhibitor|faah reuptake inhibitor
9.552558,8.247458,867,Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1,BRD-K37991163,c1ccc(C2CCNCC2COc2ccc3c(c2)OCO3)cc1,BRD-K37991163,selective serotonin reuptake inhibitor (ssri)
2.4550068,9.7126045,868,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,BRD-K38003476,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K38003476,steroid
6.546009,9.474167,869,CCN(CC)C(=O)c1ccc(O)c(OC)c1,BRD-K38055836,c1ccccc1,BRD-K38055836,respiratory stimulant
7.866923,8.6865225,870,CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O,BRD-K38197229,c1ccc(Oc2ccccc2)cc1,BRD-K38197229,solute carrier family member inhibitor
8.818762,7.053108,871,CC(C)(O)[C@H]1O[C@H]2CC[C@]3(C)[C@]4(C)[C@H](Cc5c4[nH]c4ccccc54)CC[C@@]3(O)C2=CC1=O,BRD-K38251852,O=C1C=C2C(CCC3C2CCC2Cc4c([nH]c5ccccc45)C23)OC1,BRD-K38251852,abc transporter expression enhancer|high conductance calcium activated potassium blocker|lxr agonist|potassium channel blocker
10.807748,9.326321,872,Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1,BRD-K38305202,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1,BRD-K38305202,dopamine receptor antagonist
7.0471206,8.988106,873,CCOc1ccc(NC(C)=O)cc1,BRD-K38323065,c1ccccc1,BRD-K38323065,cyclooxygenase inhibitor
5.9255548,8.906983,874,Cn1c2[nH]c(nc2c(=O)n(C)c1=O)C1CCCC1,BRD-K38347298,O=c1[nH]c(=O)c2nc(C3CCCC3)[nH]c2[nH]1,BRD-K38347298,adenosine receptor antagonist
10.947621,7.717964,875,CN(C)CCCN1c2ccccc2CCc2ccccc12,BRD-K38436528,c1ccc2c(c1)CCc1ccccc1N2,BRD-K38436528,norepinephrine reuptake inhibitor|serotonin reuptake inhibitor
5.712114,8.598761,876,C\C=C1\CC(=C)[C@@](C)(O)C(=O)OCC2=CCN3CC[C@@H](OC1=O)[C@@H]23,BRD-K38449220,C=C1CC(=C)C(=O)OC2CCN3CC=C(COC(=O)C1)C23,BRD-K38449220,cytochrome p450 inhibitor
6.572783,5.078971,877,CC(C)(C)c1cc(C=C(C#N)[N+]#[C-])cc(c1O)C(C)(C)C,BRD-K38477985,c1ccccc1,BRD-K38477985,protein tyrosine kinase inhibitor|tyrosine kinase inhibitor
5.7790594,8.706818,878,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,BRD-K38684403,N=C1CCCCOC(=O)CC(OC2CCCCO2)CC(OC2CCCCO2)CCC1,BRD-K38684403,bacterial 50s ribosomal subunit inhibitor
2.5124304,9.718106,879,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,BRD-K38775274,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K38775274,glucocorticoid receptor agonist
6.8086452,6.2218585,880,COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1,BRD-K38903228,O=C1CC(c2ccccc2)Oc2cc(OC3CCCC(COC4CCCCO4)O3)ccc21,BRD-K38903228,flavanone glycoside
7.137317,8.384761,881,Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O,BRD-K39120595,c1ccc(Sc2ccccc2)cc1,BRD-K39120595,autotaxin inhibitor
5.2328897,6.5125985,882,CN1CCc2cc(O)cc-3c2[C@H]1Cc1ccc(O)c(O)c-31,BRD-K39187410,c1ccc2c(c1)CC1NCCc3cccc-2c31,BRD-K39187410,antiamyloidogenic
2.4914312,9.726285,883,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,BRD-K39188321,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K39188321,glucocorticoid receptor agonist
6.520441,8.14349,884,COc1cc(C)nn1-c1nc(C)cc(OC)n1,BRD-K39339537,c1cnc(-n2cccn2)nc1,BRD-K39339537,cyclooxygenase inhibitor
4.11231,9.196539,885,CC(=O)[C@H]1[C@@H](C[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C#N,BRD-K39356024,C1=C2CCCCC2C2CCC3CCCC3C2C1,BRD-K39356024,acetylcholine release enhancer|dopamine release enhancer|gaba receptor negative allosteric modulator|glutamate receptor modulator|progesterone receptor agonist|steroid hormone inhibitor of cyp17a1 and sult2b1
5.559817,8.827828,886,CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O,BRD-K39484304,O=C1OCC2=C1CCC1C2CC2OC23CC2OC2C2OC123,BRD-K39484304,rna polymerase inhibitor
6.2195687,8.303125,887,Cc1nc(N)sc1CCN,BRD-K39670393,c1cscn1,BRD-K39670393,histamine receptor agonist
7.5003552,9.400486,888,CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C,BRD-K39733634,O=C(NS(=O)(=O)c1ccccc1-c1ccc(Cn2cnn(-c3ccccc3)c2=O)cc1)c1cccs1,BRD-K39733634,prostanoid receptor antagonist|angiotensin receptor antagonist
5.7707753,8.633064,889,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,BRD-K39746403,O=C1CCCCOC(=O)CC(OC2CCCCO2)CC(OC2CCCCO2)CCC1,BRD-K39746403,nfkb pathway inhibitor|50s ribosomal subunit inhibitor|motilin receptor agonist|rplv inhibitor
9.980117,7.6461143,890,CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12,BRD-K39915878,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1O2,BRD-K39915878,dopamine receptor antagonist|serotonin receptor antagonist
6.3544135,11.145652,891,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O,BRD-K39965020,,BRD-K39965020,ppar receptor agonist
9.497323,9.536789,892,CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1,BRD-K39987650,c1ccc(C(c2ccccc2)c2ccccn2)cc1,BRD-K39987650,laxative
6.54703,5.0566826,893,CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C,BRD-K40255344,c1ccccc1,BRD-K40255344,protein tyrosine kinase inhibitor|tyrosine kinase inhibitor
4.6512833,11.332626,894,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1,BRD-K40530731,O=C(Cc1ccccc1)OC1CC2CCC(C1)N2,BRD-K40530731,acetylcholine receptor inhibitor
12.155005,5.364519,895,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12,BRD-K40578143,c1nc(NC2CCCC2)c2ncn(C3CCCO3)c2n1,BRD-K40578143,adenosine receptor agonist
6.5197234,9.658932,896,CCCc1c(OCCCOc2ccc(OCC(O)=O)cc2)ccc(CC=O)c1O,BRD-K40656405,c1ccc(OCCCOc2ccccc2)cc1,BRD-K40656405,ppar receptor agonist
6.90155,7.291411,897,COc1cc(C)c(C(=O)Oc2cc(C)c(O)c(C(O)=O)c2C)c(O)c1C=O,BRD-K40742111,O=C(Oc1ccccc1)c1ccccc1,BRD-K40742111,lipoxygenase inhibitor
8.726627,10.468961,898,Cc1cccc(C)c1NC(=O)C[N+](C)(C)C,BRD-K40782193,c1ccccc1,BRD-K40782193,sodium channel blocker
10.549808,9.45969,899,Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1,BRD-K40887525,O=c1c(CCN2CCC(=C(c3ccccc3)c3ccccc3)CC2)cnc2sccn12,BRD-K40887525,serotonin receptor antagonist
8.206514,9.026727,900,CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1,BRD-K40901640,O=C(C=Cc1ccccc1)Nc1ccccc1,BRD-K40901640,serotonin receptor antagonist
8.549978,9.700248,901,NC(=O)NC(=O)Cc1ccccc1,BRD-K40905133,c1ccccc1,BRD-K40905133,sodium channel blocker
4.032882,6.772908,902,CC(C)(C)NC[C@H](O)COc1cccc2[nH]c(cc12)C#N,BRD-K40965114,c1ccc2[nH]ccc2c1,BRD-K40965114,adrenergic receptor antagonist
8.248655,9.878445,903,NC(=N)NC(=O)c1nc(Cl)c(nc1N)N1CCCCCC1,BRD-K40990712,c1cnc(N2CCCCCC2)cn1,BRD-K40990712,gonadotropin releasing factor hormone receptor antagonist|sodium/hydrogen antiport inhibitor|sodium/hydrogen exchanger inhibitor|urokinase inhibitor
8.624514,9.421827,904,NC(=O)CNCCC(c1ccccc1)c1ccccc1,BRD-K41143549,c1ccc(Cc2ccccc2)cc1,BRD-K41143549,glutamate receptor antagonist
7.6076713,9.420452,905,CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1,BRD-K41160163,O=C1CNC(NC(=O)Nc2ccccc2)=N1,BRD-K41160163,glutamate receptor antagonist
7.831679,6.182846,906,COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC,BRD-K41337261,c1ccc(Nc2ncnc3ccccc23)cc1,BRD-K41337261,src and abl inhibitor|vascular endothelial growth factor receptor 1 (vegfr1) inhibitor
7.410565,8.327253,907,Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1,BRD-K41406082,O=S(=O)(Nc1ccccn1)c1ccccc1,BRD-K41406082,paba antagonist
4.158139,9.530917,908,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C,BRD-K41445866,O=C1CC2CCCC2C2CCC3CCCCC3C12,BRD-K41445866,chloride channel agonist
6.998668,9.195168,909,CC(=O)Nc1ccc(O)cc1,BRD-K41524689,c1ccccc1,BRD-K41524689,cyclooxygenase inhibitor
9.134612,10.318897,910,CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1,BRD-K41564320,c1ccc(Nc2ncnc3[nH]cnc23)cc1,BRD-K41564320,tyrosine kinase inhibitor
7.2123055,9.23767,911,Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1,BRD-K41567364,O=C(Nc1ccc2ncoc2c1)Nc1ccnc2cccnc12,BRD-K41567364,orexin receptor antagonist
5.927495,11.219677,912,CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O,BRD-K41707108,,BRD-K41707108,phosphoenolpyruvate carboxylase activator
10.524826,9.510843,913,Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1,BRD-K41713976,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1,BRD-K41713976,potassium channel blocker
9.870972,6.4667597,914,NCCCCCCNS(=O)(=O)c1cccc2ccccc12,BRD-K41868777,c1ccc2ccccc2c1,BRD-K41868777,calmodulin antagonist
6.40075,6.369676,915,Oc1ccc2sc(=O)oc2c1,BRD-K41876534,O=c1oc2ccccc2s1,BRD-K41876534,carbonic anhydrase inhibitor
6.9934764,5.7956653,916,COc1ccc(C=C(C#N)C#N)cc1,BRD-K41996876,c1ccccc1,BRD-K41996876,egfr inhibitor
6.3410125,6.232204,917,Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O,BRD-K42095107,O=c1c(-c2ccccc2)coc2ccccc12,BRD-K42095107,estrogen receptor agonist
9.810405,7.957161,918,CNCCCC1c2ccccc2C=Cc2ccccc12,BRD-K42098891,C1=Cc2ccccc2Cc2ccccc21,BRD-K42098891,tricyclic antidepressant
9.488287,9.005461,919,OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1,BRD-K42221274,C1=CCN(CCON=C(c2ccccc2)c2ccccc2)CC1,BRD-K42221274,gat inhibitor
10.499681,7.6706686,920,CN(C)CCC=C1c2ccccc2C=Cc2ccccc12,BRD-K42348709,C=C1c2ccccc2C=Cc2ccccc21,BRD-K42348709,adrenergic receptor agonist|serotonin receptor agonist
8.602354,10.230608,921,Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl,BRD-K42452249,O=C(c1ccccc1)c1ccc(Nc2ccccc2)cc1,BRD-K42452249,p38 mapk inhibitor
7.9130354,7.7892036,922,Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12,BRD-K42500029,c1ccc(Nc2n[nH]c3ncncc23)cc1,BRD-K42500029,"map kinase inhibitor|mapk-interacting kinase inhibitor,"
7.965343,10.759914,923,CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1,BRD-K42635745,c1ccccc1,BRD-K42635745,adrenergic receptor antagonist
4.938175,5.378905,924,CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,BRD-K42679050,c1ccc(CONC2CCOc3ccccc32)cc1,BRD-K42679050,potassium channel activator|potassium channel agonist
8.502701,8.08616,925,O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12,BRD-K42748308,O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc21,BRD-K42748308,acetylcholine release enhancer|potassium channel blocker|voltage-gated potassium channel blocker
6.9696956,7.074706,926,CC(C)(C)c1ccc(C=CC(=O)Nc2ccc3OCCOc3c2)cc1,BRD-K43068349,O=C(C=Cc1ccccc1)Nc1ccc2c(c1)OCCO2,BRD-K43068349,trpv antagonist
6.415095,6.174851,927,Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O,BRD-K43149758,O=c1cc(-c2ccccc2)oc2ccccc12,BRD-K43149758,androgen receptor agonist
8.187024,10.196134,928,CC(C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C=O,BRD-K43245338,O=C(CNC(=O)OCc1ccccc1)NCCc1ccccc1,BRD-K43245338,calpain inhibitor|cathepsin inhibitor
7.3710017,8.293445,929,CNc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(NC)n1,BRD-K43290182,O=S(=O)(Nc1ccncn1)c1ccccc1,BRD-K43290182,serotonin receptor antagonist
7.197417,8.975049,930,CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12,BRD-K43330982,O=C(NNc1ccc2cn[nH]c2n1)Nc1ccncc1,BRD-K43330982,lysophospholipid receptor antagonist
7.5125275,7.3134017,931,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O,BRD-K43389675,O=C1c2ccccc2C(=O)c2cc3c(cc21)CCCC3OC1CCCCO1,BRD-K43389675,rna synthesis inhibitor|topoisomerase inhibitor
6.381813,4.453778,932,C[C@@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1,BRD-K43405658,O=C(C=Cc1ccccc1)NCc1ccccc1,BRD-K43405658,protein tyrosine kinase inhibitor
7.0865545,8.652086,933,CC(=O)Nc1nnc(s1)S(N)(=O)=O,BRD-K43457670,c1nncs1,BRD-K43457670,carbonic anhydrase inhibitor
6.014451,8.9370985,934,CCC[C@H]1CC2=C(C[C@@H](CC)CC3=C1C(=O)OC3=O)C(=O)OC2=O,BRD-K43468059,O=C1OC(=O)C2=C1CCCC1=C(CC2)C(=O)OC1=O,BRD-K43468059,mycotoxin
3.2339447,9.49125,935,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,BRD-K43736954,O=C1C=C2CCC3C4CCCC4CC(=O)C3C2CC1,BRD-K43736954,glucocorticoid receptor agonist
9.662035,10.010074,936,CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,BRD-K43744935,C(=C(c1ccccc1)c1ccccc1)c1ccccc1,BRD-K43744935,estrogen receptor antagonist|selective estrogen receptor modulator (serm)|estrogen receptor agonist|estrogen receptor modulator|pkc inhibitor
8.8694315,9.148853,937,C(Nc1ncnc2ccccc12)c1ccccc1,BRD-K43796186,c1ccc(CNc2ncnc3ccccc23)cc1,BRD-K43796186,egfr inhibitor
6.387416,6.2153554,938,Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,BRD-K43797669,O=c1c(-c2ccccc2)coc2ccccc12,BRD-K43797669,tyrosine kinase inhibitor
8.56404,9.596952,939,NC(=N)NCc1cccc(I)c1,BRD-K43860855,c1ccccc1,BRD-K43860855,antineoplastic
8.364025,9.149404,940,OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,BRD-K44067360,c1ccc(Nc2ccccc2)cc1,BRD-K44067360,chloride channel blocker
7.4964943,9.207685,941,C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1,BRD-K44084986,O=C(Nc1ccncc1)C1CCCCC1,BRD-K44084986,rho associated kinase inhibitor
5.9508677,8.306728,942,Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1,BRD-K44849676,S=C(NCCc1ccccc1)N1CCCc2ccccc2C1,BRD-K44849676,trpv agonist
6.9658623,8.65104,943,CN(C)C(=O)Cc1c(nc2ccc(C)cn12)-c1ccc(C)cc1,BRD-K44876623,c1ccc(-c2cn3ccccc3n2)cc1,BRD-K44876623,benzodiazepine receptor agonist
7.5650525,9.687339,944,NCCNC(=O)c1ccc(Cl)cc1,BRD-K44899736,c1ccccc1,BRD-K44899736,monoamine oxidase inhibitor
6.432192,8.717957,945,CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O,BRD-K45033733,c1ncc2nc[nH]c2n1,BRD-K45033733,dna polymerase inhibitor
9.858498,6.425649,946,NCCCCNS(=O)(=O)c1ccc2c(Cl)cccc2c1,BRD-K45068323,c1ccc2ccccc2c1,BRD-K45068323,calmodulin antagonist
4.933142,5.3720894,947,CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,BRD-K45117373,c1ccc2c(c1)CCCO2,BRD-K45117373,potassium channel activator|potassium channel agonist
8.054877,9.628685,948,CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O,BRD-K45158365,c1ccc(-c2ccccc2-c2nn[nH]n2)cc1,BRD-K45158365,angiotensin receptor antagonist
4.3984857,7.1653233,949,COCCNC(=O)COc1ccc(OCCNC[C@@H](O)COc2ccccc2)cc1,BRD-K45296539,c1ccc(OCCCNCCOc2ccccc2)cc1,BRD-K45296539,adrenergic receptor agonist
6.613841,9.084116,950,CC\C(c1ccc(O)cc1)=C(\CC)c1ccc(O)cc1,BRD-K45330754,C(=Cc1ccccc1)c1ccccc1,BRD-K45330754,estrogen receptor agonist
5.2818923,8.866677,951,CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O,BRD-K45401373,C1CCC2C(C1)CCC1C2CCC2C3CCCC3CCC21,BRD-K45401373,apoptosis stimulant
10.105951,7.0556045,952,CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1,BRD-K45435259,c1ccc(C2CNCCc3ccccc32)cc1,BRD-K45435259,dopamine receptor antagonist
10.137282,8.54476,953,C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1,BRD-K45479396,c1ccc(N2CCN(CCCOc3ccc4c(c3)OCO4)CC2)cc1,BRD-K45479396,serotonin receptor agonist
5.9048405,8.5847435,954,CCN(CC)C(=O)N1CCN(C)CC1,BRD-K45542189,C1CNCCN1,BRD-K45542189,lipoxygenase inhibitor
10.708355,9.311784,955,Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1,BRD-K45662124,O=C(CCCN1CCC2(CC1)C(=O)N(Cc1ccccc1)CN2c1ccccc1)c1ccccc1,BRD-K45662124,dopamine receptor ligand
10.678829,9.281367,956,Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1,BRD-K45861246,O=C(CCCN1CCN(c2ccccn2)CC1)c1ccccc1,BRD-K45861246,dopamine receptor antagonist
7.277922,6.5092688,957,COc1ccc(C=Cc2cc(OC)cc(OC)c2)c(OC)c1,BRD-K45988865,C(=Cc1ccccc1)c1ccccc1,BRD-K45988865,organosilicon compound used as an internal standard in nmr spectroscopy
7.365143,9.845238,958,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O,BRD-K46018455,O=C(NCCc1ccccc1)c1ccccc1,BRD-K46018455,ppar receptor agonist
2.9680784,9.566713,959,CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC,BRD-K46137903,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K46137903,phospholipase activator
10.267558,10.506886,960,CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1,BRD-K46142322,O=C(CCC1CCNCC1)c1ccccc1,BRD-K46142322,serotonin receptor partial agonist
8.3057995,6.6833735,961,C(C1=NCCN1)c1ccccc1,BRD-K46211610,c1ccc(CC2=NCCN2)cc1,BRD-K46211610,adrenergic receptor antagonist
9.705473,10.089643,962,CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,BRD-K46317332,c1ccc(Cc2ccccc2)cc1,BRD-K46317332,nitric oxide synthase inhibitor
8.177302,8.899173,963,Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F,BRD-K46384212,O=S(=O)(Nc1ccccc1)c1ccccc1,BRD-K46384212,phospholipase activator
6.3846393,6.4343143,964,Cc1cc(=O)oc2cc(O)ccc12,BRD-K46424862,O=c1ccc2ccccc2o1,BRD-K46424862,monoamine oxidase inhibitor
6.3869867,8.7795925,965,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1nc(N)[nH]c2=O,BRD-K46435977,O=c1[nH]cnc2[nH]cnc12,BRD-K46435977,dna polymerase inhibitor
7.2507353,9.343566,966,CN(C)CCCc1cc(ccc1O)C(=O)Nc1ccc(cc1)-c1ccncc1,BRD-K46441700,O=C(Nc1ccc(-c2ccncc2)cc1)c1ccccc1,BRD-K46441700,serotonin receptor antagonist
9.063411,9.462016,967,COc1ccc(CCCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)cc1,BRD-K46469693,c1ccc(CCCn2ncc3c2ncn2nc(-c4ccco4)nc32)cc1,BRD-K46469693,adenosine receptor antagonist
3.5198798,9.484572,968,C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O,BRD-K46556543,O=C1C=C2C=CC3C4CCCC4CCC3C2CC1,BRD-K46556543,mineralocorticoid receptor antagonist
7.393058,9.282798,969,Clc1cc(Cl)c(NC(=O)Nc2ccncc2)c(Cl)c1,BRD-K46678324,O=C(Nc1ccccc1)Nc1ccncc1,BRD-K46678324,rho associated kinase inhibitor
10.893848,8.758415,970,COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1,BRD-K46766488,O=C(NCCN1CCN(c2cccc3ccccc23)CC1)c1ccccc1,BRD-K46766488,serotonin receptor agonist
7.940535,9.261437,971,CC(C)(C(=O)c1cccnc1)c1cccnc1,BRD-K46862739,O=C(Cc1cccnc1)c1cccnc1,BRD-K46862739,cytochrome p450 inhibitor
8.826488,8.15425,972,Cc1cc(=O)n(-c2ccccc2)n1C,BRD-K46937689,O=c1cc[nH]n1-c1ccccc1,BRD-K46937689,cyclooxygenase inhibitor
6.420762,4.5193143,973,Oc1ccc(cc1O)\C=C(/C#N)C(=O)NCc1ccccc1,BRD-K47105409,O=C(C=Cc1ccccc1)NCc1ccccc1,BRD-K47105409,jak inhibitor
7.690763,6.322904,974,COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC,BRD-K47150025,O=C(Nc1ccccc1)Nc1ccc(Oc2ccnc3ccccc23)cc1,BRD-K47150025,pdgfr alpha and c-kit inhibitor|vascular endothelial growth factor receptor 2 (vegfr2) inhibitor|vegfr inhibitor
6.2344375,11.231249,975,CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O,BRD-K47192521,,BRD-K47192521,platelet aggregation inhibitor
7.916791,9.15458,976,CN(C)C\C=C(/c1ccc(Br)cc1)c1cccnc1,BRD-K47207162,C=C(c1ccccc1)c1cccnc1,BRD-K47207162,serotonin reuptake inhibitor
9.7515745,9.585345,977,CN(C)CCOC(c1ccccc1)c1ccccc1,BRD-K47278471,c1ccc(Cc2ccccc2)cc1,BRD-K47278471,histamine receptor antagonist
9.780136,9.696473,978,CN(C)CCN(Cc1cccs1)c1ccccn1,BRD-K47323024,c1ccc(NCc2cccs2)nc1,BRD-K47323024,histamine receptor antagonist
7.9040375,10.155605,979,NCCCC[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O,BRD-K47328134,O=C(CCc1ccccc1)NCCc1ccccc1,BRD-K47328134,heparin activation inhibitor
8.145577,8.084736,980,Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C,BRD-K47598052,c1ccc(-c2n[nH]c3ncncc23)cc1,BRD-K47598052,src inhibitor
7.4457574,8.6285715,981,CC(=O)Oc1cccc(C(O)=O)c1OC(C)=O,BRD-K47608922,c1ccccc1,BRD-K47608922,chelating
6.2417693,8.090985,982,CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1,BRD-K47631482,c1ccc(CNC2CCCCC2)cc1,BRD-K47631482,mucolytic
2.4911568,9.73971,983,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O,BRD-K47635719,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K47635719,glucocorticoid receptor agonist
9.748356,8.515966,984,Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1,BRD-K47639036,O=C(OCCN1CCCCC1)c1cccc2c(=O)cc(-c3ccccc3)oc12,BRD-K47639036,acetylcholine receptor antagonist
8.738673,6.99962,985,Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1,BRD-K47659338,C1=C(c2c[nH]c3ccccc23)CCNC1,BRD-K47659338,serotonin receptor agonist
6.357477,6.8437943,986,COc1c(OC[C@@H](O)C(C)(C)O)ccc2c(OC)c3ccoc3nc12,BRD-K47693913,c1ccc2nc3occc3cc2c1,BRD-K47693913,furoquinoline alkaloid
7.181135,7.959695,987,NS(=O)(=O)c1cccc2c1c(cc1nc(O)c(O)nc21)[N+]([O-])=O,BRD-K47717570,c1ccc2c(c1)ccc1nccnc12,BRD-K47717570,glutamate receptor antagonist
6.1367054,7.0868998,988,COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12,BRD-K47869605,O=C1OCC2Cc3cc4c(cc3C(c3ccccc3)C12)OCO4,BRD-K47869605,microtubule inhibitor|tubulin polymerization inhibitor
10.064302,8.574598,989,C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1,BRD-K47936004,c1cnc(N2CCN(Cc3ccc4c(c3)OCO4)CC2)nc1,BRD-K47936004,dopamine receptor agonist
6.544186,4.9103484,990,NC(=C(C#N)C#N)C(\C#N)=C\c1cc(O)c(O)c(O)c1,BRD-K47943470,c1ccccc1,BRD-K47943470,egfr inhibitor
6.2817764,8.639713,991,CCCc1cc(=O)[nH]c(=S)[nH]1,BRD-K48168960,O=c1cc[nH]c(=S)[nH]1,BRD-K48168960,thyroid peroxidase inhibitor
8.161395,7.9816,992,NS(=O)(=O)Cc1noc2ccccc12,BRD-K48300629,c1ccc2oncc2c1,BRD-K48300629,sodium channel blocker
7.338139,7.67357,993,Cc1nc2c(O)cccc2c(=O)[nH]1,BRD-K48692744,O=c1[nH]cnc2ccccc12,BRD-K48692744,parp inhibitor
10.295098,10.112781,994,COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1,BRD-K48722258,O=C(OCCCN1CCCN(CCCOC(=O)c2ccccc2)CC1)c1ccccc1,BRD-K48722258,adenosine reuptake inhibitor
7.8564296,6.198842,995,CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1,BRD-K48735772,c1ccc(Nc2ncnc3cnccc23)cc1,BRD-K48735772,egfr inhibitor|epidermal growth factor receptor (egfr) inhibitor
6.255086,8.933849,996,CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O,BRD-K49027941,O=c1[nH]c(=O)c2[nH]c(-c3ccccc3)nc2[nH]1,BRD-K49027941,adenosine receptor antagonist
8.925169,9.46449,997,Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1,BRD-K49049886,c1coc(-c2nc3c4ccccc4ncn3n2)c1,BRD-K49049886,adenosine receptor antagonist
9.077393,6.6774497,998,CCOC(=O)c1cc2c(cn1)[nH]c1ccccc21,BRD-K49061529,c1ccc2c(c1)[nH]c1cnccc12,BRD-K49061529,gaba benzodiazepine site receptor inverse agonist
6.6062555,7.182241,999,COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1,BRD-K49111258,O=C(c1ccco1)N1CCN(c2ncc3ccccc3n2)CC1,BRD-K49111258,adrenergic receptor antagonist
7.9493003,6.2838326,1000,CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1,BRD-K49294207,c1ccc(Nc2ncnc3cnc(N4CCCCC4)nc23)cc1,BRD-K49294207,egfr inhibitor
8.868393,6.832411,1001,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12,BRD-K49448285,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12,BRD-K49448285,cdk inhibitor
9.724234,7.737358,1002,COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24,BRD-K49481516,C1=CC23CCNCc4cccc(c42)OC3CC1,BRD-K49481516,acetylcholinesterase inhibitor
8.365969,8.543565,1003,C(c1cnc[nH]1)c1ccncc1,BRD-K49519092,c1cc(Cc2cnc[nH]2)ccn1,BRD-K49519092,histamine receptor agonist
2.8308961,9.616249,1004,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,BRD-K49577446,O=C1C=CC2C(=C1)CCC1C2CCC2C1CC1OCOC12,BRD-K49577446,cytochrome p450 inhibitor
6.572047,4.9770217,1005,Oc1ccc(C=C(C#N)C#N)cc1O,BRD-K49657628,c1ccccc1,BRD-K49657628,egfr inhibitor|tyrosine kinase inhibitor
10.7444,9.507065,1006,Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1,BRD-K49671696,O=C(c1ccccc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1,BRD-K49671696,serotonin receptor antagonist
7.8236213,9.187812,1007,OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1C=CC(=O)Nc1ccccc1,BRD-K49890030,O=C(C=Cc1c[nH]c2ccccc12)Nc1ccccc1,BRD-K49890030,glutamate receptor antagonist
9.863739,10.617281,1008,Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12,BRD-K49945136,O=C(OCC1CCNCC1)c1c[nH]c2ccccc12,BRD-K49945136,serotonin receptor antagonist
10.200368,10.564431,1009,COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,BRD-K50018155,O=C(CCC1CCNCC1)c1ccccc1,BRD-K50018155,serotonin receptor partial agonist
10.272258,8.715479,1010,C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1,BRD-K50135270,c1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1,BRD-K50135270,dopamine uptake inhibitor
8.504515,7.21077,1011,Nc1ccc2C(=O)NC(=O)c3cccc1c23,BRD-K50214219,O=C1NC(=O)c2cccc3cccc1c23,BRD-K50214219,parp inhibitor
8.255638,9.17475,1012,C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1,BRD-K50325075,c1ccc(C(NCc2cccnc2)(c2ccccc2)c2ccccc2)cc1,BRD-K50325075,potassium channel blocker|slow afterhyperpolarization channel blocker
7.313761,9.888758,1013,CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1,BRD-K50388907,O=C(c1ccccc1)c1ccccc1,BRD-K50388907,ppar receptor agonist
8.574399,10.196948,1014,Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl,BRD-K50398167,c1ccc(Nc2ccccc2)cc1,BRD-K50398167,cyclooxygenase inhibitor
10.354841,11.012921,1015,CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC,BRD-K50417881,O=C(NCC1CCCN1)c1ccccc1,BRD-K50417881,dopamine receptor antagonist
6.356616,8.333304,1016,Cc1ncsc1CCCl,BRD-K50422030,c1cscn1,BRD-K50422030,gaba receptor antagonist
5.282044,6.5790234,1017,COc1cc2CCN(C)[C@H]3Cc4ccc(Oc5cc(C[C@H]6N(C)CCc7cc(OC)c(OC)c(Oc1cc23)c67)ccc5OC(=O)c1ccc(cc1)[N+]([O-])=O)cc4,BRD-K50464341,O=C(Oc1ccc2cc1Oc1ccc(cc1)CC1NCCc3ccc(cc31)Oc1cccc3c1C(C2)NCC3)c1ccccc1,BRD-K50464341,calmodulin antagonist
7.828105,6.1606083,1018,COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC,BRD-K50495309,c1ccc(Oc2ccc(Nc3ncnc4ccccc34)cc2)cc1,BRD-K50495309,src inhibitor
7.0626574,6.481685,1019,Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1,BRD-K50660797,O=C(OC1Cc2ccccc2OC1c1ccccc1)c1ccccc1,BRD-K50660797,bacterial dna gyrase inhibitor
9.134305,10.246613,1020,CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1,BRD-K50836978,c1ccc(Nc2ncnc3[nH]cnc23)cc1,BRD-K50836978,cdk inhibitor
8.59683,9.433245,1021,Oc1c(CC=C)cccc1C=NNC(=O)CN1CCN(Cc2ccccc2)CC1,BRD-K50841342,O=C(CN1CCN(Cc2ccccc2)CC1)NN=Cc1ccccc1,BRD-K50841342,caspase activator
7.455593,8.26256,1022,Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C,BRD-K50859149,O=S(=O)(Nc1ccno1)c1ccccc1,BRD-K50859149,bacterial antifolate
10.857067,8.670406,1023,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1,BRD-K50891186,O=C(NCCCCN1CCN(c2ccccc2)CC1)c1ccc(-c2ccccc2)cc1,BRD-K50891186,dopamine receptor antagonist
6.7913547,9.504075,1024,CCCCc1c([nH]c2nccnc12)-c1ccc(OC)cc1,BRD-K51276371,c1ccc(-c2cc3nccnc3[nH]2)cc1,BRD-K51276371,cdk inhibitor|cftr channel activator|glycogen synthase kinase inhibitor|jnk inhibitor
8.072098,5.136253,1025,COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1,BRD-K51318897,c1ccc(Sc2ccc3nc[nH]c3c2)cc1,BRD-K51318897,tubulin polymerization inhibitor
7.870017,10.750749,1026,C[C@H](NCCc1ccc(O)cc1)[C@H](O)c1ccc(O)cc1,BRD-K51465424,c1ccc(CCNCCc2ccccc2)cc1,BRD-K51465424,adrenergic receptor agonist
6.4691334,4.703471,1027,CCOc1cc(\C=C(\C#N)C(N)=O)cc(CSc2ccccc2)c1O,BRD-K51476772,c1ccc(CSc2ccccc2)cc1,BRD-K51476772,tyrosine kinase inhibitor
9.284088,9.834765,1028,C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1,BRD-K51541829,c1ccc(CCCN2CCC(Cc3ccccc3)CC2)cc1,BRD-K51541829,ionotropic glutamate receptor antagonist
7.914196,8.680812,1029,NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1,BRD-K51575138,c1ccc(-c2cccs2)cc1,BRD-K51575138,ikk inhibitor
10.358064,11.012567,1030,CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O,BRD-K51671335,O=C(NCC1CCCN1)c1ccccc1,BRD-K51671335,dopamine receptor antagonist
4.1479473,9.562568,1031,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C,BRD-K51751936,O=C1CC2CCCC2C2CCC3CCCCC3C12,BRD-K51751936,benzodiazepine receptor agonist
8.72034,9.07338,1032,Ic1ccc(CCNC(=N)SCCCc2c[nH]cn2)cc1,BRD-K51918615,N=C(NCCc1ccccc1)SCCCc1c[nH]cn1,BRD-K51918615,histamine receptor antagonist|histamine receptor inhibitor|ionotropic glutamate receptor antagonist
6.4696546,8.286546,1033,Cc1ncc(n1CCO)[N+]([O-])=O,BRD-K52020312,c1c[nH]cn1,BRD-K52020312,dna inhibitor
6.2015014,11.247054,1034,C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O,BRD-K52075040,C1CO1,BRD-K52075040,fatty acid synthase inhibitor
6.2585917,8.590649,1035,CCCn1c2nc(N)nn2cc(C)c1=O,BRD-K52219182,O=c1ccn2ncnc2[nH]1,BRD-K52219182,phosphodiesterase inhibitor
7.612802,9.318059,1036,CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N,BRD-K52313696,O=C(Nc1ccccc1)c1ccccc1,BRD-K52313696,hdac inhibitor
8.744309,6.2881947,1037,COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1,BRD-K52394958,O=S(CC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1,BRD-K52394958,tachykinin antagonist
10.54644,9.250658,1038,CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,BRD-K52397688,c1ccc(C(CCCN2CCNCC2)c2ccccc2)cc1,BRD-K52397688,dopamine receptor antagonist|faah inhibitor|serotonin receptor antagonist
5.9416456,11.432312,1039,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O,BRD-K52459643,O=C1CCCC1,BRD-K52459643,prostanoid receptor agonist
10.349219,7.641169,1040,CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12,BRD-K52512893,c1ccc2c(c1)CNc1ccccc1O2,BRD-K52512893,prostanoid receptor antagonist
8.347857,8.196828,1041,OC(=O)c1ccc2c3nc4ccccc4n3c(=O)c3cccc1c23,BRD-K52620403,O=c1c2cccc3cccc(c32)c2nc3ccccc3n12,BRD-K52620403,calcium/calmodulin dependent protein kinase inhibitor|calmodulin inhibitor
8.777588,10.4527235,1042,CCN(CC)CC(=O)Nc1c(C)cccc1C,BRD-K52662033,c1ccccc1,BRD-K52662033,histamine receptor agonist
4.910626,5.350157,1043,CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N,BRD-K52721684,O=C1C=C(OC2CCOc3ccccc32)CC1,BRD-K52721684,potassium channel activator
8.7946205,5.783747,1044,CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)\C=C\c1cc(OC)c(OC)c(OC)c1,BRD-K52930707,O=C(C=Cc1ccccc1)OC1CCC2CC3c4[nH]c5ccccc5c4CCN3CC2C1,BRD-K52930707,ace inhibitor
10.864122,7.6943984,1045,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12,BRD-K52989797,c1ccc2c(c1)CCc1ccccc1N2,BRD-K52989797,serotonin transporter (sert) inhibitor
6.902194,8.25767,1046,[O-][N+](=O)c1cnc(s1)N1CCNC1=O,BRD-K53123955,O=C1NCCN1c1nccs1,BRD-K53123955,phosphofructokinase inhibitor
9.009641,8.565149,1047,Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1,BRD-K53263234,C(=NOCc1ccccc1)c1c(-c2ccccc2)nc2sccn12,BRD-K53263234,constitutive androstane receptor (car) agonist
8.976125,7.3395452,1048,CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41,BRD-K53318339,C1=Cn2c3c(c4ccccc42)CCN2CCCC1C32,BRD-K53318339,phosphodiesterase inhibitor
6.0522833,7.127088,1049,COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O,BRD-K53523901,O=C1OCC(Cc2ccccc2)C1Cc1ccccc1,BRD-K53523901,adiponectin receptor agonist|ap inhibitor|aryl hydrocarbon receptor antagonist|hiv integrase inhibitor|mek inhibitor|nfkb pathway inhibitor|topoisomerase inhibitor
7.026418,7.9283257,1050,Oc1nc2cc(C#N)c(cc2nc1O)[N+]([O-])=O,BRD-K53545112,c1ccc2nccnc2c1,BRD-K53545112,glutamate receptor antagonist
10.571982,7.6511717,1051,CN(C)CCC=C1c2ccccc2CCc2ccccc12,BRD-K53737926,C=C1c2ccccc2CCc2ccccc21,BRD-K53737926,norepinephrine inhibitor
10.466042,9.349771,1052,Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12,BRD-K53857191,O=c1c(CCN2CCC(c3noc4ccccc34)CC2)cnc2n1CCCC2,BRD-K53857191,dopamine receptor antagonist
6.0444274,8.877609,1053,COCc1nc2c([nH]1)n(CC(C)C)c(=O)n(C)c2=O,BRD-K53878242,O=c1[nH]c(=O)c2nc[nH]c2[nH]1,BRD-K53878242,phosphodiesterase inhibitor
9.051547,9.226668,1054,CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O,BRD-K53979406,c1ccc(COc2ccc(-c3ccccc3)cc2)cc1,BRD-K53979406,glycine transporter inhibitor|glyt-1 inhibitor
10.369552,11.022292,1055,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,BRD-K54094468,O=C(NCC1CCCN1)c1ccccc1,BRD-K54094468,dopamine receptor antagonist
7.0986834,9.604881,1056,Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1,BRD-K54095730,O=C(CCCc1ccc(-c2ccccc2)cc1)Nc1ccccc1,BRD-K54095730,p38 mapk inhibitor
8.307946,6.7361636,1057,C(Oc1ccccc1C1CC1)C1=NCCN1,BRD-K54142781,c1ccc(C2CC2)c(OCC2=NCCN2)c1,BRD-K54142781,adrenergic receptor agonist
6.890094,7.880688,1058,Oc1ccc(cc1-n1c2ccc(cc2[nH]c1=O)C(F)(F)F)C(F)(F)F,BRD-K54210043,O=c1[nH]c2ccccc2n1-c1ccccc1,BRD-K54210043,calcium channel activator|large conductance potassium channel activator
7.5804467,7.583232,1059,C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1,BRD-K54233340,c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1,BRD-K54233340,ampk inhibitor|dna damaging|tgf beta receptor inhibitor
6.9405236,7.832232,1060,Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1,BRD-K54330070,c1ccc(-c2nc(-c3ccccc3)c(-c3ccncc3)[nH]2)cc1,BRD-K54330070,p38 mapk inhibitor
6.655805,6.3586516,1061,COc1ccc(cc1)-c1c(O)c2c(OC)c3C=CC(C)(C)Oc3cc2oc1=O,BRD-K54411430,O=c1oc2cc3c(cc2cc1-c1ccccc1)C=CCO3,BRD-K54411430,camp inhibitor
5.7111616,9.14246,1062,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,BRD-K54529596,C1CCNC1,BRD-K54529596,ace inhibitor
10.542857,9.495591,1063,Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1,BRD-K54665485,O=c1c(CCN2CCC(=C(c3ccccc3)c3ccccc3)CC2)cnc2sccn12,BRD-K54665485,diacylglycerol kinase inhibitor
8.053861,7.8269176,1064,C=C1C[C@@H]2COC(=O)[C@]2(Cc2ccc3ccccc3c2)C1,BRD-K54704028,C=C1CC2COC(=O)C2(Cc2ccc3ccccc3c2)C1,BRD-K54704028,glutamate receptor antagonist
7.6196265,9.904332,1065,OC(=O)c1n(Cc2ccc(Cl)cc2)c2ccc(Cl)cc2c1Sc1ccccc1,BRD-K54708045,c1ccc(Cn2cc(Sc3ccccc3)c3ccccc32)cc1,BRD-K54708045,ppar receptor agonist
10.6606865,7.6375394,1066,CN(C)CC\C=C1/c2ccccc2CSc2ccccc12,BRD-K54759182,C=C1c2ccccc2CSc2ccccc21,BRD-K54759182,norepinephrine reuptake inhibitor
5.081308,9.529386,1067,C[C@H](CCC(=O)NCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,BRD-K54771420,C1CCC2C(C1)CCC1C3CCCC3CCC21,BRD-K54771420,cholesterol inhibitor
6.364738,6.6175914,1068,Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1,BRD-K54790157,O=c1ccc2cc3ccoc3cc2o1,BRD-K54790157,dna synthesis inhibitor
4.782303,8.178004,1069,CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1,BRD-K55034111,O=c1cc[nH]c2cc(N3CCNCC3)ccc12,BRD-K55034111,bacterial dna gyrase inhibitor
12.147838,8.753526,1070,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O,BRD-K55191674,O=C(Cc1ccccc1)NC1C(=O)N2CCSC12,BRD-K55191674,penicillin binding protein inhibitor
8.321704,6.729864,1071,C1CN=C(N1)c1ccc2ccccc2n1,BRD-K55344148,c1ccc2nc(C3=NCCN3)ccc2c1,BRD-K55344148,imidazoline receptor ligand
9.167331,7.7654705,1072,Clc1cccc(SC2CCNCC2)n1,BRD-K55424922,c1ccc(SC2CCNCC2)nc1,BRD-K55424922,serotonin receptor agonist
8.991578,7.164256,1073,C1CCc2c(C1)n1CCNCc3cccc2c13,BRD-K55430733,c1cc2c3c(c1)c1c(n3CCNC2)CCCC1,BRD-K55430733,serotonin receptor agonist
8.284737,7.199087,1074,COc1ccc(cc1)C(=C1C(=O)Nc2ccccc12)c1ccc(OC)cc1,BRD-K55454768,O=C1Nc2ccccc2C1=C(c1ccccc1)c1ccccc1,BRD-K55454768,voltage-independent calcium influx blocker
10.736492,9.25953,1075,Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1,BRD-K55468218,O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccccc1,BRD-K55468218,dopamine receptor antagonist
8.409223,9.248918,1076,OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1,BRD-K55529781,c1cncc(Cc2ccc3occc3c2)c1,BRD-K55529781,thromboxane synthase inhibitor
6.4937725,6.3275757,1077,COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O,BRD-K55567017,O=c1c(-c2ccccc2)coc2ccccc12,BRD-K55567017,alcohol dehydrogenase inhibitor
6.6080527,9.225254,1078,Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1,BRD-K55677650,c1ccc(CC2CCN(CCOc3ccccc3)CC2)cc1,BRD-K55677650,ionotropic glutamate receptor antagonist
8.715785,8.839098,1079,Cc1nc2c(OCc3ccccc3)cccn2c1CC#N,BRD-K55748775,c1ccc(COc2cccn3ccnc23)cc1,BRD-K55748775,atpase inhibitor|potassium-competitive acid antagonist
8.615284,7.688202,1080,O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1,BRD-K55930204,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,BRD-K55930204,hydantoin antiepileptic
6.7096257,9.75566,1081,O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1,BRD-K56047318,O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1,BRD-K56047318,triacylglycerol lipase inhibitor
6.5607367,7.5632515,1082,COCc1cc(O)c(O)c(O)c1-c1c(COC)cc(O)c(O)c1O,BRD-K56064827,c1ccc(-c2ccccc2)cc1,BRD-K56064827,pkc inhibitor
8.317665,6.726324,1083,C1CN=C(N1)c1cc2ccccc2cn1,BRD-K56115039,c1ccc2cc(C3=NCCN3)ncc2c1,BRD-K56115039,imidazoline receptor ligand
9.86062,8.620399,1084,OCCOCCN1CCN(Cc2cccc(Oc3ccccc3)c2)CC1,BRD-K56403959,c1ccc(Oc2cccc(CN3CCNCC3)c2)cc1,BRD-K56403959,cc chemokine receptor ligand
5.855069,8.383873,1085,C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,BRD-K56429665,C=C1CCCCC1=CC=C1CCCC2C(CC=CCC3CC3)CCC12,BRD-K56429665,vitamin d receptor agonist
7.6306925,8.055636,1086,CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C,BRD-K56509348,O=S(=O)(Nc1ccno1)c1cccc2ccccc12,BRD-K56509348,endothelin receptor antagonist
6.3325114,8.040072,1087,Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1,BRD-K56558538,c1ccc(CNC2CCCCC2)cc1,BRD-K56558538,sodium channel blocker
8.72535,10.5077305,1088,CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C,BRD-K56596464,c1ccccc1,BRD-K56596464,sodium channel blocker
9.642601,12.165159,1089,CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13,BRD-K56699285,O=C(NCC1CNC2Cc3c[nH]c4cccc(c34)C2C1)OCc1ccccc1,BRD-K56699285,dopamine receptor agonist|serotonin receptor antagonist
9.739666,9.677026,1090,CN(C)CCN(Cc1ccccc1)c1ccccn1,BRD-K57033106,c1ccc(CNc2ccccn2)cc1,BRD-K57033106,histamine receptor antagonist
8.585435,10.18586,1091,CCN(C(=O)\C=C\C)c1ccccc1C,BRD-K57179821,c1ccccc1,BRD-K57179821,antipruritic
7.2031593,6.1995854,1092,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1,BRD-K57222227,O=C(c1ccccc1)n1ccc2ccccc21,BRD-K57222227,cyclooxygenase inhibitor
9.62314,8.4329195,1093,O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1,BRD-K57304726,O=C(OCCN1CCOCC1)C1(c2ccccc2)CCCCC1,BRD-K57304726,sigma receptor agonist
5.8029876,9.511977,1094,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O,BRD-K57545991,O=C(CNCCCc1ccccc1)N1CCCC1,BRD-K57545991,angiotensin converting enzyme inhibitor
5.8100195,9.427697,1095,CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O,BRD-K57569181,O=c1[nH]c(=O)c2[nH]cnc2[nH]1,BRD-K57569181,phosphodiesterase inhibitor
5.771145,8.196148,1096,C1CCc2nnnn2CC1,BRD-K57718010,C1CCc2nnnn2CC1,BRD-K57718010,gaba receptor antagonist
2.5214255,9.702987,1097,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C,BRD-K57886322,O=C1C=CC2C(=C1)CCC1C2CCC2C1CC1OCOC12,BRD-K57886322,glucocorticoid receptor agonist
8.34672,8.404365,1098,Cc1cc2ncc(nc2cc1C)-c1ccccc1,BRD-K57926513,c1ccc(-c2cnc3ccccc3n2)cc1,BRD-K57926513,pdgfr receptor inhibitor
9.954912,10.316305,1099,CCN(CC)CCCCCCCCOC(=O)c1cc(OC)c(OC)c(OC)c1,BRD-K58220566,c1ccccc1,BRD-K58220566,pkc inhibitor|sodium channel blocker|calcium channel blocker
7.287895,7.870659,1100,Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O,BRD-K58265391,O=S1(=O)CCCc2ccccc21,BRD-K58265391,diuretic
7.422024,7.689049,1101,Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1,BRD-K58299615,c1ccc(-c2nc3ccc(-c4nc5ccccc5[nH]4)cc3[nH]2)cc1,BRD-K58299615,amyloid precursor protein inhibitor|beta amyloid aggregation inhibitor
5.9685063,6.9670286,1102,COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC,BRD-K58466253,c1ccc2c(c1)CC[n+]1cc3ccccc3cc1-2,BRD-K58466253,serotonin release inhibitor
6.8867054,7.253278,1103,Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1,BRD-K58685305,O=C1c2ccccc2C(=O)c2ccccc21,BRD-K58685305,11-beta hydroxysteroid dehydrogenase inhibitor
8.681721,7.663137,1104,C[C@]12N[C@H](Cc3ccccc13)c1ccccc21,BRD-K58930050,c1ccc2c(c1)CC1NC2c2ccccc21,BRD-K58930050,glutamate receptor antagonist
4.5828104,9.077542,1105,C[C@@H]1[C@@H]2NC[C@@H](C)C[C@H]2O[C@]11CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC2=C1C,BRD-K58938839,C1=C2CC3C4CCCCC4=CCC3C2CCC12CC1NCCCC1O2,BRD-K58938839,smoothened receptor antagonist|hedgehog pathway inhibitor
7.374914,6.3582063,1106,COc1ccc(C(=O)c2ccccc2)c(O)c1,BRD-K59037100,O=C(c1ccccc1)c1ccccc1,BRD-K59037100,lipase inhibitor
10.681521,7.602005,1107,CN(C)CC\C=C1/c2ccccc2Sc2ccc(Cl)cc12,BRD-K59058766,C=C1c2ccccc2Sc2ccccc21,BRD-K59058766,dopamine receptor antagonist
8.808097,6.9340434,1108,Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12,BRD-K59184148,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1ccccc1,BRD-K59184148,glycogen synthase kinase inhibitor
5.817618,9.507412,1109,CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12,BRD-K59273480,O=c1[nH]c(=O)c2[nH]cnc2[nH]1,BRD-K59273480,adenosine reuptake inhibitor|phosphodiesterase inhibitor
7.105618,7.04448,1110,COc1cccc(NC(=O)C=Cc2ccc(Cl)cc2)c1,BRD-K59331372,O=C(C=Cc1ccccc1)Nc1ccccc1,BRD-K59331372,trpv antagonist
8.616912,8.188756,1111,O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1,BRD-K59332007,O=C1N(c2ccccc2)c2ccccc2C1(Cc1ccncc1)Cc1ccncc1,BRD-K59332007,acetylcholine release enhancer|acetylcholine release stimulant|neurotransmitter agonist|voltage-gated potassium channel blocker
7.305794,9.663872,1112,Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1,BRD-K59419204,O=C(NN1CCOCC1)c1cc(-c2ccccc2)n(-c2ccccc2)n1,BRD-K59419204,cannabinoid receptor antagonist|cannabinoid receptor inhibitor
6.540555,4.9769883,1113,CC(C)(C)c1cc(cc(c1O)C(C)(C)C)\C=C(/C#N)C(N)=S,BRD-K59469039,c1ccccc1,BRD-K59469039,angiogenesis inhibitor
6.7340217,7.1813226,1114,O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1,BRD-K59522102,O=C(C=CC=Cc1ccc2c(c1)OCO2)N1CCCCC1,BRD-K59522102,monoamine oxidase inhibitor
7.949155,10.246164,1115,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O,BRD-K59574735,c1ccccc1,BRD-K59574735,leukotriene synthesis inhibitor
6.338399,6.3043146,1116,OC(=O)c1c(Br)c(Br)c(Br)c(Br)c1-c1c2ccc(O)cc2oc2cc(=O)ccc12,BRD-K59637651,O=c1ccc2c(-c3ccccc3)c3ccccc3oc-2c1,BRD-K59637651,protein synthesis inhibitor|botulin neurotoxin inhibitor|mur synthetase inhibitor
6.4402304,8.108781,1117,CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C,BRD-K59650319,O=C(NC1CCCCC1)c1cn2c(nc3ccccc32)s1,BRD-K59650319,glutamate receptor antagonist
7.8588595,9.564608,1118,OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O,BRD-K59753853,c1ccc2[nH]ccc2c1,BRD-K59753853,glutamate receptor antagonist
9.181582,7.813133,1119,CN1CC[C@@]23[C@@H]4Nc5ccccc5[C@]2(CCN4C)[C@@H]1Nc1ccccc31,BRD-K59851896,c1ccc2c(c1)NC1NCCC23C2NCCC13c1ccccc1N2,BRD-K59851896,gaba release inhibitor
7.46069,8.602308,1120,Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1,BRD-K59983611,O=C(NS(=O)(=O)c1ccccc1)c1ccccc1,BRD-K59983611,bacterial antifolate
8.756366,10.465827,1121,CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C,BRD-K60060639,c1ccccc1,BRD-K60060639,antiarrhythmic
8.490117,9.284945,1122,O=C[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)OCc1ccccc1,BRD-K60174629,O=C(C1CCCN1C(=O)OCc1ccccc1)N1CCCC1,BRD-K60174629,prolyl endopeptidase inhibitor
6.4911327,4.635783,1123,NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N,BRD-K60184833,c1ccccc1,BRD-K60184833,tyrosine kinase inhibitor
8.159202,10.310386,1124,CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O,BRD-K60230970,c1ccccc1,BRD-K60230970,proteasome inhibitor
6.491295,8.070472,1125,CN([N+][O-])c1cc(O)ccc1O,BRD-K60274257,c1ccccc1,BRD-K60274257,tyrosine phosphatase inhibitor
9.004396,6.693394,1126,COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12,BRD-K60298136,O=C(c1nccs1)c1c[nH]c2ccccc12,BRD-K60298136,aryl hydrocarbon receptor agonist|aryl hydrocarbon receptor ligand
8.804898,8.731789,1127,OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12,BRD-K60476892,c1ccc(Cn2nc(-c3ccco3)c3ccccc32)cc1,BRD-K60476892,activator of soluble guanylyl cyclase|guanylate cyclase activator|hypoxia inducible factor inhibitor
5.6696873,9.976218,1128,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12,BRD-K60511616,C1=CC2=CCCCC2CC1,BRD-K60511616,hmgcr inhibitor
2.4649734,9.7438755,1129,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,BRD-K60640630,O=C1C=CC2C(=C1)CCC1C2CCC2C(OC(=O)c3ccco3)CCC21,BRD-K60640630,glucocorticoid receptor agonist
8.396824,8.295019,1130,Cc1cccc(n1)C#Cc1ccccc1,BRD-K60690191,C(#Cc1ccccn1)c1ccccc1,BRD-K60690191,glutamate receptor antagonist
4.8714685,10.805997,1131,COc1ccc(cc1OC)C(=O)O[C@H]1CC[C@@]2(C)[C@@H]3CC[C@H]4[C@]5(O)C[C@H](O)[C@@]6(O)[C@@H](CN7C[C@@H](C)CC[C@H]7[C@@]6(C)O)[C@]5(O)C[C@]24O[C@]13O,BRD-K60923938,O=C(OC1CCC2C3CCC4C5CCC6CC7CCCCN7CC6C5CC42OC13)c1ccccc1,BRD-K60923938,sodium channel activator
10.245401,6.9571614,1132,Oc1cc2[C@H](CN(CC=C)CCc2c(Br)c1O)c1ccccc1,BRD-K60932973,c1ccc(C2CNCCc3ccccc32)cc1,BRD-K60932973,dopamine receptor agonist
8.231217,8.637133,1133,COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1,BRD-K61097567,O=C(NCc1ccccc1)c1cc(-c2ccccc2)nc2ccccc12,BRD-K61097567,tachykinin antagonist
6.7475276,8.234498,1134,CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl,BRD-K61177364,c1ccc(Nc2cc(NCC3CC3)ncn2)cc1,BRD-K61177364,crf receptor antagonist
10.136404,8.97376,1135,CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1,BRD-K61250553,c1ccc(C2CCN(CCC(c3ccccc3)c3ccccc3)CC2)cc1,BRD-K61250553,opioid receptor agonist
6.45986,6.5918403,1136,Oc1ccc2ccc(=O)oc2c1O,BRD-K61269089,O=c1ccc2ccccc2o1,BRD-K61269089,protein kinase inhibitor
5.574869,6.953461,1137,COc1ccc2[C@H](OC(=O)c2c1OC)[C@H]1N(C)CCc2cc3OCOc3cc12,BRD-K61271364,O=C1OC(C2NCCc3cc4c(cc32)OCO4)c2ccccc21,BRD-K61271364,gaba receptor antagonist
7.455333,9.200711,1138,Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O,BRD-K61323504,O=C(Nc1ccccc1)Nc1ccccc1,BRD-K61323504,cc chemokine receptor antagonist
2.4508808,9.722158,1139,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,BRD-K61496577,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K61496577,glucocorticoid receptor agonist
6.9048586,9.368504,1140,Oc1ccc(CC(C#N)C#N)cc1,BRD-K61590534,c1ccccc1,BRD-K61590534,egfr inhibitor
7.451695,6.9142156,1141,COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccsc1,BRD-K61737877,c1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1,BRD-K61737877,vegfr inhibitor
9.169137,6.5693946,1142,CNC(=O)c1cc2c(cn1)[nH]c1ccccc21,BRD-K61951118,c1ccc2c(c1)[nH]c1cnccc12,BRD-K61951118,gaba benzodiazepine site receptor inverse agonist
8.17982,10.436753,1143,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1,BRD-K62008436,O=C(CC(NC(=O)c1ccccc1)c1ccccc1)OC1C=C2CC(=O)C3CCC4OCC4C3C(OC(=O)c3ccccc3)C(C2)C1,BRD-K62008436,tubulin polymerization inhibitor
9.551645,7.6524687,1144,CN1CCN(CC1)c1ccc2ccccc2n1,BRD-K62056274,c1ccc2nc(N3CCNCC3)ccc2c1,BRD-K62056274,serotonin receptor agonist
8.795589,8.846894,1145,C(CC1CCNCC1)Cc1c[nH]cn1,BRD-K62206109,c1nc(CCCC2CCNCC2)c[nH]1,BRD-K62206109,histamine receptor antagonist
8.738148,9.502719,1146,CC(C)OC(=O)c1cn(Cc2c(F)cccc2F)c2sc(c(CN(C)Cc3ccccc3)c2c1=O)-c1ccc(NC(=O)C(C)C)cc1,BRD-K62221994,O=c1ccn(Cc2ccccc2)c2sc(-c3ccccc3)c(CNCc3ccccc3)c12,BRD-K62221994,gonadotropin releasing factor hormone receptor antagonist
7.4388294,8.611705,1147,CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1,BRD-K62289640,c1ccc2c(c1)CCC1CCCCC21,BRD-K62289640,cannabinoid receptor agonist
2.4389412,9.710298,1148,CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF,BRD-K62310379,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K62310379,glucocorticoid receptor agonist
6.693159,9.208958,1149,CCN(CC)c1ccc(C=NNC(=O)c2ccc(O)cc2)cc1,BRD-K62353524,O=C(NN=Cc1ccccc1)c1ccccc1,BRD-K62353524,estrogen receptor agonist
7.4576344,8.194503,1150,Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1,BRD-K62363391,O=S(=O)(c1ccccc1)c1ccccc1,BRD-K62363391,bacterial antifolate
6.696852,8.9053955,1151,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O,BRD-K62607865,N=C(C(=O)NC1CNC1=O)c1cscn1,BRD-K62607865,bacterial cell wall synthesis inhibitor
5.3659096,6.612342,1152,COc1cc2CCN3Cc4c(C[C@H]3c2cc1O)ccc(OC)c4O,BRD-K62609077,c1ccc2c(c1)CC1c3ccccc3CCN1C2,BRD-K62609077,adrenergic receptor antagonist|gaba receptor antagonist|serotonin receptor antagonist
7.565735,7.1179414,1153,COc1cccc(-c2cc(=O)c3ccccc3o2)c1N,BRD-K62810658,O=c1cc(-c2ccccc2)oc2ccccc12,BRD-K62810658,mek inhibitor
8.843464,9.1557455,1154,N(Cc1ccccc1)c1ncnc2nc[nH]c12,BRD-K62929068,c1ccc(CNc2ncnc3nc[nH]c23)cc1,BRD-K62929068,purinergic receptor activator
10.338576,9.329607,1155,Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,BRD-K62996583,O=C(CN1CCN(CCCC(c2ccccc2)c2ccccc2)CC1)Nc1ccccc1,BRD-K62996583,calcium channel blocker
6.341134,10.603917,1156,CC(C)=CCC\C(C)=C\CC\C(C)=C\CSCC(O)=O,BRD-K63089472,,BRD-K63089472,inhibitor of methyl esterification of farnesylated proteins
6.256343,11.443723,1157,CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12,BRD-K63150726,O=C(NCc1ccc2c(c1)OCO2)c1cc2ccccc2[nH]c1=O,BRD-K63150726,cannabinoid receptor inverse agonist
6.3634334,8.555924,1158,Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O,BRD-K63151507,c1ncc(Sc2nnc[nH]2)[nH]1,BRD-K63151507,lymphocyte inhibitor
10.336907,7.7363677,1159,CNCCC=C1c2ccccc2C=Cc2ccccc12,BRD-K63165456,C=C1c2ccccc2C=Cc2ccccc21,BRD-K63165456,adrenergic receptor agonist
6.4070373,6.56666,1160,COc1c2occc2cc2ccc(=O)oc12,BRD-K63430059,O=c1ccc2cc3ccoc3cc2o1,BRD-K63430059,dna synthesis inhibitor
8.5999975,7.333362,1161,Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1,BRD-K63504947,O=C1Nc2ccccc2C1=Cc1ccc[nH]1,BRD-K63504947,vegfr inhibitor
6.776122,7.106913,1162,COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1,BRD-K63516691,O=c1c2c(OCc3ncccn3)nccc2c(-c2ccccc2)cn1Cc1ccncc1,BRD-K63516691,phosphodiesterase inhibitor
7.282904,6.1733932,1163,COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12,BRD-K63533170,O=C(c1ccccc1)c1cn(CCN2CCOCC2)c2ccccc12,BRD-K63533170,cannabinoid receptor antagonist|cannabinoid receptor inverse agonist
4.3032575,9.583318,1164,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2c1ccc(=O)oc1,BRD-K63606607,O=c1ccc(C2CCC3C2CCC2C4CCCCC4CCC23)co1,BRD-K63606607,atpase inhibitor|chloride channel activator
6.9281244,9.359024,1165,CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl,BRD-K63630713,c1ccccc1,BRD-K63630713,sodium/potassium/chloride transporter inhibitor
8.038633,9.794648,1166,COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O,BRD-K63750851,O=C1OCc2ccccc21,BRD-K63750851,dehydrogenase inhibitor|inositol monophosphatase inhibitor
6.4356947,8.85412,1167,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O,BRD-K63784565,O=C1Cc2cc3n(c(=O)c2CO1)Cc1cc2ccccc2nc1-3,BRD-K63784565,topoisomerase inhibitor
5.9423246,8.28872,1168,CC#CCOC(=O)C1=CCCN(C)C1,BRD-K63792901,C1=CCNCC1,BRD-K63792901,acetylcholine receptor agonist
6.580563,9.208217,1169,Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1,BRD-K63828191,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccccc2)sc2ccccc12,BRD-K63828191,estrogen receptor antagonist|selective estrogen receptor modulator (serm)
5.930916,8.320737,1170,S=C(NC1CCCCC1)N1CCC(CC1)c1c[nH]cn1,BRD-K63874012,S=C(NC1CCCCC1)N1CCC(c2c[nH]cn2)CC1,BRD-K63874012,histamine receptor antagonist|histamine receptor inverse agonist
6.1997423,11.246751,1171,CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O,BRD-K63913457,,BRD-K63913457,vasodilator
6.3748565,6.58766,1172,CC(C)CC(=O)O[C@@H]1[C@H](OC(C)=O)c2c(OC1(C)C)ccc1ccc(=O)oc21,BRD-K63945320,O=c1ccc2ccc3c(c2o1)CCCO3,BRD-K63945320,phospholipase inhibitor
8.678263,10.263269,1173,CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O,BRD-K63979671,c1ccccc1,BRD-K63979671,compound used in hepatobiliary scans of the liver
5.981236,11.240633,1174,CCCCC\C=C/C\C=C/CCCCCCCC(N)=O,BRD-K64044582,,BRD-K64044582,acat inhibitor
8.629562,9.815789,1175,O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1,BRD-K64157027,c1ccc(CCNCCOc2ccccc2)cc1,BRD-K64157027,adrenergic receptor agonist
7.9449143,8.689855,1176,CC(C)c1onc(c1COc1ccc(C=Cc2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl,BRD-K64245000,C(=Cc1ccc(OCc2conc2-c2ccccc2)cc1)c1ccccc1,BRD-K64245000,fxr agonist
9.720299,9.791741,1177,COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1,BRD-K64341947,O=C(Nc1ccccc1)c1ccnn1Cc1ccccc1,BRD-K64341947,guanylate cyclase activator
7.5307865,8.396214,1178,CC(=O)OCCN1C(=O)c2c(C1=O)c1cc(ccc1nc2C)S(=O)(=O)N1CCOCC1,BRD-K64402243,O=C1NC(=O)c2c1cnc1ccc(S(=O)(=O)N3CCOCC3)cc21,BRD-K64402243,caspase inhibitor
7.262504,8.7667,1179,COC1CCC(CC1)C(=O)c1ccc2nc3OCCCc3cc2c1,BRD-K64670467,O=C(c1ccc2nc3c(cc2c1)CCCO3)C1CCCCC1,BRD-K64670467,glutamate receptor antagonist
6.97665,9.949975,1180,CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C,BRD-K64755930,c1cnc2[nH]ncc2c1,BRD-K64755930,phosphodiesterase inhibitor
2.5447366,9.675918,1181,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12,BRD-K64862097,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K64862097,glucocorticoid receptor agonist
3.6558163,9.418962,1182,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,BRD-K64994968,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-K64994968,progesterone receptor agonist
7.3674903,6.286172,1183,COc1ccc2cc(CCC(C)=O)ccc2c1,BRD-K65146499,c1ccc2ccccc2c1,BRD-K65146499,cyclooxygenase inhibitor
7.1907377,9.499879,1184,Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1,BRD-K65285700,O=C(NN1CCCCC1)c1nn(-c2ccccc2)c2c1Cc1ccccc1-2,BRD-K65285700,cannabinoid receptor agonist
8.203203,9.408123,1185,CCCNC(C)(C)COC(=O)c1ccccc1,BRD-K65417056,c1ccccc1,BRD-K65417056,local anesthetic
6.764216,7.832401,1186,CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O,BRD-K65503129,c1ccc(-c2n[nH]cc2-c2ccc3c(c2)OCCO3)cc1,BRD-K65503129,hsp inhibitor|hsp antagonist
6.5704694,6.1329265,1187,COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O,BRD-K65639003,O=c1c(OC2CCCCO2)c(-c2ccccc2)oc2cc(OC3CCCCO3)ccc12,BRD-K65639003,phosphodiesterase inhibitor
8.733064,9.032339,1188,C(Nc1ncnc2[nH]cnc12)c1ccco1,BRD-K65667145,c1coc(CNc2ncnc3[nH]cnc23)c1,BRD-K65667145,cell division inducer
6.5821567,7.7181106,1189,CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C,BRD-K65786282,c1ccccc1,BRD-K65786282,gaba receptor modulator
8.561571,7.6128917,1190,[I+]1c2ccccc2-c2ccccc12,BRD-K65814004,c1ccc2c(c1)[I+]c1ccccc1-2,BRD-K65814004,nitric oxide synthase inhibitor|aldehyde dehydrogenase inhibitor|cytochrome p450 inhibitor|nadph oxidase inhibitor|xanthine oxidase inhibitor
6.912449,10.318617,1191,CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1,BRD-K66093087,c1ccc(-c2cc3ccccc3[nH]2)cc1,BRD-K66093087,benzodiazepine receptor agonist
9.641046,9.032623,1192,CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1,BRD-K66206289,O=C(CC1CCCC(CCc2ccccc2)N1)c1ccccc1,BRD-K66206289,acetylcholine receptor antagonist
7.7415004,7.8175235,1193,Nc1nc2cc(Cl)ccc2o1,BRD-K66353228,c1ccc2ocnc2c1,BRD-K66353228,myorelaxant
9.480192,5.8201637,1194,O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45,BRD-K66404838,c1cc2c3c(c1)OC1CCCC4C(C2)N(CC2CCC2)CCC314,BRD-K66404838,opioid receptor agonist|opioid receptor antagonist
8.259171,7.686518,1195,O=C1CC(=O)c2ccccc2C1=O,BRD-K66707493,O=C1CC(=O)c2ccccc2C1=O,BRD-K66707493,coloring
6.1622186,7.3685455,1196,CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C,BRD-K66715657,c1ccc2c(c1)CCCC2,BRD-K66715657,dopamine receptor antagonist
8.14878,9.36446,1197,NC(=O)CCCCn1ccc(N=C(N)NCC(F)(F)F)n1,BRD-K66782112,c1cn[nH]c1,BRD-K66782112,histamine receptor antagonist
7.03479,8.709714,1198,Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N,BRD-K66874953,N=c1sc2c(n1CC(=O)c1ccccc1)CCCC2,BRD-K66874953,tp53 inhibitor
6.2024307,7.6262503,1199,C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12,BRD-K66898851,c1cc2c(c[nH+]c3c4cc5c(cc4ccc23)OCO5)c2c1OCO2,BRD-K66898851,apoptosis stimulant
6.322287,6.611998,1200,COc1cc2ccc(=O)oc2c(OC)c1OC,BRD-K66944906,O=c1ccc2ccccc2o1,BRD-K66944906,carbonic anhydrase inhibitor
8.399141,10.037612,1201,CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12,BRD-K67013324,c1ccc(Cc2cc3ccccc3[nH]2)cc1,BRD-K67013324,melatonin receptor antagonist
5.6830564,8.181185,1202,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,BRD-K67017579,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,BRD-K67017579,phosphodiesterase inhibitor
6.4790845,8.246682,1203,CN(C)c1nc(nc(n1)N(C)C)N(C)C,BRD-K67043667,c1ncncn1,BRD-K67043667,dna synthesis inhibitor
8.0365715,8.09462,1204,Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N,BRD-K67080878,O=c1ccc(-c2ccncc2)c[nH]1,BRD-K67080878,phosphodiesterase inhibitor
8.286428,9.610488,1205,OC(=O)CCCc1ccccc1,BRD-K67102207,c1ccccc1,BRD-K67102207,hdac inhibitor
8.065552,10.004388,1206,OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I,BRD-K67261995,O=C(CCCCC(=O)Nc1ccccc1)Nc1ccccc1,BRD-K67261995,ultrasound contrast
8.076638,9.273136,1207,COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1,BRD-K67277431,O=C(NCc1cccnc1)c1cccc(C(=O)NCc2cccnc2)c1,BRD-K67277431,thromboxane receptor antagonist|thromboxane synthase inhibitor
7.719031,7.9830785,1208,NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccccn1)-c1ccc2OCOc2c1,BRD-K67298865,c1ccc(-c2nc(-c3ccc4c(c3)OCO4)c(-c3ccccn3)[nH]2)cc1,BRD-K67298865,tgf beta receptor inhibitor
7.222923,9.01964,1209,CCOc1cncc(C=CCCNC)c1,BRD-K67352070,c1ccncc1,BRD-K67352070,acetylcholine receptor agonist
8.382905,8.304457,1210,Cc1cccc(C=Cc2ccccc2)n1,BRD-K67439147,C(=Cc1ccccn1)c1ccccc1,BRD-K67439147,glutamate receptor antagonist
7.8010864,9.163154,1211,NP(N)(=O)NC(=O)c1ccc(F)cc1,BRD-K67445247,c1ccccc1,BRD-K67445247,urease inhibitor
7.726705,8.933629,1212,COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12,BRD-K67537649,O=C(Nc1ccccc1)Nc1ccnc2ccccc12,BRD-K67537649,insulin growth factor receptor inhibitor
10.187136,8.753173,1213,OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1,BRD-K67680372,C1=CCN(CCOC(c2ccccc2)c2ccccc2)CC1,BRD-K67680372,gat inhibitor
10.673766,9.394561,1214,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1,BRD-K67783091,O=C(CCCN1CCC(c2ccccc2)CC1)c1ccccc1,BRD-K67783091,dopamine receptor antagonist
7.86131,6.237079,1215,Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O,BRD-K67831364,c1ccc(COc2ccc3c(Nc4ccccc4)ncnc3c2)cc1,BRD-K67831364,vascular endothelial growth factor receptor 2 (vegfr2) inhibitor|vegfr inhibitor
6.858106,8.392785,1216,COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1,BRD-K67860401,O=C(NCc1ccccc1)Nc1nccs1,BRD-K67860401,glycogen synthase kinase inhibitor
6.085732,10.91069,1217,CCCCCCCCCCCCCCCC(=O)NCCO,BRD-K68095457,,BRD-K68095457,cannabinoid receptor agonist
7.2428427,6.534945,1218,COc1ccc(cc1)-n1nc2c3CCCCCc3[nH]cc2c1=O,BRD-K68103045,O=c1c2c[nH]c3c(c-2nn1-c1ccccc1)CCCCC3,BRD-K68103045,benzodiazepine receptor agonist|gaba benzodiazepine site receptor partial agonist
8.213095,7.8866014,1219,OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O,BRD-K68143200,O=C1C=CC(=O)c2ccccc21,BRD-K68143200,cdc inhibitor
8.598936,6.191858,1220,COc1ccc(CNC(=O)C=Cc2ccc3[nH]cc(CCN(C)C)c3c2)cc1,BRD-K68190965,O=C(C=Cc1ccc2[nH]ccc2c1)NCc1ccccc1,BRD-K68190965,serotonin receptor agonist
7.454549,9.203587,1221,CC(=Cc1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C,BRD-K68246049,C(=Cc1ccc2c(c1)CCCC2)c1ccccc1,BRD-K68246049,retinoid receptor agonist
8.237414,6.67532,1222,Brc1c(NC2=NCCN2)ccc2nccnc12,BRD-K68264559,c1cnc2cc(NC3=NCCN3)ccc2n1,BRD-K68264559,adrenergic receptor agonist
8.348852,9.6640215,1223,OC(=O)Cc1nn(Cc2ccc(Br)cc2F)c(=O)c2ccccc12,BRD-K68332390,O=c1c2ccccc2cnn1Cc1ccccc1,BRD-K68332390,aldose reductase inhibitor|reductase inhibitor
7.894943,6.2275586,1224,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,BRD-K68336408,c1ccc(Nc2ncnc3ccccc23)cc1,BRD-K68336408,egfr inhibitor
9.909045,6.4056,1225,NCCCCCCNS(=O)(=O)c1ccc2c(Cl)cccc2c1,BRD-K68341547,c1ccc2ccccc2c1,BRD-K68341547,calmodulin antagonist
9.123902,6.5611587,1226,CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C,BRD-K68392338,c1ccc2c(c1)[nH]c1cnccc12,BRD-K68392338,benzodiazepine receptor antagonist
9.771637,6.522315,1227,Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1,BRD-K68402494,O=S(=O)(c1cccc2ccccc12)N1CCCNCC1,BRD-K68402494,myosin light chain kinase inhibitor
9.760471,10.20455,1228,CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1,BRD-K68507560,C1CCC(C2CCCCC2)CC1,BRD-K68507560,acetylcholine receptor antagonist
5.981995,10.861625,1229,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O,BRD-K68552125,O=C1C=CC2C1CC=CC1C3CC3CCC21,BRD-K68552125,pkc activator|cd antagonist
8.364558,7.4362216,1230,CCOC(=O)NNc1nncc2ccccc12,BRD-K68553471,c1ccc2cnncc2c1,BRD-K68553471,antihypertensive
7.3358703,7.6789064,1231,COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F,BRD-K68558722,c1ccc(-c2ccnn2-c2ccccc2)cc1,BRD-K68558722,cyclooxygenase inhibitor
3.6116798,9.464241,1232,CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C,BRD-K68620903,O=C1C=C2C=CC3C4CCCC4CCC3C2CC1,BRD-K68620903,progesterone receptor agonist
8.805217,7.1724057,1233,CCCCN1C(=O)[C@H]2Cc3c([nH]c4ccccc34)[C@@H](N2C1=O)c1ccc(OC)cc1,BRD-K68873215,O=C1NC(=O)N2C1Cc1c([nH]c3ccccc13)C2c1ccccc1,BRD-K68873215,phosphodiesterase inhibitor
6.0270853,10.936444,1234,CCCCCCCC(=O)O[C@@H]1[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]3OC(=O)[C@@](C)(O)[C@@]3(O)[C@H](C[C@](C)(OC(C)=O)[C@@H]12)OC(=O)CCC,BRD-K69023402,O=C1CC2CCCC3CCC=C3C2O1,BRD-K69023402,atpase inhibitor|calcium channel blocker|pkc activator
5.595885,9.026487,1235,CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O,BRD-K69032158,C1CCNC1,BRD-K69032158,dipeptidyl peptidase inhibitor
10.732276,8.61267,1236,COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1,BRD-K69195780,O=C1c2ccccc2C(=O)N1CCCCN1CCN(c2ccccc2)CC1,BRD-K69195780,serotonin receptor agonist
6.881119,9.277461,1237,CC(C)[C@]1(O)[C@@H](OC(=O)c2ccc[nH]2)[C@@]2(O)[C@@]3(C)C[C@]4(O)O[C@@]5([C@H](O)[C@@H](C)CC[C@]35O)[C@@]2(O)[C@@]14C,BRD-K69556541,O=C(OC1CC2C3CC4C1C2C1(CCCCC41)O3)c1ccc[nH]1,BRD-K69556541,calcium channel blocker
8.631037,8.748955,1238,N[C@@](CC1c2ccccc2Oc2ccccc12)([C@H]1C[C@@H]1C(O)=O)C(O)=O,BRD-K69763916,c1ccc2c(c1)Oc1ccccc1C2CCC1CC1,BRD-K69763916,glutamate receptor antagonist
8.113873,8.16742,1239,CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O,BRD-K69837166,O=c1[nH]c2ccccc2n1C1=CCN(CC2CCCCCCC2)CC1,BRD-K69837166,nociceptin/orphanin fq (nop) receptor antagonist
8.207985,9.41112,1240,C[C@@H](O)CNC(C)(C)CC(=O)N[C@@H]1CCc2ccccc2N(Cc2ccc(cc2)-c2ccccc2-c2nn[nH]n2)C1=O,BRD-K70241288,O=C1CCCc2ccccc2N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,BRD-K70241288,growth hormone releasing peptide ligand agonist
6.7080507,8.214353,1241,Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C,BRD-K70246307,O=c1nc2[nH]c3ccccc3nc-2c(=O)[nH]1,BRD-K70246307,vitamin b
6.025464,7.4036474,1242,CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1,BRD-K70281171,c1ccc2c(c1)CCC2,BRD-K70281171,dopamine receptor antagonist
5.7483315,8.584427,1243,NC12CC3CC(CC(C3)C1)C2,BRD-K70330367,C1C2CC3CC1CC(C2)C3,BRD-K70330367,glutamate receptor antagonist
10.609231,7.6020064,1244,OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,BRD-K70487031,C(CCN1CCNCC1)=C1c2ccccc2Sc2ccccc21,BRD-K70487031,dopamine receptor antagonist
10.073466,8.329961,1245,Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1,BRD-K70778732,O=c1n(CCCN2CCN(c3ccccc3)CC2)nc2ccccn12,BRD-K70778732,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor
10.817336,7.6945662,1246,CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12,BRD-K70792160,c1ccc2c(c1)Nc1ccccc1O2,BRD-K70792160,akt inhibitor
4.0710397,9.235111,1247,C[C@@H]1[C@H]2CC[C@H](C)CN2[C@H]2C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]3(C)[C@@H]12)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O,BRD-K70881766,C1=C2CC(OC3OCCC(OC4CCCCO4)C3OC3CCCCO3)CCC2C2CCC3C(CC4C3CC3CCCCN34)C2C1,BRD-K70881766,acetylcholinesterase inhibitor
7.9026737,6.292608,1248,CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1,BRD-K70914287,c1ccc(Nc2ncnc3cnc(NC4CCNCC4)nc23)cc1,BRD-K70914287,egfr inhibitor|tyrosine kinase inhibitor
8.3100395,9.442192,1249,CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O,BRD-K70976396,O=C(Cc1cccs1)NC1C(=O)N2C=CCSC12,BRD-K70976396,bacterial cell wall synthesis inhibitor
5.695021,7.1363463,1250,CN1CCC2=C[C@H](O)[C@H]3OC(=O)c4cc5OCOc5cc4[C@H]3[C@H]12,BRD-K71003802,O=C1OC2CC=C3CCNC3C2c2cc3c(cc21)OCO3,BRD-K71003802,plant alkaloid
8.117694,7.579611,1251,Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O,BRD-K71266197,O=C1c2ccccc2C(=O)c2c(Nc3cccc4ccccc34)cccc21,BRD-K71266197,ntpdase inhibitor
8.751533,9.0302515,1252,Clc1ccc(CNC(=N)SCCCc2c[nH]cn2)cc1,BRD-K71430621,N=C(NCc1ccccc1)SCCCc1c[nH]cn1,BRD-K71430621,histamine receptor antagonist|histamine receptor inverse agonist
7.431357,7.956866,1253,NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O,BRD-K71499074,c1ccccc1,BRD-K71499074,carbonic anhydrase inhibitor
8.43354,9.531084,1254,OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1,BRD-K71534238,c1ccc(NCc2cccc(Oc3ccccc3)c2)cc1,BRD-K71534238,free fatty acid receptor agonist
9.057607,10.077144,1255,CC(C)n1cnc2c(NCc3ccccc3)nc(NCCO)nc12,BRD-K71726959,c1ccc(CNc2ncnc3[nH]cnc23)cc1,BRD-K71726959,cdk inhibitor
7.6881404,8.956499,1256,COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl,BRD-K71731651,O=C(Nc1ccccc1)Nc1ccon1,BRD-K71731651,acetylcholine receptor agonist
8.516818,9.741925,1257,CC(C)c1cnc(NC(=O)Cc2ccccc2)s1,BRD-K71799778,O=C(Cc1ccccc1)Nc1nccs1,BRD-K71799778,cdk inhibitor
8.160273,8.124297,1258,NC(=O)N1c2ccccc2C=Cc2ccccc12,BRD-K71799949,C1=Cc2ccccc2Nc2ccccc21,BRD-K71799949,carboxamide antiepileptic
7.3838677,7.9358597,1259,Nc1cc(Nc2ccc(cc2)S(N)(=O)=O)ncn1,BRD-K71860425,c1ccc(Nc2ccncn2)cc1,BRD-K71860425,cdk inhibitor
6.3762436,9.023092,1260,CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccc(OCC(=O)Nc2ccc(cc2)C#N)cc1,BRD-K72024482,O=C(COc1ccc(-c2nc3[nH]c(=O)[nH]c(=O)c3[nH]2)cc1)Nc1ccccc1,BRD-K72024482,adenosine receptor antagonist
6.4876494,6.5020776,1261,COc1c(oc2cc3oc(=O)ccc3cc12)C(C)C,BRD-K72034655,O=c1ccc2cc3ccoc3cc2o1,BRD-K72034655,apoptosis inducer|antileukemic
5.869406,9.576661,1262,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O,BRD-K72222507,O=C(CNCCCc1ccccc1)N1CCc2ccccc2C1,BRD-K72222507,ace inhibitor
7.1234617,9.298427,1263,COCCCCC(=NOCCN)c1ccc(cc1)C(F)(F)F,BRD-K72676686,c1ccccc1,BRD-K72676686,selective serotonin reuptake inhibitor (ssri)|serotonin reuptake inhibitor|serotonin uptake inhibitor
7.855107,6.1744127,1264,COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1,BRD-K72703948,O=C(Nc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)ccc23)cc1)c1ccccc1,BRD-K72703948,aurora kinase inhibitor
8.830167,6.971667,1265,O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21,BRD-K72726508,O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21,BRD-K72726508,cdk inhibitor
6.4369283,4.5339866,1266,Oc1ccc(C=C(C#N)C(=O)NCCCc2ccccc2)cc1O,BRD-K72783841,O=C(C=Cc1ccccc1)NCCCc1ccccc1,BRD-K72783841,cdk inhibitor|epidermal growth factor receptor (egfr) inhibitor|tyrosine kinase inhibitor|egfr inhibitor
10.394687,9.552232,1267,COc1cc2c(C(=O)N(COc3cc(=O)n4cccc(OCCN5CCCCC5)c4n3)S2(=O)=O)c(c1)C(C)C,BRD-K72895815,O=C1c2ccccc2S(=O)(=O)N1COc1cc(=O)n2cccc(OCCN3CCCCC3)c2n1,BRD-K72895815,leukocyte elastase inhibitor
5.508139,8.421934,1268,Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,BRD-K72903603,O=c1ccn(C2CCCO2)c(=O)[nH]1,BRD-K72903603,reverse transcriptase inhibitor
7.809188,7.807843,1269,CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1,BRD-K73109821,O=S1(=O)NC=Nc2ccccc21,BRD-K73109821,potassium channel activator
10.847759,8.65271,1270,COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1,BRD-K73196317,O=c1cc(NCCCN2CCN(c3ccccc3)CC2)[nH]c(=O)[nH]1,BRD-K73196317,adrenergic receptor antagonist
9.508753,8.737544,1271,CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1,BRD-K73290745,O=C(Cc1ccccc1)NC(CN1CCCC1)c1ccccc1,BRD-K73290745,opioid receptor agonist
3.9635906,6.7987866,1272,CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12,BRD-K73323637,O=C1CCCc2ccccc21,BRD-K73323637,adrenergic receptor antagonist
9.676849,9.639918,1273,CCCCc1cc2ccccc2c(OCCN(C)C)n1,BRD-K73391359,c1ccc2cnccc2c1,BRD-K73391359,local anesthetic
4.316489,6.811471,1274,C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12,BRD-K73397362,c1ccc2c(Oc3nc(Nc4ccc(N5CCOCC5)cc4)c4ncn(C5CCCCC5)c4n3)cccc2c1,BRD-K73397362,smoothened receptor agonist
3.4857225,9.4199295,1275,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO,BRD-K73589401,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-K73589401,mineralocorticoid receptor agonist
7.4299846,9.40621,1276,CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1,BRD-K73789395,O=C(Nc1cccc(NC(=O)c2ccccc2)c1)c1ccccc1,BRD-K73789395,raf inhibitor
6.4562454,6.1073213,1277,OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O,BRD-K73991644,O=c1c(OC2CCCCO2)c(-c2ccccc2)oc2ccccc12,BRD-K73991644,aldose reductase inhibitor|falcipain inhibitor
8.519563,9.575352,1278,ONC(=O)Cc1ccccc1,BRD-K74112339,c1ccccc1,BRD-K74112339,urease inhibitor
8.376579,7.937644,1279,CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12,BRD-K74141488,C(=Cc1ccccc1)CNCc1cccc2ccccc12,BRD-K74141488,fungal squalene epoxidase inhibitor
7.88844,8.080225,1280,Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl,BRD-K74195153,c1ccc(-c2ncncn2)cc1,BRD-K74195153,phosphodiesterase inhibitor
9.875116,12.472544,1281,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C,BRD-K74212935,O=C(NC1OC2C3CCCN3C(=O)CN2C1=O)C1C=C2c3cccc4[nH]cc(c34)CC2NC1,BRD-K74212935,dopamine agonist
7.3809137,9.116472,1282,Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F,BRD-K74305673,O=C(Nc1ccccc1)c1ccccc1,BRD-K74305673,ikk inhibitor|nfkb pathway inhibitor|protein kinase inhibitor
7.764714,7.4899154,1283,Clc1cccc(C=NC=Nc2cccc(Cl)c2)c1,BRD-K74430258,C(=NC=Nc1ccccc1)c1ccccc1,BRD-K74430258,hepatotoxicant
6.457495,9.591221,1284,CCCc1c(OCCCCc2nnn[nH]2)ccc(C(C)=O)c1O,BRD-K74765201,c1ccc(OCCCCc2nnn[nH]2)cc1,BRD-K74765201,leukotriene receptor antagonist
6.6244617,8.301784,1285,CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,BRD-K74913225,O=S1(=O)NCCc2ccsc21,BRD-K74913225,carbonic anhydrase inhibitor
9.561122,10.38717,1286,CCN(CC)CCNC(=O)c1ccc(N)cc1,BRD-K75089421,c1ccccc1,BRD-K75089421,sodium channel blocker
6.3394794,10.625476,1287,CC(=O)N[C@@H](CSC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=O,BRD-K75181824,,BRD-K75181824,inhibitor of methyl esterification of geranylgeranylated proteins
6.3274307,8.366258,1288,CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O,BRD-K75478907,c1nc(NC2CCCC2)cc(NC2CCCC2)n1,BRD-K75478907,gaba receptor modulator|gaba receptor positive allosteric modulator
6.1271524,8.178369,1289,Nc1nc2CCN(CC=C)CCc2s1,BRD-K75615183,c1nc2c(s1)CCNCC2,BRD-K75615183,adrenergic receptor agonist
9.985699,10.586427,1290,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,BRD-K75641298,c1ccccc1,BRD-K75641298,dopamine receptor antagonist
10.0371,7.528832,1291,CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12,BRD-K75958195,c1ccc2c(c1)CCc1sccc1C2=C1CCNCC1,BRD-K75958195,serotonin receptor antagonist
7.1034822,7.1001463,1292,COc1cc2ncc(nc2cc1OC)-c1ccccc1,BRD-K76064317,c1ccc(-c2cnc3ccccc3n2)cc1,BRD-K76064317,flt3 inhibitor
8.731201,8.642847,1293,NCc1ccccc1,BRD-K76133116,c1ccccc1,BRD-K76133116,membrane integrity inhibitor
8.096197,10.709794,1294,CCCCCCCCCCCCCC(=O)N[C@H](C)[C@@H](O)c1ccccc1,BRD-K76274772,c1ccccc1,BRD-K76274772,ceramidase inhibitor
8.545452,8.382359,1295,Nc1ccc(\N=N\c2ccccc2)c(N)n1,BRD-K76304753,c1ccc(N=Nc2cccnc2)cc1,BRD-K76304753,local anesthetic
7.1308117,8.858957,1296,Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1,BRD-K76568384,c1ccc(-c2nn3cccnc3c2-c2ccccc2)cc1,BRD-K76568384,estrogen receptor antagonist
6.475558,6.559326,1297,COc1cc2ccc(=O)oc2c(O)c1O,BRD-K76587808,O=c1ccc2ccccc2o1,BRD-K76587808,antioxidant
9.819283,6.508773,1298,O=S(=O)(N1CCCNCC1)c1cccc2cnccc12,BRD-K76617868,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,BRD-K76617868,rho associated kinase inhibitor
5.499118,8.421843,1299,OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O,BRD-K76634210,O=c1ccn(C2CCCO2)c(=O)[nH]1,BRD-K76634210,dna polymerase inhibitor
5.699255,7.183127,1300,COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC,BRD-K76674262,C1=CC23CCCN2CCc2cc4c(cc2C3C1)OCO4,BRD-K76674262,apoptosis stimulant|protein synthesis inhibitor
6.551991,8.841064,1301,CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C/C(O)=O,BRD-K76723084,C1=CCCCC1,BRD-K76723084,retinoid receptor agonist
7.6582985,8.654134,1302,CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O,BRD-K76775527,c1ccc(Oc2ccccc2)cc1,BRD-K76775527,cyclooxygenase inhibitor
7.7087255,7.849036,1303,Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl,BRD-K76805682,O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1,BRD-K76805682,glycogen synthase kinase inhibitor
9.650967,12.197544,1304,CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13,BRD-K76810206,O=C(OCC1CNC2Cc3c[nH]c4cccc(c34)C2C1)c1cccnc1,BRD-K76810206,adrenergic receptor antagonist
8.808601,6.3816667,1305,CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1,BRD-K76840893,c1ccc(OCC2CC2)c(OCCNCCc2c[nH]c3ccccc23)c1,BRD-K76840893,adrenergic receptor antagonist
8.279552,7.622573,1306,O=C1c2ccccc2-c2cccc3cccc1c23,BRD-K76872913,O=C1c2ccccc2-c2cccc3cccc1c23,BRD-K76872913,aromatic hydrocarbon derivative
7.3554378,7.699774,1307,[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1,BRD-K76927775,O=C1CN(N=Cc2ccco2)C(=O)N1,BRD-K76927775,dna inhibitor
7.0378013,7.8226357,1308,[O-][N+](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1,BRD-K77133231,c1ccc(-c2nc(-c3ccccc3)c(-c3ccncc3)[nH]2)cc1,BRD-K77133231,p38 mapk inhibitor
8.638707,8.659754,1309,C(COCc1ccccc1)Cc1cnc[nH]1,BRD-K77171813,c1ccc(COCCCc2cnc[nH]2)cc1,BRD-K77171813,histamine receptor modulator
2.5090904,9.716618,1310,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,BRD-K77554836,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K77554836,glucocorticoid receptor agonist
8.326906,6.726802,1311,C(C1=NCCN1)c1cccc2ccccc12,BRD-K77641333,c1ccc2c(CC3=NCCN3)cccc2c1,BRD-K77641333,adrenergic receptor agonist
7.443293,9.257768,1312,Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12,BRD-K77677632,O=C(Nc1cccnc1)Nc1ccc2[nH]ccc2c1,BRD-K77677632,serotonin receptor antagonist
7.92278,7.62667,1313,c1nc(cs1)-c1nc2ccccc2[nH]1,BRD-K77695569,c1ccc2[nH]c(-c3cscn3)nc2c1,BRD-K77695569,angiogenesis inhibitor
8.205668,6.6873527,1314,COc1nc(C)nc(Cl)c1NC1=NCCN1,BRD-K77771411,c1ncc(NC2=NCCN2)cn1,BRD-K77771411,imidazoline receptor agonist
9.772649,6.5207624,1315,Oc1nccc2c(cccc12)S(=O)(=O)N1CCCNCC1,BRD-K77793136,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,BRD-K77793136,rho associated kinase inhibitor
9.287233,7.4991,1316,C1CN(CCN1)c1ccc2ccccc2n1,BRD-K77925998,c1ccc2nc(N3CCNCC3)ccc2c1,BRD-K77925998,serotonin receptor agonist
10.786875,9.042404,1317,Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1,BRD-K77947974,O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccccc1)c1ccccc1)CC2,BRD-K77947974,dopamine receptor antagonist
8.067473,5.1680317,1318,COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1,BRD-K77987382,O=C(c1ccccc1)c1ccc2nc[nH]c2c1,BRD-K77987382,acetylcholinesterase inhibitor|microtubule inhibitor|tubulin inhibitor
7.569453,8.095469,1319,NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl,BRD-K78010432,c1ccc(NCc2ccco2)cc1,BRD-K78010432,diuretic
9.875308,6.4435043,1320,NCCCCNS(=O)(=O)c1ccc2ccccc2c1,BRD-K78084463,c1ccc2ccccc2c1,BRD-K78084463,calmodulin antagonist
4.798792,8.179842,1321,CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1,BRD-K78113049,O=c1cc[nH]c2nc(N3CCNCC3)ccc12,BRD-K78113049,topoisomerase inhibitor
8.253944,8.881668,1322,CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1,BRD-K78122587,O=C(OC1(CCNCCCc2nc3ccccc3[nH]2)CCc2ccccc2C1)C1CC1,BRD-K78122587,t-type calcium channel blocker
6.0893097,11.178321,1323,CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(=O)NCCO,BRD-K78280988,,BRD-K78280988,cannabinoid receptor agonist|potassium channel blocker|trpv agonist
6.7293506,9.006778,1324,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1,BRD-K78364995,N=C(C(=O)NC1C(=O)N2C=CCSC12)c1cscn1,BRD-K78364995,bacterial cell wall synthesis inhibitor
8.111286,9.404842,1325,CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1,BRD-K78485176,O=C(OCc1coc(=O)o1)c1cncn1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,BRD-K78485176,angiotensin receptor antagonist
6.134922,10.613226,1326,CCCC[C@@H](C)\C=C(C)\C=C(/C)C(=O)NC1=C[C@@](O)(\C=C\C=C\C=C\C(=O)NC2C(=O)CCC2=O)[C@@H]2O[C@@H]2C1=O,BRD-K78599730,O=C(C=CC=CC=CC1C=CC(=O)C2OC12)NC1C(=O)CCC1=O,BRD-K78599730,farnesyltransferase inhibitor|nfkb pathway inhibitor|ras farnesyltransferase inhibitor
7.8597074,9.410952,1327,COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1,BRD-K78633253,O=C(Nc1ccccc1)c1ccccc1,BRD-K78633253,arf inhibitor
7.000477,6.1660147,1328,COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N,BRD-K78637815,O=C(c1ccccc1)c1c(-c2ccccc2)oc2ccccc12,BRD-K78637815,cannabinoid receptor antagonist
10.630396,9.34766,1329,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1,BRD-K78643075,O=C(CCCN1CCC(c2ccccc2)CC1)c1ccccc1,BRD-K78643075,dopamine receptor antagonist
7.3074327,9.188061,1330,Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F,BRD-K78692225,O=C(Nc1ccccc1)c1cnoc1,BRD-K78692225,dihydroorotate dehydrogenase inhibitor|pdgfr tyrosine kinase receptor inhibitor
7.989513,9.820285,1331,CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1,BRD-K78815826,O=C1CC(=O)N(c2ccccc2)N1c1ccccc1,BRD-K78815826,cyclooxygenase inhibitor
6.111923,8.12375,1332,C[C@H]1[C@H]2[C@H](OC1=O)[C@@H]1C(C)=CC(=O)C1=C(C)C[C@@H]2O,BRD-K78838262,O=C1CC2CCC=C3C(=O)C=CC3C2O1,BRD-K78838262,hypolipidemic
8.528676,9.544258,1333,COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1,BRD-K78959463,O=C(c1cc[nH]c1)c1ccccc1Cc1ccccc1,BRD-K78959463,calcium channel activator
7.4575596,7.7802787,1334,NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O,BRD-K79092138,c1ccoc1,BRD-K79092138,poxb inhibitor|bacterial dna inhibitor
9.860193,10.297543,1335,CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC,BRD-K79116891,c1ccccc1,BRD-K79116891,sodium channel blocker
7.1435657,10.235237,1336,CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I,BRD-K79124250,O=C(CNC(=O)c1ccccc1)Nc1ccccc1,BRD-K79124250,radiopaque medium
8.061973,5.130272,1337,CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1,BRD-K79131256,c1ccc2[nH]cnc2c1,BRD-K79131256,tubulin polymerization inhibitor
10.824699,7.8029375,1338,CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O,BRD-K79145749,O=C1Nc2ccccc2Nc2ccccc21,BRD-K79145749,norepinephrine reuptake inhibitor
8.054878,7.6770635,1339,Nc1c(cc(Nc2ccc(Cl)cc2)c2C(=O)c3ccccc3C(=O)c12)S(O)(=O)=O,BRD-K79366068,O=C1c2ccccc2C(=O)c2c(Nc3ccccc3)cccc21,BRD-K79366068,ntpdase inhibitor
10.7693405,9.392199,1340,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O,BRD-K79425933,O=C(CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccccc1,BRD-K79425933,dopamine receptor antagonist
6.408541,10.60134,1341,CC(=O)N[C@@H](CSC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=O,BRD-K79437791,,BRD-K79437791,inhibitor of methylation of endogenous isoprenylated proteins
9.851095,7.89457,1342,CN1CCN(CC1)C(c1ccccc1)c1ccccc1,BRD-K79501723,c1ccc(C(c2ccccc2)N2CCNCC2)cc1,BRD-K79501723,histamine receptor modulator
8.731415,8.50625,1343,Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1,BRD-K79684402,C1=C(c2ccccc2)CCN(Cc2cncnc2)C1,BRD-K79684402,dopamine receptor partial agonist
7.599591,10.50785,1344,CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl,BRD-K79711234,c1ccccc1,BRD-K79711234,bacterial 50s ribosomal subunit inhibitor
7.6803904,8.100075,1345,CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1,BRD-K79759585,O=c1[nH]c(-c2cccc(S(=O)(=O)N3CCNCC3)c2)nc2cn[nH]c12,BRD-K79759585,phosphodiesterase inhibitor
7.8678174,6.206193,1346,CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,BRD-K79930101,c1ccc(COc2ccc(Nc3ncnc4ccc(-c5cscn5)cc34)cc2)cc1,BRD-K79930101,egfr inhibitor|epidermal growth factor receptor (egfr) inhibitor|erbb2 tyrosine kinase inhibitor|receptor tyrosine protein kinase inhibitor
9.666233,10.104118,1347,CCN(CC)CCOc1ccc(Cc2ccccc2)cc1,BRD-K80315159,c1ccc(Cc2ccccc2)cc1,BRD-K80315159,histamine receptor antagonist
3.781243,9.227326,1348,C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C,BRD-K80334323,O=C1CCC2=C(CCC3C2CCC2CCCC23)C1,BRD-K80334323,progestogen hormone
6.387921,6.571859,1349,COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12,BRD-K80353807,O=c1ccoc2cc3occc3cc12,BRD-K80353807,vasodilator
7.014885,9.5350275,1350,COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C,BRD-K80396088,O=C(NC1CCCCC1)NS(=O)(=O)c1ccc(CCN2C(=O)Cc3ccccc3C2=O)cc1,BRD-K80396088,sulfonylurea
10.122038,8.7263365,1351,C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1,BRD-K80451230,c1ccc(C(OC2CCCN(CCc3ccc4c(c3)OCO4)C2)c2ccccc2)cc1,BRD-K80451230,acetylcholine receptor antagonist
9.51439,7.977087,1352,COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1,BRD-K80639402,O=S(=O)(Nc1cccc(N2CCNCC2)c1)c1ccccc1,BRD-K80639402,serotonin receptor antagonist
9.69713,10.839543,1353,CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2,BRD-K80725821,O=C(NC1CN2CCC1CC2)c1cccc2[nH]cnc12,BRD-K80725821,serotonin receptor antagonist
6.7929144,7.095342,1354,Oc1ccc(cc1)\C=C\c1cc(O)cc(O)c1,BRD-K80738081,C(=Cc1ccccc1)c1ccccc1,BRD-K80738081,cytochrome p450 inhibitor|sirt activator
6.1575875,8.593599,1355,CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C,BRD-K80778372,O=C1NCc2cncn2-c2ccsc21,BRD-K80778372,gaba benzodiazepine site receptor inverse agonist
7.20078,6.8209114,1356,CC(=O)Oc1ccc(cc1)\C=C\c1cc(OC(C)=O)cc(OC(C)=O)c1,BRD-K80946661,C(=Cc1ccccc1)c1ccccc1,BRD-K80946661,p53 activator
5.850381,8.376978,1357,SC(=S)N1CCCC1,BRD-K80970344,C1CCNC1,BRD-K80970344,nfkb pathway inhibitor
10.953174,7.689892,1358,COc1ccc(cc1)[C@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@H]1OC(C)=O,BRD-K81029756,O=C1CC(c2ccccc2)Sc2ccccc2N1,BRD-K81029756,l-type calcium channel blocker|calcium channel antagonist|calcium channel blocker
6.831278,6.3956037,1359,COc1ccc2ccc(=O)oc2c1,BRD-K81209159,O=c1ccc2ccccc2o1,BRD-K81209159,acetylcholinesterase inhibitor
6.4244847,4.498068,1360,Oc1ccc(C=C(C#N)C(=O)Nc2ccccc2)cc1O,BRD-K81209512,O=C(C=Cc1ccccc1)Nc1ccccc1,BRD-K81209512,egfr inhibitor|epidermal growth factor receptor (egfr) inhibitor|tyrosine kinase inhibitor
8.933208,9.512234,1361,Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1,BRD-K81225797,c1ccc(CCn2ncc3c2ncn2nc(-c4ccco4)nc32)cc1,BRD-K81225797,adenosine receptor antagonist
7.294135,7.6105523,1362,[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1,BRD-K81272440,O=C1CN(N=Cc2ccc(-c3ccccc3)o2)C(=O)N1,BRD-K81272440,calcium channel blocker
6.2325406,7.431236,1363,COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O,BRD-K81376179,O=C(Nc1cc2c(s1)CCCC2)c1ccccc1,BRD-K81376179,flt3 inhibitor
2.6500912,9.685406,1364,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl,BRD-K81709173,O=C1C=C2CCC3C(CCC4C3CC3OCOC34)C2CC1,BRD-K81709173,glucocorticoid receptor agonist
9.292978,7.5341196,1365,CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1,BRD-K81729199,O=C1Nc2cccnc2N(C(=O)CN2CCCCC2)c2ccccc21,BRD-K81729199,acetylcholine receptor antagonist
4.1241293,8.897769,1366,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O,BRD-K81839095,O=C1CCC2C1CCC1c3ccccc3CCC12,BRD-K81839095,estrogen receptor agonist
8.741705,7.0762234,1367,O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1,BRD-K81876028,O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1,BRD-K81876028,serotonin receptor agonist
8.33145,7.39659,1368,NNc1nncc2ccccc12,BRD-K82103381,c1ccc2cnncc2c1,BRD-K82103381,vasodilator
7.234585,8.840818,1369,CC(C)c1cccc(C(C)C)c1O,BRD-K82255054,c1ccccc1,BRD-K82255054,gaba receptor agonist
8.876468,6.484076,1370,OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1,BRD-K82484965,C1=C(c2ccccc2)CCN(CCCCc2c[nH]c3ccccc23)C1,BRD-K82484965,dopamine receptor agonist
6.6278043,7.52933,1371,COc1ccn(C)c(=O)c1C#N,BRD-K82561139,O=c1cccc[nH]1,BRD-K82561139,casein kinase inhibitor
7.9200597,9.118844,1372,Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C,BRD-K82562631,O=C(c1ccccc1)c1ccc[nH]1,BRD-K82562631,cyclooxygenase inhibitor
6.2483277,7.566321,1373,CCCN(CCC)CCc1ccc(O)c(O)c1,BRD-K82577285,c1ccccc1,BRD-K82577285,dopamine receptor agonist
8.991915,10.052485,1374,Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12,BRD-K82731415,c1ccc(CNc2ncnc3[nH]cnc23)cc1,BRD-K82731415,cdk inhibitor
9.997305,7.496661,1375,CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12,BRD-K82795137,c1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,BRD-K82795137,histamine receptor antagonist
6.2116694,8.604263,1376,CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-],BRD-K82823076,O=C1NCc2cncn2-c2ccccc21,BRD-K82823076,gaba benzodiazepine site receptor inverse agonist
8.184171,9.652527,1377,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O,BRD-K82846253,O=C(Cc1ccccc1)NCc1ccccc1N1CCCCC1,BRD-K82846253,insulin secretagogue
6.012636,11.338039,1378,CCCCC[C@H](O)\C=C\C1=C(C\C=C/CCCC(O)=O)C(=O)CC1,BRD-K82865713,O=C1C=CCC1,BRD-K82865713,camp inhibitor
8.62187,6.1547847,1379,COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1,BRD-K83023055,c1ccc2[nH]ccc2c1,BRD-K83023055,melatonin receptor agonist
9.361897,8.152448,1380,FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1,BRD-K83063356,O=C1Nc2ccccc2C2(CCN(CCc3ccccc3)CC2)O1,BRD-K83063356,cc chemokine receptor antagonist|ccr antagonist
5.7519536,7.1405373,1381,CN1CCc2cc3OCOc3cc2C(=O)Cc2ccc3OCOc3c2C1,BRD-K83302049,O=C1Cc2ccc3c(c2CNCCc2cc4c(cc21)OCO4)OCO3,BRD-K83302049,histamine receptor antagonist
9.184584,8.570472,1382,C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1,BRD-K83322645,c1ccc(CN2CCC3(CCc4ccccc43)CC2)cc1,BRD-K83322645,sigma receptor antagonist|sigma receptor ligand
6.460788,6.817292,1383,COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O,BRD-K83459933,O=C1C=CC2C3Cc4ccccc4C2(CCN3)C1,BRD-K83459933,angiogenesis inhibitor
8.712169,9.21262,1384,CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12,BRD-K83508485,O=C(NCc1ccccc1)C(Cc1ccc2ccccc2c1)NC(=O)C1CCCN1C(=O)c1c[nH]c2ccccc12,BRD-K83508485,tachykinin antagonist
8.915585,9.31651,1385,CN(CC#C)Cc1ccccc1,BRD-K83597974,c1ccccc1,BRD-K83597974,monoamine oxidase inhibitor
9.092981,8.541865,1386,Cc1nn(c(C)c1C=NN1CCN(Cc2ccccc2)CC1)-c1ccccc1,BRD-K83637872,C(=NN1CCN(Cc2ccccc2)CC1)c1cnn(-c2ccccc2)c1,BRD-K83637872,smoothened receptor antagonist
8.082856,10.494401,1387,CN[C@@H](C)[C@@H](O)c1ccccc1,BRD-K84175871,c1ccccc1,BRD-K84175871,adrenergic receptor agonist
7.306467,8.389015,1388,CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O,BRD-K84266862,c1ccccc1,BRD-K84266862,phosphodiesterase inhibitor
10.203323,6.879257,1389,Oc1cc2[C@H](CNCCc2c(Cl)c1O)c1ccccc1,BRD-K84421793,c1ccc(C2CNCCc3ccccc32)cc1,BRD-K84421793,dopamine receptor agonist
4.3352957,9.605718,1390,C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1,BRD-K84595254,O=C1C=C(C2CCC3C2CCC2C4CCCCC4CCC23)CO1,BRD-K84595254,atpase inhibitor
5.895343,7.26497,1391,COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC,BRD-K84663978,O=c1[nH]c(=Nc2ccccc2)cc2n1CCc1ccccc1-2,BRD-K84663978,phosphodiesterase inhibitor|platelet aggregation inhibitor|potassium channel blocker
6.766521,6.7306805,1392,Oc1ccc(C=CC(=O)OCCc2ccccc2)cc1O,BRD-K84709232,O=C(C=Cc1ccccc1)OCCc1ccccc1,BRD-K84709232,lipoxygenase inhibitor|hiv integrase inhibitor|nfkb pathway inhibitor|nitric oxide production inhibitor|ppar receptor modulator|tumor necrosis factor production inhibitor
9.854006,8.156399,1393,COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1,BRD-K85015012,c1ccc(C2CCN(CCCn3c4ccccc4c4ccccc43)CC2)cc1,BRD-K85015012,gaba uptake inhibitor|gat inhibitor
5.8774066,8.558267,1394,CC[C@H]1[C@@H](Cc2cncn2C)COC1=O,BRD-K85090592,O=C1CC(Cc2cnc[nH]2)CO1,BRD-K85090592,acetylcholine receptor agonist
6.958144,9.299652,1395,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,BRD-K85119730,c1ccccc1,BRD-K85119730,atp channel blocker
9.127094,6.5760565,1396,CCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21,BRD-K85242180,c1ccc2c(c1)[nH]c1cnccc12,BRD-K85242180,"indoleamine 2,3-dioxygenase inhibitor"
6.9721026,8.183063,1397,Oc1nc2cc(c(cc2nc1O)[N+]([O-])=O)[N+]([O-])=O,BRD-K85266041,c1ccc2nccnc2c1,BRD-K85266041,glutamate receptor antagonist
6.4653854,9.629145,1398,C[C@]1(Cc2cc(OCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1,BRD-K85383046,O=C1c2ccccc2CC1C1CCCC1,BRD-K85383046,chloride channel blocker
8.232959,8.3162365,1399,Cc1nc(c(o1)-c1ccncc1)-c1ccccc1,BRD-K85871428,c1ccc(-c2ncoc2-c2ccncc2)cc1,BRD-K85871428,p38 mapk inhibitor
3.039587,9.582228,1400,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,BRD-K85883481,O=C1C=CC2C(=C1)CCC1C3CCCC3CC(=O)C21,BRD-K85883481,glucocorticoid receptor agonist
7.5575066,8.701968,1401,CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1,BRD-K86204871,c1ccc(C2(Cn3cncn3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1,BRD-K86204871,sterol demethylase inhibitor
5.971338,8.135163,1402,OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO,BRD-K86301799,c1nc(N2CCCCC2)c2ncnc(N3CCCCC3)c2n1,BRD-K86301799,phosphodiesterase inhibitor
8.841595,9.312952,1403,C[C@H](Cc1ccccc1)N(C)CC#C,BRD-K86434416,c1ccccc1,BRD-K86434416,monoamine oxidase inhibitor
9.012334,10.063555,1404,Cn1cnc2nc(NCCO)nc(NCc3ccccc3)c12,BRD-K86509404,c1ccc(CNc2ncnc3nc[nH]c23)cc1,BRD-K86509404,cdk inhibitor
5.586349,6.6645603,1405,CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12,BRD-K86600316,c1ccc2c(c1)CCN1CC3CCCNC3CC21,BRD-K86600316,adrenergic receptor antagonist
5.9991913,10.786623,1406,CCCCCCCCCCCC1C(=O)C(=O)CC(=O)C1=O,BRD-K86727142,O=C1CC(=O)C(=O)CC1=O,BRD-K86727142,hcv inhibitor|xiap inhibitor
12.157016,8.751256,1407,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O,BRD-K86873305,O=C1NCCN(C(=O)NC(C(=O)NC2C(=O)N3CCSC23)c2ccccc2)C1=O,BRD-K86873305,bacterial cell wall synthesis inhibitor
9.79687,12.337129,1408,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1,BRD-K86882815,c1cc2c3c(c[nH]c3c1)CC1NCCCC21,BRD-K86882815,dopamine receptor agonist|prolactin inhibitor|prolactin secretion inhibitor
6.1473026,11.357493,1409,CCCCCCCCC=CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1,BRD-K86958018,c1ccccc1,BRD-K86958018,trpv agonist
10.385896,10.004369,1410,COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O,BRD-K87048468,O=C1NC(=O)C2(CCN(CCCCC(=O)c3cccc(NS(=O)(=O)c4ccccc4)c3)CC2)N1,BRD-K87048468,serotonin receptor antagonist
6.972743,9.972288,1411,CCCCc1ccc(nc1)C(O)=O,BRD-K87049188,c1ccncc1,BRD-K87049188,chelating|dopamine beta hydroxylase inhibitor
9.142098,8.172891,1412,Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1,BRD-K87510569,O=C1Nc2ccccc2C2(CCN(CCc3coc(-c4ccccc4)n3)CC2)O1,BRD-K87510569,cc chemokine receptor antagonist
7.7601447,6.136083,1413,COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1,BRD-K87696786,c1ccc(Nc2ncnc3ccccc23)cc1,BRD-K87696786,glutamate receptor antagonist
7.7696304,8.395858,1414,NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O,BRD-K87990216,c1ccc(Oc2ccccc2N2CCCC2)cc1,BRD-K87990216,glucocorticoid receptor agonist
6.3775,6.4004316,1415,Oc1ccc2ccc(=O)oc2c1,BRD-K87991767,O=c1ccc2ccccc2o1,BRD-K87991767,carbonic anhydrase inhibitor|cyclooxygenase inhibitor
10.034838,7.538098,1416,CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12,BRD-K88090157,c1ccc2c(c1)Sc1ccccc1C2=C1CCNCC1,BRD-K88090157,antihistamine
8.328246,8.465242,1417,Cc1c(C(=O)c2cccc3ccccc23)c2cccc3OC[C@@H](CN4CCOCC4)n1c23,BRD-K88282786,O=C(c1cccc2ccccc12)c1cn2c3c(cccc13)OCC2CN1CCOCC1,BRD-K88282786,cannabinoid receptor agonist
9.417338,8.236946,1418,FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1,BRD-K88358234,C1=C(c2ccccc2)CCN(CCc2ccc3ccccc3c2)C1,BRD-K88358234,serotonin receptor agonist|nerve growth factor agonist|neurotrophic factor enhancer
6.0144978,7.3763876,1419,COc1ccc(CN2CCNCC2)c(OC)c1OC,BRD-K88366685,c1ccc(CN2CCNCC2)cc1,BRD-K88366685,3-ketoacyl coa thiolase inhibitor
9.740168,9.617289,1420,COc1ccc(CN(CCN(C)C)c2ncccn2)cc1,BRD-K88405679,c1ccc(CNc2ncccn2)cc1,BRD-K88405679,antihistamine
7.8870344,8.146046,1421,CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,BRD-K88429204,c1ccc(-c2cncnc2)cc1,BRD-K88429204,dihydrofolate reductase inhibitor
6.225919,10.774908,1422,CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC,BRD-K88544581,c1ccccc1,BRD-K88544581,acat inhibitor
7.599073,9.234983,1423,CC(C)NNC(=O)c1ccncc1,BRD-K88568253,c1ccncc1,BRD-K88568253,monoamine oxidase inhibitor
7.2332263,6.2516356,1424,COc1ccc(cc1)C(=O)N1CCCC1=O,BRD-K88611939,O=C1CCCN1C(=O)c1ccccc1,BRD-K88611939,glutamate receptor agonist
7.966865,9.503238,1425,Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1,BRD-K88677950,O=C(NOCC1CC1)c1ccccc1Nc1ccccc1,BRD-K88677950,map kinase inhibitor|mek inhibitor
6.891446,6.9706664,1426,COC(=O)C=Cc1cc(O)ccc1O,BRD-K88741031,c1ccccc1,BRD-K88741031,egfr inhibitor|tyrosine kinase inhibitor
8.562765,6.1757646,1427,CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12,BRD-K88743730,c1ccc2[nH]ccc2c1,BRD-K88743730,serotonin receptor partial agonist
8.366098,8.551384,1428,CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,BRD-K88759641,O=c1[nH]ccc2ncn(Cc3ccc(-c4ccccc4-c4nnn[nH]4)cc3)c12,BRD-K88759641,angiotensin receptor antagonist
7.918633,8.547388,1429,N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1,BRD-K88789588,c1ccc(C(c2ccccc2)n2cncn2)cc1,BRD-K88789588,aromatase inhibitor
8.841322,7.9587054,1430,N[C@H]1C[C@@H]1c1ccccc1,BRD-K88809146,c1ccc(C2CC2)cc1,BRD-K88809146,monoamine oxidase inhibitor
7.5710363,6.459095,1431,CCCCCc1c2Oc3cc(OC)cc(C(=O)CCCC)c3C(=O)Oc2cc(O)c1C(O)=O,BRD-K88849294,O=C1Oc2ccccc2Oc2ccccc21,BRD-K88849294,tyrosine phosphatase inhibitor
9.77161,12.354581,1432,CCN(CC)C(=O)N[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34,BRD-K88871508,C1=C2c3cccc4[nH]cc(c34)CC2NCC1,BRD-K88871508,dopamine receptor agonist
12.14175,8.7576685,1433,CC1(C)S[C@@H]2[C@H](NC(=O)C3(N)CCCCC3)C(=O)N2[C@H]1C(O)=O,BRD-K89046952,O=C(NC1C(=O)N2CCSC12)C1CCCCC1,BRD-K89046952,bacterial cell wall synthesis inhibitor
9.209193,9.634922,1434,CCN(CCCc1ccccc1)CCCc1ccccc1,BRD-K89055274,c1ccc(CCCNCCCc2ccccc2)cc1,BRD-K89055274,muscle relaxant
6.7159176,8.893525,1435,CC(/C=C/C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(=O)Nc1ccc(O)cc1,BRD-K89085489,O=C(C=CC=CC=CC=CC1=CCCCC1)Nc1ccccc1,BRD-K89085489,apoptosis stimulant|retinoid receptor agonist
6.5585923,8.286516,1436,CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O,BRD-K89125793,c1c[nH]cn1,BRD-K89125793,antiprotozoal
7.5202208,10.096781,1437,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O,BRD-K89152108,c1ccc(Oc2ccccc2)cc1,BRD-K89152108,thyroid hormone stimulant
6.260565,11.106311,1438,OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,BRD-K89210380,O=C1NC2CSCC2N1,BRD-K89210380,vitamin b
7.846454,9.404785,1439,OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O,BRD-K89272762,c1ccc(CCCNc2ccccc2)cc1,BRD-K89272762,chloride channel blocker
8.368499,7.881276,1440,Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1,BRD-K89274813,O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc21,BRD-K89274813,acetylcholine release enhancer
9.343834,7.5073566,1441,CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1,BRD-K89375097,O=C1Nc2cccnc2N(C(=O)CN2CCNCC2)c2ccccc21,BRD-K89375097,acetylcholine receptor antagonist
7.5369606,9.9311285,1442,Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12,BRD-K89402695,c1ccc(Cn2ccc3ccccc32)cc1,BRD-K89402695,thromboxane receptor antagonist
10.8987055,7.7344527,1443,CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,BRD-K89732114,c1ccc2c(c1)Sc1ccccc1N2CCCN1CCNCC1,BRD-K89732114,dopamine receptor antagonist
4.6651635,11.358646,1444,CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1,BRD-K89923877,O=C(Cc1ccccc1)OC1CC2NC(C1)C1OC21,BRD-K89923877,acetylcholine receptor antagonist
6.4379916,4.5483685,1445,Oc1ccc(cc1O)\C=C(/C#N)C(=O)NC1CCC(CC2CCC(CC2)NC(=O)C(\C#N)=C\c2ccc(O)c(O)c2)CC1,BRD-K89930444,O=C(C=Cc1ccccc1)NC1CCC(CC2CCC(NC(=O)C=Cc3ccccc3)CC2)CC1,BRD-K89930444,tyrosine kinase inhibitor
10.950786,7.686614,1446,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12,BRD-K89997465,c1ccc2c(c1)Nc1ccccc1S2,BRD-K89997465,dopamine receptor antagonist
3.5667086,9.428333,1447,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12,BRD-K90027355,O=C1C=C2CCC3C(CCC4C3CCC43CCC(=O)O3)C2CC1,BRD-K90027355,mineralocorticoid receptor antagonist
9.87315,6.4458876,1448,NCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12,BRD-K90259198,c1ccc2ccccc2c1,BRD-K90259198,calmodulin antagonist|potassium channel blocker|squalene monooxygenase channel blocker
8.2253,6.7033463,1449,Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1,BRD-K90333595,c1ccc(N(CC2=NCCN2)c2ccccc2)cc1,BRD-K90333595,adrenergic receptor antagonist
4.866058,6.9026175,1450,COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC,BRD-K90382497,c1ccc(COc2csc(-n3cnc4ccccc43)c2)cc1,BRD-K90382497,plk inhibitor
8.058446,8.355731,1451,Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1,BRD-K90524085,c1ccc(Nc2nnc(-c3ccccc3)c3ccccc23)cc1,BRD-K90524085,phosphodiesterase inhibitor|platelet aggregation inhibitor
10.40076,8.817059,1452,O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12,BRD-K90574421,O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2ncccn2)CC1,BRD-K90574421,serotonin receptor agonist
10.099753,8.341852,1453,CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1,BRD-K90789829,O=c1n(CCOc2ccccc2)cnn1CCCN1CCN(c2ccccc2)CC1,BRD-K90789829,adrenergic inhibitor
5.2674174,9.225773,1454,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O,BRD-K90976994,O=C1CCC2C(C1)CC(=O)C1C3CCCC3C(=O)CC21,BRD-K90976994,bile acid
7.0899134,9.058998,1455,COc1cccc(OC)c1-c1cc(nn1-c1ccc(cc1C(C)C)C(=O)N(C)CCCN(C)C)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O,BRD-K91243525,O=C(NC1C2CC3CC(C2)CC1C3)c1cc(-c2ccccc2)n(-c2ccccc2)n1,BRD-K91243525,neurotensin receptor antagonist
10.464718,7.7241826,1456,CNCCC=C1c2ccccc2CCc2ccccc12,BRD-K91263825,C=C1c2ccccc2CCc2ccccc21,BRD-K91263825,tricyclic antidepressant
8.793402,9.002572,1457,CNCCc1ccccn1,BRD-K91315211,c1ccncc1,BRD-K91315211,histamine receptor agonist
9.684448,12.213402,1458,CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1,BRD-K91336023,c1cc2c3c(c[nH]c3c1)CC1NCCCC21,BRD-K91336023,dopamine receptor agonist
7.21875,6.287729,1459,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1,BRD-K91370081,c1ccc(CC2CCCN2)cc1,BRD-K91370081,dna synthesis inhibitor
7.6848874,7.6025753,1460,NC(=O)c1ccc2[nH]ccc2c1,BRD-K91904471,c1ccc2[nH]ccc2c1,BRD-K91904471,p38 mapk inhibitor
7.226618,9.557115,1461,Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1,BRD-K92000912,O=C(NN1CCCCC1)c1cc(-c2ccccc2)n(-c2ccccc2)n1,BRD-K92000912,cannabinoid receptor antagonist
10.3709,8.557022,1462,C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1,BRD-K92015269,C(=Cc1ccccc1)CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1,BRD-K92015269,dopamine uptake inhibitor
8.234975,8.298805,1463,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1,BRD-K92049597,c1ccc(-c2cnc3ncncc3n2)cc1,BRD-K92049597,sodium channel blocker
7.55119,7.3154445,1464,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,BRD-K92093830,O=C1c2ccccc2C(=O)c2cc3c(cc21)CCCC3OC1CCCCO1,BRD-K92093830,topoisomerase inhibitor
7.5713224,8.854142,1465,CC(C)CC(=O)c1c(O)c(CC=C(C)C)c(O)c2c(cc(=O)oc12)-c1ccccc1,BRD-K92138166,O=c1cc(-c2ccccc2)c2ccccc2o1,BRD-K92138166,antibiotic
6.50832,9.483132,1466,CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nnn[nH]1,BRD-K92492521,c1ccc(OCCCCCCc2nnn[nH]2)cc1,BRD-K92492521,leukotriene receptor antagonist
6.638723,6.6376123,1467,COc1ccccc1-c1coc2cc(OC)c(OC)c(OC)c2c1=O,BRD-K92678294,O=c1c(-c2ccccc2)coc2ccccc12,BRD-K92678294,isoflavone
7.6855483,9.26114,1468,CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,BRD-K92723993,O=C(Nc1cccc(Nc2nccc(-c3cccnc3)n2)c1)c1ccc(CN2CCNCC2)cc1,BRD-K92723993,pdgfr tyrosine kinase receptor inhibitor|bcr-abl kinase inhibitor|kit inhibitor|abl kinase inhibitor|apoptosis stimulant|breast cancer resistance protein inhibitor|colony stimulating factor receptor inhibitor
6.0569096,7.550299,1469,C[N+]1=Cc2cc3OCOc3cc2CC1,BRD-K92726801,C1=[NH+]CCc2cc3c(cc21)OCO3,BRD-K92726801,haemostatic
5.860379,9.4378805,1470,CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC,BRD-K92731339,C1CCC2NCCC2C1,BRD-K92731339,ace inhibitor
5.7247396,8.698811,1471,C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O,BRD-K92758126,C=C1CC23CC1CCC2C12C=CCC(C(=O)O1)C2C3,BRD-K92758126,nfkb pathway inhibitor
8.557159,10.144615,1472,Cc1cccc(Nc2ccccc2C(O)=O)c1C,BRD-K92778217,c1ccc(Nc2ccccc2)cc1,BRD-K92778217,cyclooxygenase inhibitor
4.1949816,6.8879986,1473,CC(C)NC[C@@H](O)COc1cccc2ccccc12,BRD-K92830582,c1ccc2ccccc2c1,BRD-K92830582,adrenergic receptor antagonist
10.663535,9.371052,1474,CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1,BRD-K92984783,O=C(CCCN1CCCCC1)c1ccccc1,BRD-K92984783,serotonin receptor antagonist
8.133129,10.222614,1475,C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)CCl,BRD-K93080877,c1ccccc1,BRD-K93080877,tripeptidyl peptidase inhibitor
6.938238,9.903498,1476,CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O,BRD-K93176058,c1ccc(-c2ccccc2)cc1,BRD-K93176058,retinoid receptor agonist
10.875174,8.581964,1477,COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1,BRD-K93188295,O=C1Cc2ccccc2C(=O)N1CCN1CCN(c2ccccc2)CC1,BRD-K93188295,adrenergic receptor antagonist
9.724539,6.540531,1478,Ic1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1,BRD-K93201660,O=S(=O)(c1cccc2ccccc12)N1CCCNCC1,BRD-K93201660,myosin light chain kinase inhibitor
7.4772496,9.188704,1479,[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1,BRD-K93258693,O=C(Nc1ccccc1)c1ccccc1,BRD-K93258693,ppar receptor antagonist
6.919067,10.687392,1480,COc1ccc(cc1)-c1ccc(N)[n+](CCCC(O)=O)n1,BRD-K93280214,c1ccc(-c2ccc[nH+]n2)cc1,BRD-K93280214,gaba receptor antagonist
7.2156115,7.3500857,1481,COc1c(C=O)c(O)cc2C(=O)c3ccccc3C(=O)c12,BRD-K93325701,O=C1c2ccccc2C(=O)c2ccccc21,BRD-K93325701,src inhibitor
8.495355,9.414977,1482,Cc1cc(no1)C(=O)NNCc1ccccc1,BRD-K93332168,O=C(NNCc1ccccc1)c1ccon1,BRD-K93332168,monoamine oxidase inhibitor
8.485131,8.929491,1483,C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1,BRD-K93441486,c1ccc(C(=C2CC[NH2+]CC2)c2ccccc2)cc1,BRD-K93441486,acetylcholine receptor antagonist
7.9064107,8.156865,1484,Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl,BRD-K93460210,c1ccc(-c2cncnn2)cc1,BRD-K93460210,serotonin receptor antagonist
10.46873,8.667131,1485,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1,BRD-K93461745,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,BRD-K93461745,serotonin receptor agonist
7.586234,7.202737,1486,COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1,BRD-K93480852,O=S(=O)(Nc1ccccc1CNCC=Cc1ccccc1)c1ccccc1,BRD-K93480852,calcium/calmodulin dependent protein kinase inhibitor
3.1870277,9.501642,1487,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,BRD-K93568044,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-K93568044,glucocorticoid receptor agonist
6.7255406,9.471684,1488,CCCCc1c([nH]c2nccnc12)-c1ccc(O)cc1,BRD-K93658967,c1ccc(-c2cc3nccnc3[nH]2)cc1,BRD-K93658967,cdk inhibitor|cftr channel activator|glycogen synthase kinase inhibitor|jnk inhibitor
9.613184,10.012411,1489,CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1,BRD-K93754473,C(=C(c1ccccc1)c1ccccc1)c1ccccc1,BRD-K93754473,estrogen receptor antagonist|selective estrogen receptor modulator (serm)
8.710249,7.9171658,1490,CN1[C@@H](CCC1=O)c1cccnc1,BRD-K94144010,O=C1CCC(c2cccnc2)N1,BRD-K94144010,nicotine metabolite
9.984882,7.087542,1491,CN1CCc2cc(Cl)c(O)cc2[C@@H]2[C@@H]1CCc1ccccc21,BRD-K94270326,c1ccc2c(c1)CCNC1CCc3ccccc3C21,BRD-K94270326,dopamine receptor antagonist
7.253299,6.189186,1492,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1,BRD-K94379058,O=C(Cc1cn(C(=O)c2ccccc2)c2ccccc12)N1CCOCC1,BRD-K94379058,cannabinoid receptor inverse agonist
5.722598,9.940411,1493,CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12,BRD-K94441233,O=C1CCCC(CCC2CC=CC3=CCCCC32)O1,BRD-K94441233,hmgcr inhibitor
10.726027,9.087249,1494,Fc1ccc(OCCCN2CCC3(CC2)N(CNC3=O)c2ccccc2)cc1,BRD-K94512704,O=C1NCN(c2ccccc2)C12CCN(CCCOc1ccccc1)CC2,BRD-K94512704,dopamine receptor antagonist
6.977238,6.4106617,1495,Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1,BRD-K94689771,O=C1CC(c2ccccc2)Oc2ccccc21,BRD-K94689771,cyp1b1 inhibitor
6.643527,9.206617,1496,CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1,BRD-K94832621,O=C(c1ccc(N2CCNCC2)cc1)c1c(-c2ccccc2)sc2ccccc12,BRD-K94832621,estrogen receptor antagonist|selective estrogen receptor modulator (serm)
6.9021583,7.239776,1497,OC(=O)c1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1,BRD-K94841585,O=C1c2ccccc2C(=O)c2ccccc21,BRD-K94841585,laxative|free radical generator
9.396877,7.975484,1498,FC(F)(F)c1cccc(c1)N1CCNCC1,BRD-K94887716,c1ccc(N2CCNCC2)cc1,BRD-K94887716,serotonin receptor agonist
6.2572513,8.467134,1499,Cc1nc(=O)c2CSCCc2[nH]1,BRD-K94920105,O=c1nc[nH]c2c1CSCC2,BRD-K94920105,parp inhibitor
6.9908004,7.7715907,1500,C[S+](O)c1ccc(CSc2nc(c([nH]2)-c2ccc(F)cc2)-c2ccncc2)cc1,BRD-K95202259,c1ccc(CSc2nc(-c3ccncc3)c(-c3ccccc3)[nH]2)cc1,BRD-K95202259,p38 mapk inhibitor
7.17952,9.3085985,1501,CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O,BRD-K95237249,c1ccccc1,BRD-K95237249,uricosuric blocker
6.7370214,8.810273,1502,C\C=C(c1ccc(O)cc1)\C(c1ccc(O)cc1)=C\C,BRD-K95309561,C=C(C(=C)c1ccccc1)c1ccccc1,BRD-K95309561,estrogen receptor agonist
8.813291,7.7044415,1503,Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1,BRD-K95435023,O=C1Nc2ccc(S(=O)(=O)Cc3ccccc3)cc2C1=Cc1cc(C(=O)N2CCCC2CN2CCCC2)c[nH]1,BRD-K95435023,c-met inhibitor|hepatocyte growth factor receptor inhibitor
6.665108,8.001337,1504,CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C,BRD-K95603879,c1ccccc1,BRD-K95603879,atpase inhibitor
7.226016,8.386338,1505,Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F,BRD-K95609758,O=c1oc(-c2ccccc2)nn1Cc1ccccc1,BRD-K95609758,potassium channel activator
8.546212,7.2879486,1506,CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)c2ccccc12,BRD-K95655893,O=C1Nc2ccccc2C1=Cc1cccc2ccccc12,BRD-K95655893,vegfr kinase inhibitor
8.052734,8.363673,1507,C=CC(=O)c1ccc2ccccc2c1,BRD-K95676198,c1ccc2ccccc2c1,BRD-K95676198,jak inhibitor
5.559329,6.702326,1508,COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC,BRD-K95739795,O=C1CCN2CCc3ccccc3C2C1,BRD-K95739795,vesicular monoamine transporter inhibitor
6.39826,8.30342,1509,CCN(CC)c1cc(C)nc2ncnn12,BRD-K95763993,c1cnc2ncnn2c1,BRD-K95763993,pdgfr receptor inhibitor
8.062901,8.003421,1510,CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12,BRD-K95785537,c1ccc(-c2n[nH]c3ncncc23)cc1,BRD-K95785537,src inhibitor
6.6061354,7.679985,1511,CC(C)(Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)C=O,BRD-K95851186,c1ccccc1,BRD-K95851186,gaba receptor modulator
7.624163,9.369345,1512,CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1,BRD-K95899059,O=C(Nc1ccc2[nH]c3c(c2c1)CCCC3)c1ccccc1,BRD-K95899059,serotonin receptor agonist
8.469323,9.710444,1513,CC(C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O,BRD-K95992530,O=C1CNC(=O)CNC(=O)C(Cc2ccccc2)NC(=O)CNC(=O)CN1,BRD-K95992530,integrin antagonist
6.04263,8.148428,1514,C[C@H]1[C@@H]2CCC(C)=C3[C@@H]([C@H]2OC1=O)C(C)=CC3=O,BRD-K96119599,O=C1CC2CCC=C3C(=O)C=CC3C2O1,BRD-K96119599,melanin inhibitor
6.079367,11.251581,1515,CCCCCCCC\C=C/C\C=C/C\C=C/CCCC(O)=O,BRD-K96144918,,BRD-K96144918,kpl-1 tumor suppressor
8.252151,9.611088,1516,CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O,BRD-K96263742,O=C(NC1CCCCC1)N(CCCCC1CCCCC1)CCc1ccccc1,BRD-K96263742,ppar receptor agonist
7.0647836,7.290944,1517,COc1ccccc1\C=C/C(O)=O,BRD-K96271548,c1ccccc1,BRD-K96271548,antioxidant
6.390029,10.436154,1518,CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1nc[nH]n1,BRD-K96402602,c1nc[nH]n1,BRD-K96402602,ppmtase inhibitor
4.104293,9.225413,1519,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1,BRD-K96527333,O=C1CCC2C1CCC1C3CCCCC3=CCC21,BRD-K96527333,gaba receptor modulator
8.84778,8.70091,1520,OC(=O)c1nn(Cc2ccc(Cl)c(Cl)c2)c2ccccc12,BRD-K96670504,c1ccc(Cn2ncc3ccccc32)cc1,BRD-K96670504,glucokinase inhibitor
8.144866,7.688415,1521,COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl,BRD-K96720755,O=C(C1C(c2ccccc2)c2ccccc2N1S(=O)(=O)c1ccccc1)N1CCCC1,BRD-K96720755,vasopressin receptor antagonist
7.9262366,8.029484,1522,NS(=O)(=O)C#Cc1ccccc1,BRD-K96799727,c1ccccc1,BRD-K96799727,hsp inhibitor
6.8508463,7.8939657,1523,Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1,BRD-K96809896,c1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1,BRD-K96809896,p38 mapk inhibitor
8.704128,8.215394,1524,Cc1ccc(=O)n(c1)-c1ccccc1,BRD-K96862998,O=c1ccccn1-c1ccccc1,BRD-K96862998,tgf beta receptor inhibitor
9.325754,8.23666,1525,OC(C1CCNCC1)(c1ccccc1)c1ccccc1,BRD-K97061094,c1ccc(C(c2ccccc2)C2CCNCC2)cc1,BRD-K97061094,histamine receptor antagonist
6.651732,8.193086,1526,Brc1c(Br)c(Br)c2[nH]nnc2c1Br,BRD-K97118047,c1ccc2[nH]nnc2c1,BRD-K97118047,casein kinase inhibitor
10.782306,9.418069,1527,Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O,BRD-K97158071,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccccc1,BRD-K97158071,dopamine receptor antagonist
8.354368,9.937227,1528,NC(=N)NC(=O)c1nc(Cl)c(N)nc1N,BRD-K97181089,c1cnccn1,BRD-K97181089,sodium channel blocker
7.4682674,6.2916684,1529,COc1ccc2c(c1)cc(C)c1nnc(SCC(=O)Nc3cccc(c3)C(C)=O)n21,BRD-K97330509,O=C(CSc1nnc2ccc3ccccc3n12)Nc1ccccc1,BRD-K97330509,src inhibitor
8.555719,7.368004,1530,CN(C)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3cc4CCCCc4[nH]3)c2c1,BRD-K97354755,O=C1Nc2ccccc2C1=Cc1cc2c([nH]1)CCCC2,BRD-K97354755,src inhibitor
8.408436,7.2414913,1531,Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1,BRD-K97365803,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,BRD-K97365803,pi3k inhibitor
6.410291,6.2120075,1532,Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O,BRD-K97399794,O=c1cc(-c2ccccc2)oc2ccccc12,BRD-K97399794,polar auxin transport inhibitor
9.825169,12.410358,1533,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,BRD-K97440753,O=C(NC1OC2C3CCCN3C(=O)C(Cc3ccccc3)N2C1=O)C1CNC2Cc3c[nH]c4cccc(c34)C2C1,BRD-K97440753,adrenergic receptor antagonist|prolactin inhibitor
6.332003,6.294128,1534,Oc1ccc2c(c1)oc1c2c(=O)oc2cc(O)ccc12,BRD-K97509413,O=c1oc2ccccc2c2oc3ccccc3c12,BRD-K97509413,age inhibitor|estrogen receptor agonist|estrogen receptor ligand
7.3837004,7.931571,1535,Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O,BRD-K97521363,c1ccccc1,BRD-K97521363,glycolysis inhibitor
8.542706,6.202419,1536,COc1ccc2[nH]cc(CCNC(C)=O)c2c1,BRD-K97530723,c1ccc2[nH]ccc2c1,BRD-K97530723,melatonin receptor agonist|nitric oxide synthase inhibitor
9.7932825,9.701769,1537,COc1ccc(cc1)CN(CCN(C)C)c1ccccn1,BRD-K97564742,c1ccc(CNc2ccccn2)cc1,BRD-K97564742,histamine receptor antagonist
8.351431,9.769364,1538,N\C(NCc1ccccc1)=N/C(=O)c1nc(Cl)c(N)nc1N,BRD-K97688263,O=C(N=CNCc1ccccc1)c1cnccn1,BRD-K97688263,sodium channel blocker
7.0526433,9.429302,1539,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,BRD-K97746869,c1ccccc1,BRD-K97746869,atp channel blocker
8.053635,9.363509,1540,[O-][N+](=O)OCCNC(=O)c1cccnc1,BRD-K97752965,c1ccncc1,BRD-K97752965,atp channel activator|nitric oxide donor|potassium channel agonist
6.0260534,8.958014,1541,Cn1c2nc[nH]c2c(=O)n(C)c1=O,BRD-K97799481,O=c1[nH]c(=O)c2[nH]cnc2[nH]1,BRD-K97799481,adenosine receptor antagonist
2.4926114,9.721067,1542,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C,BRD-K97810537,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K97810537,glucocorticoid receptor agonist
2.956998,9.581162,1543,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,BRD-K98039984,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K98039984,glucocorticoid receptor agonist
6.6779904,7.801447,1544,COc1nccc(n1)-c1c(ncn1C1CCC(O)CC1)-c1ccc(F)cc1,BRD-K98143437,c1ccc(-c2ncn(C3CCCCC3)c2-c2ccncn2)cc1,BRD-K98143437,p38 mapk inhibitor|interleukin inhibitor|tumor necrosis factor production inhibitor
8.488803,8.451897,1545,Cc1ccc(O)c(N=Nc2ccccc2)n1,BRD-K98157055,c1ccc(N=Nc2ccccn2)cc1,BRD-K98157055,glutamate receptor antagonist
7.8086014,7.4621873,1546,Clc1ccc2oc(=O)[nH]c2c1,BRD-K98174813,O=c1[nH]c2ccccc2o1,BRD-K98174813,bacterial 30s ribosomal subunit inhibitor
6.283684,8.639657,1547,CCN1C(=O)C=CC1=O,BRD-K98297262,O=C1C=CC(=O)N1,BRD-K98297262,"1,3-beta-glucan synthase inhibitor"
3.5719151,9.446344,1548,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO,BRD-K98521173,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-K98521173,mineralocorticoid receptor agonist
